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Abstract 
 
Pritesh Mistry 
A Knowledge Based Approach of Toxicity Prediction for Drug Formulation 
Modelling Drug Vehicle Relationships Using Soft Computing Techniques 
Keywords: Predictive toxicology, Drug formulation, Random forest, Decision trees, Big data, 
Data mining, Area-under-curve (AUC) 
This multidisciplinary thesis is concerned with the prediction of drug formulations for the 
reduction of drug toxicity. Both scientific and computational approaches are utilised to 
make original contributions to the field of predictive toxicology. 
The first part of this thesis provides a detailed scientific discussion on all aspects of drug 
formulation and toxicity. Discussions are focused around the principal mechanisms of drug 
toxicity and how drug toxicity is studied and reported in the literature. Furthermore, a 
review of the current technologies available for formulating drugs for toxicity reduction is 
provided. Examples of studies reported in the literature that have used these technologies 
to reduce drug toxicity are also reported. The thesis also provides an overview of the 
computational approaches currently employed in the field of in silico predictive toxicology. 
This overview focuses on the machine learning approaches used to build predictive QSAR 
classification models, with examples discovered from the literature provided. 
Two methodologies have been developed as part of the main work of this thesis. The first is 
focused on use of directed bipartite graphs and Venn diagrams for the visualisation and 
extraction of drug-vehicle relationships from large un-curated datasets which show 
changes in the patterns of toxicity. These relationships can be rapidly extracted and 
visualised using the methodology proposed in chapter 4. 
The second methodology proposed, involves mining large datasets for the extraction of 
drug-vehicle toxicity data. The methodology uses an area-under-the-curve principle to 
make pairwise comparisons of vehicles which are classified according to the toxicity 
protection they offer, from which predictive classification models based on random forests 
and decisions trees are built. The results of this methodology are reported in chapter 6. 
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1 
1 Introduction 
 
This thesis is concerned with the application of pharmaceutical drug formulations and their 
influence on drug toxicity. Drug formulation information is gathered and processed to 
understand how formulations reduce drug toxicity and whether this knowledge can be 
used to formulate for the general case. 
Original contributions are made in the field of data visualisation, data extraction methods 
and data classification methods of toxicity data which shows a difference in toxicity with a 
change in formulation. The effectiveness of these methods is demonstrated using real 
scientific data. 
1.1 Background and Motivation 
Toxicity is a major concern implicated in the attrition rates of drug candidates consisting of 
new chemical entities (NCE). As a result of continued efforts to improve the efficacy and 
bioavailability of NCEs a shift in attrition rates has been observed from poor efficacy and 
bioavailability to other stages of the developmental pipeline [1, 2], particularly the toxicity 
concerns that are apparent today [1]. A clinical phase study of the NCEs for the period of 
2011 to 2012 highlighted that failures due to toxicity concerns were higher in phase III and 
beyond compared with phase II [3]. It was suggested that toxicity as the cause may only 
become apparent in larger patient trials. The problem is further exacerbated by our need 
for therapies against more aggressive diseases such as cancer, which carries a 
developmental failure rate of ~95 % [1]. The financial cost of attrition is large; it was 
estimated that the cost of bringing a new drug to market in 2000 was $802 million (USD) 
2 
 
 
with an annual increase of 7.4 % suggested [4], that cost today equates to over $2 billion 
(USD) spread over 15 years [4-7]. Failure further down the developmental stages are 
inevitably more costly but we can learn from the continuous improvements made on the 
bioavailability and efficacy fronts to lead the way for improvements on toxicity and safety 
issues. 
Analysis of the attrition rates per therapeutic area uncovers distinctive trends for which 
attrition rates are more problematic. Oncology carries the highest failure rates for toxicity 
reasons [3], largely accounted for by the need for novel mechanisms of action, where proof 
of concept in the clinic coupled with the cytotoxic nature of the drug candidates is difficult 
to contain within disease areas. If acceptable efficacy and proof of concept for new 
oncology drugs can be achieved then the aim is to dissociate this from any toxicity they 
may inflict. 
One approach for lowering toxicity is for medicinal chemists to reformulate the chemical 
structure during the hit to lead optimisation stage of early drug discovery. Whilst this can 
be successful it is not without compromise and can affect the efficacy, solubility, 
permeability or any other desirable property the compound was originally designed for.  
An alternative approach is through the use of drug formulations; that is to use innovative 
pharmaceutical formulations that allow the safer use of drugs without altering their 
chemical structure. Whilst formulations that improve the solubility, permeability and 
efficacy of a drug have been brought to market [8, 9], their use for toxicity reduction is not 
as well established. Demonstrating the functionality of a drug formulation for toxicity 
reduction can be advantageous during development and when formulating the final 
product. For cytotoxic drugs which fall under the oncology therapeutic area, it can push the 
toxicity threshold, expanding the therapeutic index range over which a drug can be safely 
administered. The advantages translated to the patient are immense, allowing more 
effective treatment with potentially increased efficacy. 
Although formulating for cytotoxic drugs seems to be the most immediate necessity, in 
principle formulating for other therapeutic areas where toxicity is a concern is also 
possible. Successfully lowering toxicity of otherwise efficacious drugs would result in huge 
financial savings enabling drugs to be brought to market sooner. 
Formulation efforts that overcome non-toxicological issues such as improving the solubility 
or permeability of a drug compound are relatively well understood with respect to their 
3 
 
 
mechanisms of action [10-14]. For toxicity however, the mechanisms of action are not as 
well defined and as a result, formulating to reduce toxicity can be a hit or miss process. An 
understanding of the underlying mechanistic principles of how formulations mitigate drug 
toxicity may allow more informed decisions to be made about formulating for new 
compounds. This knowledge may also allow rules to be formed for the general case. 
Producing such rules would involve obtaining or gathering data from which knowledge can 
be extracted and modelled for decision making (Figure 1.1). A collection of examples for 
which formulations have been clinically shown to reduce toxicity for a range of different 
compounds may allow a database or dataset to be compiled which can be mined and 
modelled to produce generalised rules. Achieving this would allow NCEs and currently 
available drugs to be formulated to reduce their toxicity burden on the host. 
 
Figure 1.1. Modelling drug formulation data for the general case. Collected data which includes 
drug information, toxicity profiles and formulations that reduce toxicity can be modelled and 
decisions made for the general case. 
 
1.2 Problem Description 
Drug toxicity is a complex process that involves multiple pathways which manifest into an 
observable toxicity. Toxicity observed during the developmental process of NCEs becomes 
costly and time consuming in bringing the right compound to market with an acceptable 
safety profile. Compounds which display organ, mechanism-based or off-target toxicity are 
just some of the safety concerns that result in drug development failures. Drug 
formulations can help reduce some of these unwanted toxicities, but deciding which 
formulation will be successful is not a straightforward process. The use of computational 
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intelligence may help with this problem but it is recognised that this is a relatively new area 
of research.  
The current work on using computational intelligence for predictive toxicology purposes 
focuses on the prediction of specific toxicities [15-19]. This field of research draws 
enormous amounts of interest from not only the pharmaceutical industry but many other 
disciplines, owing largely to the potential of reducing or eliminating biological testing and 
reducing costs substantially. A range of in silico systems for predicting a variety of toxicities, 
such as, genotoxicity, mutagenicity or hepatotoxicity exist today. Such systems are built on 
computational human reasoning (expert systems), modelling of biochemical profiles 
(molecular modelling) or the use of experimentally produced data, providing a library of 
knowledge (data driven). Although this work can provide a foundation to build upon it does 
not provide a complete framework for which formulation predictions for toxicity reduction 
can be made. 
To do this we first need to understand the physiological and cellular mechanisms that 
contribute to the manifestation of a toxicity outcome. Generally it is accepted that a 
toxicity outcome is caused by a cascade of events. These events begin with an initial 
exposure followed by a multitude of interactions between the invading toxicant and 
organism which culminates into the observable or measurable toxic effect. 
For a formulation to reduce or prevent toxicity it must therefore interfere with some 
aspect of this toxicity pathway. This could be at the initial exposure event or further down 
the cascade. Although different chemical compounds will instigate different toxicity 
pathways there may be some common ground between two or more drug compounds. 
These drugs could be related by some measure of similarity or completely unrelated. If we 
can uncover these commonalities then a formulation that reduces toxicity for one 
compound by interfering with a common pathway should in principle work for the other 
compound too. 
This thesis therefore aims to address the following question: 
Can we predict formulations to reduce toxicity? 
Discovering common toxicity pathways for different compounds is one approach that will 
be explored, although the limitations of this method for many drug compounds and in 
particular NCE’s is that the major toxicity pathways are not always fully known. For this 
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reason alternative approaches are essential to fully explore the possibilities of this 
problem. The use of QSAR models to relate drug structure to possible toxicity outcomes is 
the other major area of study this thesis focuses on. If the activity, which in this case is the 
toxicity, of a compound can be related to its chemical structure then we can use this 
information to link other chemical structures with similar structural properties. Such 
models are data dependent and so the right information needs to be present for such 
models to be built. 
1.3 Aims 
This thesis aims to address the issues discussed above; more specifically it aims to 
introduce early workings of an area of research that is relatively unexplored; to build 
models which are able to predict formulations that would allow for toxicity reduction for 
the general case. A summary of these aims is given below: 
 Explore the underlying principles/pathways of drug toxicity, 
 What are the outcomes/endpoints of drug toxicity, 
 Discover drug formulations that reduce toxicity, 
 Define the current in silico computational approaches used in the general field of drug 
toxicity, 
 Obtain and collate scientific data that can be mined, visualised and extracted for 
interesting data relationships, 
 Use machine learning approaches to build classification models that are able to predict 
formulations for toxicity reduction for the general case, 
 Provide scientific interpretations where possible of any models built. 
Although this research will focus on the novel approaches in formulation prediction to 
reduce toxicity, the methodological aspects of this work can in theory be implemented for 
other areas of research where data driven modelling would be appropriate. 
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1.4 Methodology and Data 
This thesis is concerned with discovering, visualising and building models for the prediction 
of drug formulations to reduce toxicity. To achieve these aims the following existing 
methodologies were used: 
 Graph theory and Venn diagram representation for visual representation and data 
extraction. 
 The principles of the area under the curve (AUC), to discriminate between the 
differences in toxicity protection afforded by different drug vehicles. 
 Decision tree and Random forest ensemble methods for building classification models. 
The data used for the work in this thesis came from several sources which were compiled 
into a format suitable to aid with answering the main research questions of this thesis. Two 
main data sources were used for the work in this thesis, they are: 
 Data extracted from primary literature sources (journal papers) and compiled into a 
useable form 
 Oncology data obtained from the National Institutes of Health’s (NIH) Developmental 
Therapeutics Program (DTP) [20] 
1.5 Thesis Structure 
This thesis is arranged into seven chapters and one appendix: 
 Chapter 2 – presents a detailed literature review of the scientific aspects of drug 
toxicity and drug formulation. 
This chapter discusses the different types of drug toxicity frequently studied and reported 
in the literature. The principle mechanisms of drug toxicity are also discussed with regards 
to their pharmacokinetic and pharmacodynamic actions. A review and discussion of the 
current technologies available for drug formulations are presented in this chapter, with 
examples provided of their practical application in reducing drug toxicity. These 
technologies largely impact the pharmacokinetic or pharmacodynamic actions of a drug to 
achieve a reduction in toxicity. 
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 Chapter 3 – presents an overview of the current computational machine learning 
approaches available for in silico classification modelling.  
This chapter introduces the various computational machine learning algorithms that have 
been used in predictive toxicology studies with examples from the literature provided. An 
overview how predictive models are built is also provided and covers topics such as, data 
collection, data curation, data representation, chemical data representation, model 
validation and performance measures. 
 Chapter 4 – presents the methodology developed for the visualisation and 
representation of drug toxicity data using graph theory and Venn diagrams for the 
extraction of interesting drug-vehicle relationships.  
The methodology proposed in this chapter is demonstrated in practice through the use of 
the NIH dataset, from which interesting drug-vehicle relationships are readily visualised 
and extracted from a largely un-curated dataset. Mining the graphs thus allows interesting 
drug-vehicle relationships to be extracted and plotted using Venn diagrams to identify 
crossover sections that highlight multiple points of interest. 
 Chapter 5 – presents a methodology developed for the extraction and classification of 
toxicity data using the proposed area under the curve with interpolation and 
extrapolation approach. 
In this chapter, aspects of big data analysis and the challenges associated with such work 
are discussed. A methodology developed, based on the area under the curve principle with 
interpolation and extrapolation, is applied to the NIH dataset, for the extraction and 
classification of vehicles to build models with. Twelve pairwise vehicle comparisons are 
made from which several different binary classification models are built using random 
forest and decision tress. The results of these models are reported in chapter 6. 
 Chapter 6 – presents the results of the 12 binary classification models built using the 
area under the curve with interpolation and extrapolation approaches.  
The successful results generated using random forest and decision trees for each of the 
models are discussed with findings from the decision tree models used to provide scientific 
interpretation of the results. Furthermore, from the decision tree data it was possible to 
create partially ordered sets of vehicles for one group of compounds containing aziridine 
ring structures, from which rules could be formed. 
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 Chapter 7 – presents the conclusions drawn from the work presented in this thesis and 
provides suggestions for future work and directions of research. 
 Appendix A – includes the NIH dataset used in this thesis, curated drug structures and 
classification tables for the 12 pairwise comparisons. 
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2 
2 Literature Review 
 
This chapter provides an informative discussion based on extensive literature reviews 
covering all aspects of drug toxicity with regards to formulation. It has been structured to 
provide a thorough scientific understanding of the study of drug toxicity with respect to 
formulation work, referencing the primary sources of information discovered during 
literature searches. 
The chapter begins with an overview of drug toxicity and the various different types of 
toxicity that are frequently studied using in vitro and in vivo scientific experiments. The 
principal mechanisms of drug toxicity are discussed which show how a drug’s toxic profile 
can be linked to its pharmacokinetic and pharmacodynamics behaviour.  
Information about what a drug formulation is and the types of drugs that benefit from drug 
formulations are discussed. The different technologies currently available for drug 
formulation which have been demonstrated to reduce toxicity are also discussed and 
explanations to their mechanism of actions are reported where information was available 
to do so. References to the literature are also provided where appropriate. 
The chapter ends by constructing toxicity protection pathways which help visualise how 
formulations avert toxicity at various points of an adverse outcome pathway. 
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2.1 Drug Toxicity 
Drug toxicity is an inherent problem associated with pharmaceutical drug therapy. The 
extent of the toxicity is dependent on many factors making it a multivariate problem. Some 
of the variables associated with toxicity include species, age, sex, dose, in vivo exposure, 
route of administration, metabolism and excretion. All drugs are toxic to some degree and 
are considered to exhibit both primary intended effects and secondary unintended effects, 
known as side effects or adverse effects. Toxicology can be considered as the study of 
these adverse effects on living organisms at the cellular, biochemical and molecular level. 
The mechanisms that contribute to a toxicity outcome are related by a series of complex 
events which begin with an initial exposure (dose) that induces a multitude of physiological 
and biochemical interactions, culminating into a toxic effect. Understanding the underlying 
principles of these interactions will allow a drug’s toxic profile to be discovered and help 
ameliorate any adverse effects through formulation efforts. 
2.1.1 Toxicity Testing 
Experimentally, there are many well designed in vitro and in vivo toxicology tests that have 
been developed to study drug toxicity which vary in cost, time and information gain. 
Toxicity testing comprises of several components which include: 
1. A biological system: which can be in vitro cell lines or in vivo animal models 
2. A defined endpoint: which defines what toxicity assessment is to be made (cell viability, 
hepatoxicity, mutagenicity, ototoxicity etc.) 
3. A method of measuring the endpoint: cell survival (haemolysis of RBCs), QT interval 
(heart), glomerular filtration rate (kidneys) 
4. An analysis method to translate the result to a toxicity for example: if glomerular 
filtration rate is reduced then how much of a reduction is needed for impaired function 
(i.e. toxicity) 
5. A means of translating the in vitro and in vivo data into relevant human data (allometric 
scaling) 
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2.1.1.1 In Vitro Toxicity Testing 
In vitro toxicity testing typically involves the use of bacterial or mammalian cell cultures to 
screen for toxicity by assessment of the basal function of cells (i.e. common cellular 
functions). In vitro testing is relatively cheap to perform with a high throughput rate that 
can produce large number of data quickly. With an increasing emphasis within the scientific 
community to reduce the use of animals in toxicity testing [21] in vitro tests are increasingly 
used at the initial stages of development. Although in vitro tests were originally thought of 
as “hazard alert” tests, assessing cell viability as an indication of cytotoxicity, they are much 
more refined and developed today. In vitro test assays today are able to quantify metabolic 
rates, gene expression levels, membrane permeability, mitochondrial function, and even 
distinguish between the different cell death events of necrosis and apoptosis [22].  
In vitro toxicity testing can be performed on many cell types (e.g. RBCs, hepatocytes, kidney 
epithelial cells and fibroblasts) [23, 24]. Toxicity endpoints may include the inhibition of cell 
growth, the release of cytosolic enzymes or the consumption of O2 and ATP. Organ specific 
toxicities can be assessed in specialised cultured cells pertaining to a particular organ. 
Membrane integrity or specific cellular metabolism functions can be assessed for toxicity; 
for instance, the metabolism of glycogen in primary hepatocytes or the beating rate in 
myocardial cells [25].  
Of the formulation work discovered in the literature, it was found that the majority of in 
vitro toxicity testing was largely related to RBC haemolysis measurements [26-28] with 
much fewer in vitro toxicity tests reporting the use of kidney [24, 29], liver [23, 30] or heart 
cells [31]. 
2.1.1.2 In Vivo Toxicity Testing 
In vivo toxicity testing uses laboratory animals to assess haematological and histological 
parameters [32-34] as a measure of cellular dysfunction which provide indications of organ 
toxicities. Haematological assessment typically involves the use of biomarkers (short for 
biological markers) that are objectively measured from a sample of blood (see section 
2.3.2). Histological examinations are assessments of organ tissue, which are stained and 
observed under a microscope to understand the morphology of the toxicity inflicted upon 
the different cells of a particular organ (see section 2.3.3). In vivo testing allows the toxicity 
to be assessed within a functional biological system, enabling a laboratory to examine 
different dosing schedules, administration routes and species. In vivo testing can provide 
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real time data over a specified period of time with multipoint toxicity endpoints 
investigated simultaneously.  
The majority of the formulation work found in the literature typically used rats or mice as 
part of their in vivo toxicity testing experiments. Blood cell counts and clinical chemistry 
parameters were measured to assess various organ toxicity endpoints [33, 35, 36]. Many of 
the in vivo toxicity studies found in the literature additionally assessed the differences in 
the pharmacokinetics between formulated and non-formulated drugs. The differences 
observed were then used to provide scientific interpretations for why a formulation was 
able to reduce the toxicity of a drug [29, 35]. In this thesis, the term ‘non-formulated’ refers 
to the alternative administration of the drug used to compare the formulated drug against.  
Both in vitro and in vivo toxicity testing do however come with some disadvantages. For in 
vitro studies the results are difficult to translate into a biological toxicity response. Cells in 
culture can behave differently to cells in vivo and a collective organism toxicity profile 
cannot be easily constructed from in vitro results. Furthermore pharmacokinetic 
parameters relating to the absorption, distribution, metabolism (biotransformation) and 
excretion (ADME) which dictate the exposure levels of organs cannot be adequately 
assessed in vitro. 
In vivo results are on the whole more informative of how an entire organism behaves when 
exposed to a toxicant. Biotransformations, membrane permeability, intrinsic intercellular 
synthetic pathways and inter-organ influences are more likely to be preserved in a living 
organism than in a cultured cell line [25]. The disadvantage of animal studies however, is 
that the data do not always correlate with human toxicity data. Different species will 
sometimes metabolise drugs differently; these differences can result in very different 
toxicity profiles for the same drug when tested in different species [37, 38]. For this reason 
it is sometimes difficult to predict the toxic effect in humans from rat or mice data, with a 
concordance of approximately 43% suggested for the prediction of human toxicity from 
rodent data [39]. 
2.2 Types of Toxicity 
For NCEs in development there are many toxicity endpoints that need to be satisfied before 
compounds can progress through the clinical stages prior to market approval. Preclinical 
toxicological investigations typically include toxicokinetic and non-clinical pharmacokinetic 
(PK) studies, general toxicity studies, reproduction toxicity studies, genotoxicity studies, 
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and for drugs that are intended for extended use, an assessment of its carcinogenicity is 
required [40]. The earliest toxicity considerations for NCEs typically involve investigations of 
their acute, chronic, sub-acute and sub-chronic toxicities for which there are accepted 
practises recommended by various regulatory bodies [41-50] that aim to uphold the 
principles of the 3Rs (Replacement, Reduction and Refinement) [21]. 
In vitro and in vivo studies can then be designed around assessing any specific toxicological 
concerns such as that of hepatotoxicity, nephrotoxicity and cardiotoxicity amongst others. 
Of the various toxicity endpoints that were studied with respect to the formulation work 
discovered in the literature, a brief overview of these toxicities is provided below. Although 
alternative interpretations for these toxicities may exist, they are discussed here to reflect 
how they were collectively described within the literature discovered. 
 Acute toxicity – is defined as the adverse effects observed immediately or a short time 
following (within 24 hours) a single or multiple dose of a substance [51].  
 Systemic toxicity – is defined as the toxicity that can be seen in some part of the body 
or in the behaviour of an animal that is not considered normal behaviour. A reduced 
body weight or organ weight, apathy, lethargy, anaphylaxis, somnolence and loss of 
appetite can all be considered as symptoms of systemic toxicity [52]. 
 Local toxicity – is defined as the toxicity observed at the site of administration as a 
result of exposure to a toxicant [53, 54]. 
 Hepatotoxicity – is defined as the clinical and pathological injury inflicted upon the liver 
which impairs its function when compared to baseline levels. Due to the liver’s function 
as the major site of drug metabolism, and interposed between the gastrointestinal 
tract and systemic circulation, it is one of the most susceptible organs to drug toxicity 
[23, 30]. 
 Nephrotoxicity – is defined as the injury caused by a toxicant on the kidneys resulting in 
impaired renal function, often measured as a decrease in glomerular filtration rate [24, 
29, 33]. 
 Cardiotoxicity – is defined as impaired or failed heart function as a result of exposure to 
a toxicant. Cardiotoxicity can result from cardiomyocyte death via apoptosis and 
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necrosis, or cardiomyocyte dysfunction resulting in arrhythmia, which can be reversible 
[31, 34]. 
 Ototoxicity – is the defined as toxicity to the ear and more specifically to the cochlea 
and auditory nerve. Symptoms of ototoxicity include hearing loss, vertigo and tinnitus 
[55, 56]. 
 Pulmonary toxicity – is the defined as the adverse effects resulting in an impairment in 
lung performance. Pulmonary toxicity can result in breathlessness, fatigue, 
inflammation and swelling [57, 58]. 
 Testicular toxicity – is defined as the toxicity which results in a decreased reproductive 
function. Testicular toxicity may affect spermatogenesis, as well as the hormone levels 
of testosterone or follicle-stimulating hormone [34, 58, 59]. 
 Myelotoxicity – is defined as the decrease in the cells responsible for immunity as a 
result of bone marrow suppression. Since all immune cells originate from 
haematopoietic cells in the bone marrow then a myelotoxic compound by definition 
can also be considered immunotoxic. A decrease in the production of leukocytes, 
erythrocytes, and thrombocytes increases the chances of infection, anaemia and 
severe bleeding [60, 61]. 
2.3 Measuring Toxicity 
Toxicity can be measured and reported in several ways depending on the type of 
experiment used to study the toxicity of a drug. In vitro and in vivo toxicity studies generate 
different types of toxicity measurements which can be related to the toxicities described 
above. The toxicity measurements reported in the literature work can be split into three 
different types: dose measurements, biomarker measurements and histopathological 
indications. These methods for toxicity can provide distinct information about the nature of 
a drug’s toxicity but may also be interlinked to build an overall toxicity profile of a drug. 
2.3.1 Dose Measurements 
Dose measurements are used when attempting to quantify how toxic a drug substance is 
and can be compared by means of dose amount required to cause lethality; for instance if a 
drug causes lethality in mice at a dose of 10 mg/kg body weight and another causes 
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lethality at a dose of 0.1 mg/kg body weight, then evidently the latter is much more toxic. 
Some of the dose measurements that were reported in the literature are listed below: 
 MTD – Maximum tolerated dose is the maximum dose administrable that does not 
result in unacceptable toxicity, organ dysfunction or death [51]. 
 LD50 – The median lethal dose is the dose required to kill half the tested population 
over a specified period of time [27, 62]. 
 Cell viability – Cell viability dose measurements are in vitro examinations which use 
RBCs (haemolysis) or primary cell lines that are exposed to a toxicant. The dose at 
which cell viability is reduced by a certain percentage is reported. The lysis of RBCs is 
generally considered an indication of acute or systemic toxicity. The viability of primary 
cell types is an indication of potential organ toxicity in vivo [23, 24, 26-31]. 
 NOAEL – The No-observable-adverse-effect-level (NOAEL) is the dose level at which no 
adverse effect is observed. 
2.3.2 Biomarker Measurements 
Biomarkers are endogenous measureable macromolecules that can be measured as an 
indicator of biological state or integrity. Biomarkers are useful for taking real time 
measurements over an extended period of time so that long term exposure studies can be 
investigated. They may be more reproducible as signs of toxicity than other measurements 
and can be specific not only to an organ but for specific types of injuries. Due to the 
specialised function of organs such as that of the liver (detoxification of xenobiotics) and 
kidneys (removal of organic molecules from the blood), they possess specialised cells which 
express unique enzymes and other biomolecules that allow them to carry out their 
function. When a drug acts upon an organ to cause toxicity, it frequently results in the 
necrosis or apoptosis of the organ’s cells, the contents of which are released into the 
bloodstream. These unique biomarkers can then be sampled from the blood and assessed 
for specific toxicities. Because biomarkers are quantifiable they can be used to assess the 
severity of the toxicity. The biomarkers that were frequently reported in drug formulation 
literature are briefly discussed below: 
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2.3.2.1 Hepatotoxicity 
The biomarkers most commonly used to assess drug induced liver injury (DILI) are alanine 
transaminase (ALT) and aspartate transaminase (AST). Whilst AST is found in other tissue 
types, ALT is predominantly found in the liver and is therefore a more specific biomarker of 
liver toxicity. The ratio of AST to ALT is sometimes used to differentiate liver injury from 
other organ damage. Elevated levels of AST and ALT are clinical indications of liver 
dysfunction, although ALT levels are sometimes more elevated than AST in certain types of 
injury, for example in hepatitis [63]. ALT and AST levels do not always correlate well with 
histopathology data and so alternative biomarkers can be assessed [23, 64, 65].  
Glutathione S-transferase (GST) is an inducible phase II detoxification enzyme that catalyses 
the conjugation of glutathione to phase I metabolites. GST is found uniformly distributed 
around the centrilobular region of the liver whereas the aminotransferases are principally 
found in the periportal hepatocytes. Furthermore GST shows good correlations between its 
measured levels and histopathological data [63, 65, 66].  
Gamma-glutamyl transpeptidase (GGT) is an enzyme that transfers γ-glutamyl functional 
groups to amino acids. Although present in the kidneys and pancreas, GGT serum levels can 
be used as a biomarker for hepatobiliary injury and in particular for cholestasis [67, 68]. 
Sorbitol dehydrogenase (SDH) catalyses the reaction of converting sorbitol to fructose, it is 
primarily found in the cytoplasm of hepatocytes and can be considered a specific 
biomarker hepatocellular injury [69]. 
2.3.2.2 Nephrotoxicity  
Kidney injury results in the reduction of the glomerular filtration rate (GFR), which 
compromises the kidneys’ ability to excrete waste, leading to renal failure [70, 71]. Blood-
urea-nitrogen (BUN) and serum creatinine (SCr) are the biomarkers frequently used to 
assess kidney toxicity. Urea is produced from the digestion of proteins and creatinine from 
the breakdown of creatine phosphate in muscles. Both urea and creatinine are filtered out 
by the kidneys for excretion. Elevated levels of BUN or creatinine within the blood are 
indications of a decrease in glomerular filtration rate which in turn is a sign of renal 
dysfunction or toxicity [33, 72, 73]. A delayed onset in the reduction of GFR is sometimes 
an issue when using BUN and SCr as biomarkers, making them non-sensitive and non-
specific to injury [63, 74]. They are also influenced by a variety of factors including age, 
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gender, muscle mass and diet making them variable between individuals and sometimes 
inconsistent within the same individual [71, 74]. 
The lysosomal brush border enzyme N-acetyl-β-D-glucosaminidase (NAG) is sometimes 
preferred and abundantly found in proximal tubular cells [63, 72]. 
Total protein can also be used as a biomarker of kidney injury as damage to the podocytes 
present in the Bowman’s capsule results in a leakage of plasma proteins. If the 
reabsorption of these proteins reaches a saturation point due to this injury or if damage to 
the tubular protein reabsorption complex occurs, proteinuria can result despite regular 
glomerular filtration rate [63, 75, 76]. 
2.3.2.3 Myelotoxicity 
Biomarkers of bone marrow toxicity can be assessed using cytology and flow cytometry 
data. Leucocytes, erythrocytes and thrombocytes are cells of the blood that are commonly 
used as biomarkers for bone marrow toxicity [60]. Since blood cells are produced within 
the bone marrow a reduction in the cell count from baseline levels would suggest some 
form of bone marrow suppression or toxicity. Flow cytometry methods are able to classify 
and differentiate between the major cell lines but unable to evaluate cellular morphology. 
For this reason flow cytometry is often coupled with cytology studies [35, 59, 60]. 
2.3.3 Histopathology Indications 
Histopathology examinations provide qualitative assessments of the changes in cellular 
morphology as a result of toxicity. The morphological assessment of the gross and 
microscopic appearance of organs can provide a broad knowledge of the mechanisms of 
drug toxicity. Where biomarkers may fail to identify the sites of organ injury, 
histopathological examinations are more transparent to the location of injury and provide 
visual data relating to the integrity of the cellular architecture [77]. By examining the 
morphological changes within the cellular network of organs it is possible to identify the 
toxicity outcomes those changes relate to [33, 34, 59, 68]. 
Organ weights and body weight changes are also ways to assess the acute and systemic 
toxic profile of a toxicant when compared to a control [52]. Although not strictly a 
histopathological assessment, the weight of organs (tissues) can be reflective of organ 
toxicities [34, 52, 59]. A reduction in organ weight over a period of time when exposed to a 
toxicant demonstrates necrosis and loss of cellular matter of that organ. This not only 
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implies organ susceptibility to a toxicant but can also demonstrate the distribution profile 
of the toxicant in vivo. 
2.4 Principal Mechanisms of Drug Toxicity 
Before a drug can exert any toxic effect it must reach and come into contact with the site at 
which it produces toxicity. To do this a drug’s physicochemical properties must allow it to 
be absorbed into the body, avoid rapid elimination and travel to this site. Understanding 
how a drug travels through a body can provide insights into the toxicity profile of a drug. 
ADME studies are therefore key to understanding the fate and, more importantly, the toxic 
manifestations of a drug. Once a drug has reached its intended target it must then undergo 
a series of molecular interactions which ultimately disrupt the architecture of specialised 
cells often leading to necrosis or apoptosis of the cell. A drug’s toxic profile can therefore 
be broken down into two principal stages that can be explained using the principles of 
pharmacokinetics and pharmacodynamics. 
2.4.1 Pharmacokinetics 
Pharmacokinetics (PK) is the study of a drug’s fate as it travels through an organism. More 
specifically it is considered as the study of the time course of a drug’s absorption, 
distribution, metabolism and excretion (ADME). Pharmacokinetic studies are important for 
understanding the body’s actions towards a drug so that effective therapy can be applied. 
The term toxicokinetics is sometimes used when pharmacokinetic principles are applied to 
study the relationship between the systemic exposure of a drug and its toxicity [50, 78]. 
ADME studies provide a scientific model based on experimentation and mathematical 
interpretation to understand how the body responds when challenged with a drug 
substance. Essentially toxicity can occur at any of the points along the route the drug takes 
from the point of administration and absorption through to the point of excretion. The site 
of drug absorption is important since it allows a drug passage into the body. The most 
important physicochemical properties that affect the rate of absorption are the lipophilicity 
and solubility of the drug [79]. Absorption generally occurs via three major routes which 
include the gastrointestinal tract, the lungs and the surface of the skin and can be 
considered as non-invasive administration routes. Drugs that are difficult to administer 
non-invasively can be given by alternative routes, including the intravenous (i.v.), 
intramuscular (i.m.), subcutaneously (s.c.) and intraperitoneal (i.p.) routes. These sites are 
therefore susceptible to any toxic effects of the drug and dictate how a drug will enter into 
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the bloodstream. Absorption through the skin takes a drug into the peripheral blood supply 
whilst absorption through the lungs leads into the pulmonary circulation. For orally 
administered drugs that enter through the gastrointestinal tract absorption is via the portal 
vein which leads into the liver. Intravenously administrated drugs have the advantage of 
entering systemic circulation instantaneously whilst drugs administered intramuscularly, 
subcutaneously or intraperitoneally require an absorption step before entering systemic 
circulation. Once within the bloodstream a drug is carried and distributed around the body 
where it is able to enter specific organs and disrupt cellular functions. Accumulation of 
sufficient concentrations of drug within organs can lead to specific organ toxicity and 
dysfunction. 
It is important to note that pharmacokinetic measurements are influenced by experimental 
protocol and considerations need to be taken for several experimental conditions including 
the dose, route of administration, and species selection. Several key pharmacokinetic 
parameters are useful when explaining drug toxicity and are discussed briefly below: 
Area under the Curve (AUC): The AUC refers to the area under the plasma concentration 
time curve and is a measure of a drug’s concentration from the point of administration to 
the point where the concentration in the plasma is considered negligible. It can also be 
used as a measure of drug levels over time in specific tissues. The AUC is useful when 
comparing different routes of administration since it indicates how quickly a drug gets into 
and out of systemic circulation and is a good indicator of total drug exposure.  A reduction 
in AUC could therefore be argued as a means to reduce toxicity [80, 81]. For a typical AUC 
plot following oral administration see Figure 2.1 below, the Cmax and Tmax are also 
established from AUC plots.  
Cmax and Tmax: The Cmax is the maximum concentration that is observed over the measured 
time period and the Tmax is the time at which this occurred. The Cmax is one of the most 
important pharmacokinetic parameters with regards to drug toxicity, with some 
toxicological concerns showing better correlations  with Cmax levels than with AUC [82].  If 
the peak exposure dose of a drug exceeds its toxicity threshold then toxicity will occur 
(Figure 2.1). Maintaining the Cmax below the drug’s toxicity threshold can prevent toxicity 
[80]. This rationale can be explained by looking at the therapeutic index (TI) of a drug, 
which is the ratio of the dose required to produce a toxic effect and the dose required for a 
therapeutic effect. A drug with a high threshold is easier to manage since the margins 
between toxicity and therapy are wider and so the in vivo drug concentrations do not need 
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to be closely monitored. Alternatively, for a drug that has a low therapeutic threshold the 
margins between safety and toxicity are narrow and the Cmax value of the administered 
drug must be closely monitored to avoid any toxicity (Figure 2.1). 
 
Figure 2.1. Area under the plasma concentration time curve for a single oral dose administered at 
time zero showing Cmax, Tmax and the therapeutic index window. With the Cmax value exceeding the 
toxic level it is likely that an adverse outcome will be observed. 
 
Volume of Distribution (Vd): Sometimes referred to as the apparent volume of distribution 
is the volume of plasma in which the total amount of drug would need to be dissolved to 
reflect the concentration measured in plasma. It is a reflection of the drug binding in 
plasma as well as tissues. Since only unbound drug is assumed to pass biological 
membranes the plasma-protein binding of a drug will affect the volume of distribution. For 
a drug that has a high volume of distribution, it indicates that a large amount of the drug 
has reached the intracellular fluid of organs and tissues. This accumulation may leave 
susceptible organs prone to toxicity issues [83, 84]. Alternatively a drug that results in acute 
or systemic toxicity and remains largely within the bloodstream, may be safer if it was 
directed elsewhere [80]. 
Clearance (Cl): The clearance is a measure of the volume of plasma cleared of drug per unit 
time. Although the clearance is constant, the amount of drug contained in the clearance 
volume will change in relation to the plasma drug concentration. It is the sum of all 
clearance processes such as hepatic metabolism, biliary secretion renal metabolism and 
renal filtration [85, 86]. Most drugs are eliminated via the liver and kidneys and so hepatic 
and renal clearances are important in measuring this pharmacokinetic parameter. The 
clearance rate will have an influence on the mean residence time (MRT) of a drug, which is 
the average time a drug resides within the body [86]. For a drug that has the potential to 
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cause toxicity a low clearance rate would augment the situation, allowing the drug to 
accumulate and exceed its toxicity threshold. 
Elimination half-life (t1/2): The elimination half-life is defined as the time required for the 
concentration of a drug to reach half its original value [86]. It is influenced largely by the Vd 
and the Cl of the drug indicating the half-life can change if these parameters are altered 
[85]. The half-life is useful to estimate how long therapy may need to be stopped for if 
toxicity is observed in a patient, assuming the drug follows a linear one-compartmental 
model. Because the elimination half-life is a quantitative measure of the presence of drug 
within the body it is commonly used to establish the dosing schedule. The half-life may also 
help explain the relationship between a drug and tissue accumulation, protein binding and 
receptor binding, all potential causes of toxicity. 
Elimination rate constant (ke): The elimination rate constant is the amount of change in 
drug concentration due to elimination over time. It is linked to the Vd given that a large 
volume would take longer to clear which could translate to toxicity. A zero-order rate 
constant would suggest that elimination is constant, independent of plasma drug 
concentration, whereas a first-order rate would indicate a drug’s elimination is 
proportional to its concentration. Although the amount of drug eliminated in a first-order 
rate changes with plasma drug concentration, the fraction of drug eliminated remains 
constant. The elimination rate constant therefore represents the fraction of drug 
eliminated per unit of time. A first-order rate constant would revert back to a zero-order 
rate when the drug concentration exceeds a limit, for example during an overdose. 
Pharmacokinetic parameters describe a dynamic, multi-factorial complex sequence of 
physiological events that could help explain toxicological outcomes and provide important 
information which includes: 
 The in vivo plasma concentration of a drug, which cannot be accurately determined 
from the dose since not all the dose may be absorbed. 
 The concentration of a drug at a particular site which could potentially be a target 
organ that is susceptible to any toxicity related to that drug. 
 The AUC plot of the drug which determines the overall exposure to a drug. 
 The maximum in vivo concentration reached which can be useful during drug 
monitoring for adverse effects. 
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 The elimination kinetics of a drug which determines how long lasting an exposure to a 
drug may be. 
2.4.2 Pharmacodynamics 
Pharmacodynamics is the study of the effects a drug has on an organism. To understand 
toxicity fully we must appreciate both the pharmacokinetic and pharmacodynamic aspects 
of a drug’s toxicity profile. Whilst pharmacokinetic studies are useful for understanding 
how a drug is absorbed, distributed, metabolised and excreted, they do not fully explain 
how a drug interacts with biological molecules and membranes to result in a toxic 
outcome. Pharmacodynamic (or toxicodynamic) studies are useful when explaining the 
chain of events a drug may instigate leading to some form of toxicity. Upon administration 
a drug must first reach its site of toxicity before any adverse outcomes can develop. This 
relationship is explained by the pharmacokinetic parameters described above. Once the 
drug has reached its intended site a series of biochemical interactions are triggered at the 
cellular level. These biochemical interactions can be collectively described as an adverse 
outcome pathway (AOP). For example the conversion of acetaminophen to its toxic 
metabolite N-acetyl-p-benzoquinone imine (NAPQI) by cytochrome P450s leading to the 
depletion of the endogenous antioxidant glutathione (GSH) allowing NAPQI to interact with 
biomolecules causing liver toxicity [87-89]. 
An AOP builds on the more commonly used definition, mode-of-action (MOA), to describe 
and relate a series of events leading to an adverse outcome. Unlike the MOA, the AOP 
involves exposure to a chemical and the effects observed on an individual and population 
level, for example, population decline [90, 91]. Although the literature definition of an AOP 
is continuously evolving it can be thought of as beginning with an exposure to a chemical, 
which for in vivo studies would be described by the pharmacokinetic parameters of a drug. 
It ends by describing the impact this exposure will have on a population. The AOP pathway 
incorporates the toxicity pathway which begins with a molecular initiating event (MIE) and 
describes the events occurring at a cellular level and the MOA pathway which additionally 
describes the impact of the toxicity pathway at the organ and individual level [92]. Figure 
2.2 conceptualises these pathways showing the overlap of their events and how they can 
be thought of collectively as an adverse outcome pathway. 
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Although an AOP spans multiple levels of biological organisation it will initially depend on 
the pharmacokinetic profile of a drug. For a drug to be cardiotoxic for instance it must first 
reach the heart before any toxicity pathway can be initiated [93] 
 
Figure 2.2. Adverse outcome pathway showing the extents of the toxicity pathway and mode-of-
action pathway with respect to the toxicity profile of a drug governed by pharmacokinetic and 
pharmacodynamic principles (Adapted from [90, 91]). 
 
The bioavailability of a drug, which is the amount of a drug reaching systemic circulation 
and its biodistribution profile, which explains what organs a drug is able to reach, can be 
explained by the pharmacokinetics of a drug. Once the drug has reached its target organ 
several key events are described which help sequence the chain of events which 
subsequently occur. These key events can then be considered as the pharmacodynamics 
response of a drug. The MIE is the first of these events and is described as the initial 
interaction between a drug and a biomolecule, such as a ligand-receptor interaction or 
binding to proteins and nucleic acids [90]. The physicochemical properties of a drug will 
allow certain MIEs to occur. For this reason the chemical structure of a drug is important 
and several MIEs are possible, leading to multiple toxicity endpoints. To complicate 
matters, it is generally accepted that several drugs with vastly different chemical structures 
may lead to the same toxicity endpoint [92]. Once the MIE has occurred a cascade of 
downstream events are then activated. Some of these downstream events are described as 
key events, which relates to a change in biological state that is measurable and leads to the 
progression of an adverse outcome, for example the depletion of endogenous antioxidants 
or the activation of inflammatory responses [87, 88, 94, 95]. These key events are therefore 
quantifiable through some measure and provide a cut off level below which toxicity is not 
observed [93]. For example in section 2.3.2, biomarkers were discussed as a measure of 
toxicity. Key events in the progression of liver toxicity can thus be considered as the 
elevation of the biomarkers ALT and AST. If a significant increase in the concentration of 
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those biomarkers is detected then sufficient injury to the liver has occurred for there to be 
a change in the biological state of the liver or its cellular functions. Finally to link the MIE 
and the key events to an adverse outcome we must define key relationship events. Key 
relationship events are connecting events that occur throughout an adverse outcome 
pathway that are not molecular initiating events or key events. They are can be described 
as the steps that link one key event to another and are identified as one upstream and one 
downstream event. Through identification of upstream events it may be reasonable to infer 
or extrapolate the downstream events which may result [90-93]. 
2.5 Drug Formulation 
Active pharmaceutical ingredients (API) are seldom administered alone; rather they are 
given in combination with one or more non-medicinal agents resulting in a drug 
formulation. Informed decisions regarding the selection of these agents, sometimes 
referred to as excipients, can serve specialised functions. Formulations can therefore be 
considered as carriers that provide some beneficial aid to the drug they carry. This 
beneficial aid may serve specific functions that improve the therapeutic efficacy of the 
drug, possibly by improving its solubility, permeability or stability for instance.  
Routinely the primary objective of a drug formulation is to ensure the delivery of a drug at 
a desired location, in the right form, at the correct rate and dose, whilst maintaining the 
chemical integrity of the compound. Once the pharmacokinetic and pharmacodynamics 
profiles of a drug are known, formulators can then begin to address innate deficiencies that 
may hinder the effectiveness of a compound. Formulations therefore profoundly impact 
the ADME profile of a drug and the associated pharmacodynamic response. Ideally a drug 
that has been formulated would be dosed orally due to high patient compliance although in 
practice this is not always possible. Formulation approaches therefore consider 
administration routes since this can impact the adverse outcome a drug may exhibit. 
In the first instance a formulator will make decisions based solely on the molecular 
properties of a drug (log P, pKa, molecular weight) ensuring that the formulation is at least 
compatible with the drug in question and the excipients used are biocompatible. To add a 
dimension of complexity to the problem, formulating for toxicity reduction then considers 
the in vitro and in vivo toxicity data to ensure the formulation can bring an acceptable 
element of safety with the clinical use of the drug. 
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2.6 Drugs with Toxicities Reduced by Formulation 
All drugs will present some kind of toxicity provided a sufficient dose is administered [71]. 
The toxicity of many well studied drugs follows a predictable time course and can be 
regulated by closely monitoring the dose an individual is exposed to. If an individual shows 
any signs of toxicity then the dose is reduced or stopped until they sufficiently recover. In 
principle this practice does work but is tedious in providing effective therapy to a patient. 
Reducing the administered dose to overcome toxicity may inadvertently reduce the dose to 
a concentration that is therapeutically ineffective. 
Formulating a drug to reduce its toxicity is therefore an interesting challenge for the 
pharmaceutical community. Formulations that address poor solubility or permeability 
issues are commonplace within the industry [8, 9] but formulations that avert or reduce 
toxicity are much less understood and studied. 
The decision to formulate for toxicity reduction must arise from the need to allow the safer 
use of therapeutically effective drugs that are hindered by their toxicity profiles and for 
which no suitable alternative exists; it is therefore not surprising that cytotoxics and anti-
infectives are the major classes of the compounds that have been formulated in this way. 
Cytotoxics, given their mode of action are naturally some of the most toxic drugs [96, 97] in 
use today and anti-infectives such as the aminoglycosides are known to be highly 
neurotoxic and nephrotoxic [98-101]. Other classes of drugs formulated for toxicity 
reduction include the analgesics [66, 102, 103] and antidiabetics [104].  
A list of the more commonly formulated drugs for toxicity reduction that were reported 
within the literature are listed in Table 2.1. The list provided is by no means exhaustive, 
rather it is there to provide an overview of the types of drugs that have been formulated 
for toxicity reduction. 
Many of the drugs in Table 2.1 have been formulated using several different approaches, 
each achieving a reduction in their toxicity when compared to the non-formulated drug.  
It is important to state that all the formulation efforts discovered from the literature were 
either in vitro experiments or in vivo animal experiments. Although in vivo human data for 
some formulations may exist, they were not easily accessible or widely available. 
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Table 2.1. List of commonly formulated drugs to ameliorate toxicity and their therapeutic class. 
 
Drug Therapeutic Class Drug Therapeutic Class 
Acetaminophen Analgesic Hamycin Anti-infective 
Albendazole Anti-infective Irinotecan Cytotoxic 
Amphotericin B Anti-infective Mitomycin C Cytotoxic 
Annamycin Anti-infective/Cytotoxic Mitoxantrone Cytotoxic 
Camptothecin Cytotoxic Nimesulide Analgesic 
Cantharidin Cytotoxic Nimodipine Anti-ischaemia 
Cisplatin Cytotoxic Nobiliside A Cytotoxic 
Clofazimine Anti-infective Nystatin Anti-infective 
Clotrimazole Anti-infective Paclitaxel Cytotoxic 
Cyclosporin Immunosuppresant Propofol Anesthesia 
Diclofenac Analgesic Repaglinide Anti-diabetic 
Docetaxel Cytotoxic Stavudine Anti-infective 
Doxorubicin Cytotoxic Topotecan Cytotoxic 
Gentamicin Anti-infective N/A N/A 
 
2.7 Current Methods of Formulation 
The formulation approaches that are shown to reduce drug toxicity are discussed in this 
section. The range of formulation technologies can be loosely grouped into five different 
types: 
1. Encapsulating formulations – E.g. Liposomes, polymeric micelles 
2. Micro/nano formulations – E.g. Disks, spheres, suspensions, emulsions, colloids, 
dispersions 
3. Lipid based formulations – E.g. Liposomes, suspensions, emulsions, colloids 
4. Complexation formulations – E.g. Cyclodextrins, dendrimers, liposomes, micelles 
5. Antidote formulations – E.g. Vitamins, protein extracts, oils, cyclodextrins 
Although the formulations can be grouped into the categories above, there exists an 
element of cross-over between them with the possibility that formulations can be in more 
than one category. For example, liposomes can be categorised as encapsulating, 
micro/nano, lipid based and complexation based formulations. 
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It is possible to group these technologies into four main strategies by which they operate to 
reduce toxicity. These mechanisms of action are briefly discussed below: 
Strategy 1: Active organ protection; provides toxicity relief through the co-administration 
of other agents which provide a counter measure to the toxic manifestation of a drug. This 
strategy largely covers the use of antidotal formulations for toxicity reduction. 
Strategy 2: Avoiding susceptible targets; which circumvents toxicity by preventing a toxin 
reaching an organ or other target that is prone to its toxic effects. If a drug can be encased, 
encapsulated or diverted so that it cannot interact with such an organ then it is reasonable 
to assume that any adverse effects can be avoided. This strategy uses encapsulating, 
complexation and lipid based formulations to achieve its mechanism of action. 
Strategy 3: Active Targeting; a strategy which actively targets a drug to the site of 
infection/disease, thereby accumulating in lesser amounts at sites where unwanted 
toxicities may occur. This strategy uses encapsulating based formulations to target a drug 
to the site it is required and away from susceptible tissues. 
Strategy 4: Availability Enhancement; if we can enhance the availability of a drug (through 
improved solubility and permeability for example) this dictates that the dose and therefore 
the exposure of the drug (toxin) can be reduced. Improving solubility of a drug also 
prevents toxicities relating to aggregation and precipitation in aqueous environments. This 
strategy makes use of the encapsulating, complexation, lipid based and nano/micro based 
formulation technologies. 
Of the four strategies, strategy 1 would mainly act upon the pharmacodynamic aspects of a 
drug’s toxicity, whereas strategies 2, 3 and 4 would be governed by the pharmacokinetic 
aspects of a drug’s toxicity profile. 
An informative discussion about the preparation, practical use and properties of the 
commonly used technologies for toxicity reduction is given below: 
2.7.1 Liposomes 
Liposomes are lipid bilayer spherical vesicles first described by Bangham et al. (1964) [105]. 
They are composed of phospholipids which consist of a glycerol backbone attached to a 
polar (hydrophilic) phosphate head group and a non-polar (hydrophobic) tail chain. Tail 
chains vary in length typically from 3 to 24 carbons. Unsaturated tail chains consist of long 
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fatty acids with at least one carbon-carbon double bond (C=C). Phosphatidylcholines (PC), 
also known as lecithin are the principal phospholipids used due to their double fatty acid 
chain which form bilayers in water in preference to micelles [106, 107]. They are derived 
naturally from soya bean and egg yolk and their relatively low cost makes them an ideal 
choice for liposome construction. When placed in water the tail chains repel each other 
and are forced to aggregate forming a lipid bilayer membrane with the tail chains facing 
inwards and the head groups facing out (Figure 2.3). The tail chains along the perimeter of 
this membrane remain exposed to the aqueous environment and have an energy 
associated with them. To minimise this instability the membrane closes forming a spherical 
vesicle. A further energy penalty is incurred as the bilayer membrane bends, the energy of 
the system first increases and then decreases as the edges meet and disappear as 
additional phospholipids are incorporated into the final spherical vesicle which 
encapsulates an internal aqueous core (Figure 2.3) [108-110]. Phosphatidylethanolamine 
(PE), phosphatidylglycerol (PG) and phosphatidylserine (PS) make up the other frequently 
used phospholipids, with sphingolipids, cholesterol and hydrophilic polymer conjugated 
lipids also contributing to the structure and properties of liposomes [111]. 
 
Figure 2.3.Phospholipid assembly in liposome formation. (A) Phospholipid bilayer membrane with 
outward facing hydrophilic head group and inward facing hydrophobic tail chains. (B) Membrane 
closing to minimise instability of perimeter tail chains exposed to aqueous environment. (C) 
Complete assembly of liposome encapsulating hydrophilic drugs (red) within the core and 
hydrophobic drugs (green) within the lipid bilayer. Attached polymers onto the surface of the 
liposome allow them to avoid RES uptake and provide targeting abilities. 
 
Using naturally occurring phospholipids in their construction means they are generally 
considered biologically inert, biodegradable, weakly immunogenic with low intrinsic toxicity 
[109, 112]. Due to their amphiphilic nature liposomes are able to entrap hydrophilic drugs 
within their aqueous core whilst hydrophobic drugs are carried within their lipid bilayer 
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(Figure 2.3). Liposomes may also be used for the effective encapsulation and delivery of 
drugs intended for topical application, peptides and nucleic acids [113-120]. 
Liposomes can be formulated to differ in size, charge, composition and lamellarity. 
Typically they range in size from approximately 20 nm to several micrometres [108, 121]. 
They can be classed in several ways according to their structure, size, function, composition 
and preparation method [112]. Uni-lamellar vesicular (ULV) liposomes are constructed of a 
single membrane bilayer and range from 20 nm to 100 nm in diameter. Multi-lamellar 
vesicles (MLV) and multi-vesicular (MVL) liposomes are generally larger with a diameter 
range of up to 1 µm [108, 109, 112]. The choice of liposomal bilayer components influences 
properties such as the rigidity, fluidity, charge density, permeability, release kinetics and 
targeting ability with biological components upon administration. For instance unsaturated 
phospholipids used in the construction of liposomes result in more permeable less stable 
bilayers, a result of the carbon-carbon double bonds creating a kink in their tail chains 
which prevents tight packing [108]. Incorporating PS into the bilayer helps to increase the 
aqueous space of liposomes [122] whilst cholesterol influences the fluidity of the 
membrane, increasing its rigidity, resulting in a longer retention and slower release rate of 
encapsulated drugs in vivo [123]. For improving the circulation times of liposomes, lipids 
are conjugated to polymers such as polyethylene glycol (PEG) [51, 109, 124]. Such surface 
coatings can offer steric hindrance to opsonin adsorption onto bilayers reducing their 
uptake and removal from circulation by the cells of the reticuloendothelial system (RES) 
[125, 126]. Ligands can also provide targeting properties to liposomes, allowing more 
efficient therapy by targeting encapsulated drugs to areas of therapeutic requirement. This 
also reduces drug wastage by allowing drugs to reach sites not normally accessible by the 
free drug whilst also avoiding elimination by the RES [35, 127-129]. 
2.7.1.1 Liposomes in Toxicity Formulations 
Liposomes are extremely diverse in structure and capabilities and as a result they have 
been shown to reduce the toxicity of drugs by the methods described in strategies 2, 3 and 
4 of section 2.7. Liposomes can be considered as complexation based, encapsulation based, 
lipid based and micro/nano based formulations (see section 2.7). Due to the diverse nature 
of liposome construction many objectives can be fulfilled through liposomal formulation. 
Liposomal technology used for toxicity reduction has been shown to improve the solubility 
and permeability of difficult to administer drugs, provide controlled release capabilities, 
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target drugs to sites of toxicity and also prevent the interaction of a drug with susceptible 
tissues.  
Many classes of drugs have been formulated for toxicity reduction through the use of 
liposomes. Some of these classes include: antibacterial aminoglycosides, antifungal 
polyenes and cytotoxic anticancer drugs.  
Aminoglycosides are an interesting class of drug that have been successfully formulated for 
toxicity reduction through liposomal encapsulation. Aminoglycosides such as netilmicin, 
gentamicin, tobramycin, amikacin, kanamycin, streptomycin, and sisomicin have all been 
shown to be potent nephrotoxins in vivo. They accumulate within the renal cortex, 
although concentrations are not necessarily correlated to toxicity [130, 131]. Retention of 
aminoglycosides within the epithelial cell lining of the S1 and S2 segments of the proximal 
tubules after glomerular filtration results in morphological and functional changes which 
lead to renal failure and can be detected as a gradual rise in serum creatinine [132, 133]. 
To mitigate this toxicity several studies have provided evidence for the successful 
formulation of aminoglycosides with liposomes. It was previously reported that cationic 
polybasic aminoglycosides have a high affinity for anionic acidic phospholipids such as 
phosphatidylinositol (PI) found on renal brush border membranes [134]. Mimoso et al. 
(1997) [62] therefore prepared liposomes to encapsulate netilmicin with a lipid 
composition of phosphatidylcholine:cholesterol:phosphatidylinositol, at a molar ratio of 
5:1:4. When administered intravenously into mice a reported LD50 value of >50 mg/kg was 
reported for the formulated drug when compared to the non-formulated value of 24 ± 4 
mg/kg. The authors proposed that a reduction in toxicity was due to the inclusion of 
phosphatidylinositol into the liposomal membrane which competed for the drug over renal 
phosphatidylinositol, thereby ensuring the drug avoided interaction with the kidneys. The 
inclusion of phosphatidylcholine also improved the encapsulation efficiency of the 
liposome for netilmicin. Pharmacokinetic data reported by the group demonstrated an 
increase in the half-life (t1/2) of the formulated drug and a decrease in the volume of 
distribution (Vd) when compared to the non-formulated drug. Similar pharmacokinetic 
profiles were reported for the liposomal encapsulation of gentamicin [135] (Table 2.2). 
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Table 2.2. Pharmacokinetic data of liposomal encapsulated netilmicin and gentamicin. Vd units – 
L/kg* or mL (at steady state)†. Data adapted from [62, 135]. 
 
Drug/Formulation Species 
Admin 
route 
Dose 
(mg/kg) 
AUC 
(µg.h/mL) 
t1/2 
(min) 
Vd Reference 
Netilmicin (non-
formulated)* 
Mice i.v. 4.0 
- 
12.1 15.7 
[62] 
Netilmicin-Liposome* Mice i.v. 4.0 - 137.6 2.9 
Gentamicin (non-
formulated)† 
Mice i.v. 20.0 
8.08 
61.8 3.68 
[135] 
Gentamicin-Liposome† Mice i.v. 20.0 185.25 228.6 0.59 
Gentamicin (non-
formulated)† 
Rats i.v. 20.0 
37.51 
36.0 0.47 
[135] 
Gentamicin-Liposome† Rats i.v. 20.0 426.55 241.2 0.28 
 
These data suggest liposomal encapsulation of aminoglycosides markedly alters the 
pharmacokinetics and reduces toxicity by diverting the drug away from the kidneys, as the 
reduction in the Vd and increase in AUC compared to free drug indicate. A lower Vd 
demonstrates the encapsulated drug spends more time in systemic circulation rather than 
distributed amongst peripheral tissue and organs. This formulation would therefore satisfy 
the mechanism of action suggested by strategy 2 of section 2.7, whereby toxicity is reduced 
by avoiding accumulation within susceptible organs (i.e. the kidneys). 
Bermudez et al. (1990) [136] reported similar acute toxicity improvements when 
formulating the aminoglycoside amikacin into liposomes. They proposed that although 
liposomes are taken up mainly by the liver and spleen, amikacin would be slowly released 
by phagocytic cells which would result in a high sustained level of drug within the serum; 
which reflects the pharmacokinetic data reported by Mimoso et al. (1997) [62]. 
Furthermore biodistribution studies of the aminoglycoside gentamicin encapsulated into 
liposomes have shown accumulation to be prevalent within the liver but minimal amounts 
within the kidneys when administered intravenously in vivo using animal models [124, 135, 
137], reflecting the nephroprotection offered through liposomal encapsulation of 
aminoglycosides. 
Polyene antifungal drugs such as amphotericin B, nystatin and hamycin have also benefited 
from encapsulation through liposomal formulation. Amphotericin B is currently the only 
antifungal treatment for systemic mycotic infections in man [138, 139]. However acute 
toxic adverse effects including, fever, nausea, chills, emesis and hypokalaemia limit the use 
of the drug. In addition nephrotoxicity, detected by an increase in serum creatinine and 
urea becomes apparent with continued use resulting in irreversible kidney impairment 
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[140]. To attenuate this toxicity, several studies have reported promising results using 
liposomes to ameliorate the toxicity of polyene drugs. For example Szoka et al. (1987) [141] 
prepared several amphotericin B encapsulating liposomal formulations with different lipid 
compositions and reported that cholesterol-containing liposomes offered the greatest 
toxicity protection when injected i.v. into mice, with an LD50 of 19 mg/kg compared to 2.3 
mg/kg for the non-formulated drug. Interestingly the size of the liposome proved 
significant, with larger cholesterol-containing liposomes and multilamellar liposomes 
producing lethality at a lower dose than small unilamellar liposomes.  
Acute toxicity studies of liposomal encapsulated amphotericin B that incorporated 
cholesterol and polyethylene glycol derivatised distearoyl phosphatidylethanolamine (PEG-
DSPE) have also been reported with a MTD of the formulated drug to be 13 mg/kg when 
injected i.v. into mice whereas for the non-formulated drug a MTD of 0.8 mg/kg was 
recorded [51]. The inclusion of PEG-DSPE was responsible for an increased blood residence 
time of the liposomes which may have prevented amphotericin B from reaching the 
kidneys in sufficient enough concentrations to cause toxicity, which suggests that their 
mechanism of action for toxicity prevention is via strategy 2 discussed in section 2.7. Other 
studies have supported these findings, providing pharmacokinetic data that shows a 
reduced accumulation of drug within the kidneys but an increased accumulation within the 
liver and spleen [140]. 
From these data it was proposed that liposomal encapsulation reduces the toxicity of 
amphotericin B by three principal mechanisms: 1) it changes the interaction of 
amphotericin B with its receptors. It is known that amphotericin B binds preferentially to 
ergosterol in fungal cells and causes toxicity in animals by binding to cholesterol in 
mammalian cells [139, 142, 143]. The inclusion of cholesterol into liposomal formulations 
therefore competes with cholesterol in mammalian cells for amphotericin B, thereby 
reducing toxicity, 2) it changes the organ distribution of the drug as shown by a reduced 
accumulation within the kidneys and 3) it alters the rate at which the drug is released from 
the liposome since cholesterol inclusion provides rigidity and stability, it slows down the 
rate at which the drug is released from the liposome and becomes free to reach its target 
receptors.  
Other polyenes that have benefited from liposomal encapsulation include hamycin and 
nystatin. Cholesterol inclusion into liposomal formulations for hamycin were shown in vitro 
to reduce RBC lysis toxicity and in vivo improve the MTD of the drug when administered i.v. 
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to mice [144]. A relatively simplistic liposomal formulation using dimyristoyl 
phosphatidylcholine (DMPC) and dimyristoyl phosphatidylglycerol (DMPG) to encapsulate 
nystatin was also shown to reduce the lysis of RBCs in vitro when compared to the non-
formulated drug. Interestingly the addition of empty liposomes to non-formulated drug 
significantly reduces the lysis of RBCs in vitro. This liposomal formulation of nystatin 
administered i.v. to mice resulted in a MTD of 16 mg/kg compared to the non-formulated 
drug which has a MTD of 4 mg/kg [145, 146]. 
Finally, cytotoxic anticancer drugs are an interesting group of compounds for which 
liposomal formulation has been shown to improve their therapeutic index and reduce 
toxicity. Of particular interest are the anthracycline antibiotics that are effective anti-
neoplastic agents used in the treatment of adult and paediatric cancers. Anthracyclines 
such as doxorubicin, epirubicin and annamycin are however limited by toxicities such as 
haematopoietic suppression, emesis, nausea, alopecia and dose related cardiotoxicity 
[147]. Although multiple mechanisms are involved in the toxicity pathway of anthracycline 
induced cardiotoxicity, oxidative stress – resulting in lipid peroxidation and depletion of 
antioxidants which produces a loss of myofibrils and vacuolisation of myocardial cells – 
seems to be one of the most common causes of cardiomyopathy and heart failure. 
Several studies on the liposomal encapsulation of doxorubicin have reported positive 
findings. Herman et al. (1983) [148] developed positively charged cardiolipin liposomes to 
encapsulate doxorubicin. Upon administration of a 1.75 mg/kg i.v. dose of the formulated 
and non-formulated drug given at 3-week intervals over a period of 21 weeks (7 injections) 
to five beagle dogs they reported a reduction in food consumption and a significant loss in 
body weight of the non-formulated group. This group also showed signs of toxicity upon 
administrations, by shaking, staggering and lying down, which was also apparent in the 
formulated group but to a lesser extent. Alopecia was noted in the non-formulated dogs 
but was entirely prevented in the liposomal formulation of doxorubicin. This study also 
reported heart histopathology data and showed lesions consisting of vacuolisation and 
myofibrillar loss was noted in all 5 dogs of the non-formulated group. In contrast, there 
were no abnormalities found in the liposomal encapsulated group. No evidence of tissue 
abnormalities were found in the lungs, liver, kidneys, spleen or small intestine of 
formulated and non-formulated drug. Bone marrow suppression between the groups was 
also comparable as a reduction in WBC, RBC, haemoglobin and haematocrit was reported. 
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Similar data on the cardiotoxicity protection offered though liposomal encapsulation of 
doxorubicin and annamycin have been reported in other in vivo studies using mice and rat 
models [60, 149, 150]. van Hoesel et al. (1984) [149] additionally reported on the 
biodistribution of the negatively and positively charged liposomes that were developed for 
doxorubicin encapsulation. They showed that doxorubicin levels in the heart and kidneys 
through liposomal formulation were reduced compared to the non-formulated drug which 
partly explains the cardioprotective nature of doxorubicin liposomal encapsulation (Table 
2.3). 
From the data in Table 2.3 it becomes apparent that both the negatively and positively 
charged liposomes were significantly able to reduce concentrations within the heart over a 
24hr period when compared to the non-formulated doxorubicin. 
Table 2.3. Biodistribution of liposome encapsulated doxorubicin following an i.v. injection of 1 
mg/mL into rats. Plasma concentration expressed in µg/L and tissue concentration expressed in 
mg/kg tissue weight. Data adapted from [149]. 
 
Tissue 
Doxorubicin 
(non-formulated) 
Doxorubicin in -ve 
liposomes 
Doxorubicin in +ve 
liposomes 
Plasma (4hr) 5.89 ± 0.56 2.04 ± 0.50 35.0 ± 4.06 
Heart (4hr) 6.72 ± 0.67 2.53 ± 0.43 0.74 ± 0.26 
Kidneys (4hr) 12.97 ± 1.00 4.41 ± 0.67 1.26 ± 0.51 
Liver (4hr) 3.76 ± 0.56 18.3 ± 2.5 1.44 ± 0.36 
Spleen (4hr) 4.53 ± 0.88 54.6 ± 12.0 2.63 ± 0.93 
Plasma (24hr) 2.84 ± 0.57 2.03 ±  0.39 0.44 ± 0.25 
Heart (24hr) 3.28 ± 0.86 0.66 ± 0.37 0.58 ± 0.04 
Kidneys (24hr) 5.58 ± 1.10 1.76 ± 0.28 0.24 ± 0.05 
Liver (24hr) 1.13 ± 0.10 30.2 ± 10.0 1.06 ± 0.42 
Spleen (24hr) 4.02 ± 0.57 2.04 ± 0.33 5.06 ± 1.89 
 
Interestingly whilst negatively charged liposomes seemed to accumulate within the liver 
and spleen, positively charged liposomes remained within the plasma at the 4hr stage but 
over a 24hr period also accumulated within the liver and spleen. 
Liposomal formulation of doxorubicin also provides a good example of targeted delivery for 
toxicity reduction which corresponds to strategy 3 of the section 2.7. The theory suggests 
that if a drug can be specifically targeted to a site of disease then it will naturally 
accumulate to lesser amounts in susceptible tissue thereby avoiding toxicity. This theory 
was tested by Li et al. (2009) [127], who developed stealth liposomes containing 
polyethelyene glycol (PEG) and the ligand transferrin. Liposomes containing PEG are able to 
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avoid uptake by the RES, whilst the transferrin receptor is known to be highly expressed at 
tumour sites [127]. In vivo pharmacokinetic studies of these liposomes in health rats 
revealed significant changes in the AUC and clearance of the drug from the plasma when a 
single dose of 5 mg/kg was administered i.v. (Table 2.4).  
Table 2.4 shows liposomal encapsulation of doxorubicin with or without conjugated 
transferrin ligands are able to significantly increase the AUC, MRT and terminal half-life (t1/2 
(β)) of doxorubicin. The volume of distribution (Vd) and plasma clearance (Cl) was also 
reduced suggesting doxorubicin in liposomal formulations remained within systemic 
circulation compared to non-formulated doxorubicin. 
Table 2.4. Pharmacokinetics of doxorubicin encapsulated into liposomes containing PEG and 
transferrin ligands. Rats dosed at 5 mg/kg i.v. Data adapted from [127]. 
 
Drug/Formulation Species 
Admin 
route 
AUC 
(µg/ml) h 
Vd 
(L/kg) 
Cl  
(L/(kg h) 
MRT  
(h) 
t1/2 (β) 
(h) 
Doxorubicin (non-
formulated) 
Rats i.v. 
0.538 ± 
0.145 
4.000 ± 
1.000 
50.000 ± 
1.500 
2.431 ± 
0.050 
5.476 ± 
1.690 
Doxorubicin-Liposome 
(containing PEG) 
Rats i.v. 
1276.458 ± 
195.444 
0.150 ± 
0.025 
0.020 ± 
0.005 
23.464 ± 
1.128 
20.584 ± 
0.905 
Doxorubicin-Liposome 
(containing PEG & 
transferrin) 
Rats i.v. 
1221.262 ± 
80.795 
0.205 ± 
0.015 
0.020 ± 
0.000 
22.585 ± 
2.594 
22.238 ± 
2.059 
 
To determine whether these changes in pharmacokinetics would also confer better 
targeting capabilities, the formulations were injected i.v. into tumour bearing mice (HepG2 
cells) at a dose of 5 mg/kg. The AUC for various tissues samples was reported over a 96 
hour period (Table 2.5). 
Table 2.5. Biodistribution study of liposome encapsulated doxorubicin. Tumour bearing mice were 
administered an i.v dose of 5 mg/kg. AUC tissue units – h.µg/g 
 
Tissue 
Doxorubicin (non-
formulated) 
Doxorubicin-Liposome 
(containing PEG) 
Doxorubicin-Liposome 
(containing PEG & 
transferrin) 
Heart 114.4 77.6 87.2 
Liver 105.8 190.9 252.9 
Spleen 180.9 269.3 253.0 
Lung 74.5 121.1 110.2 
Kidney 120.0 110.4 105.1 
Tumour 46.1 166.1 238.7 
 
The biodistribution data in Table 2.5 provides some interesting insights into these 
liposomal formulations. Both liposomal formulations (with and without transferrin ligands) 
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showed a significant reduction in the accumulation of drug in the heart compared to non-
formulated doxorubicin and would therefore reduce the cardiotoxic burden of the drug. 
The liver, spleen and lung concentrations were also significantly different for the non-
formulated drug compared to the two liposomal formulations. These organs all showed a 
larger accumulation compared to the non-formulated drug, which possibly suggests a 
redistribution of drug that would normally accumulate within the heart but is now 
accumulating within the liver, spleen and lungs. The differences in kidney accumulation 
were insignificant between the three different administrations. Of particular interest was 
the accumulation of drug within the inoculated tumour. The study reports that 
accumulation of drug within the tumour of mice administered liposomes containing both 
PEG and transferrin, was significantly higher than the non-formulated drug and the PEG 
only liposomes. These data suggest that transferrin conjugated liposomes encapsulating 
doxorubicin are able to successfully target tumour sites and avoid accumulation within the 
heart, thereby reducing the cardiotoxicity of the drug and improving the efficacy [127].  
The avoidance of liposomal encapsulated doxorubicin to accumulate within the heart 
explains the reduction in cardiotoxicity seen with the many liposomal formulations of 
doxorubicin described above and as such complies with strategies 2 and 3 discussed in 
section 2.7. 
From the liposomal drug formulations that have been shown to reduce drug toxicity it is 
evident that difference in liposomal charge, size and composition and conjugation are 
important in achieving toxicity reductions. There are insufficient data to derive a general 
rule that can be applied to liposomal composition which would imply toxicity protection to 
a wide variety of drugs, so currently liposomal formulations have to be assessed on a case 
by case basis. 
2.7.2 Polymeric Micelles 
Micelles are small spherical structures that spontaneously form when amphiphilic 
surfactant molecules are placed in water. As with phospholipids aggregating to form 
liposomes, surfactant molecules in water form aggregates (clustered monomers) with their 
hydrophilic heads in contact with the water orientating their hydrophobic single tails within 
the micelle centre forming a core-shell structure [106, 107]. Their ability to self-associate is 
a result in the decrease in free energy of the system. As the concentration of surfactant 
molecules within a system increases it approaches a critical micelle concentration (CMC) 
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[151] where unfavourable energy sequesters the hydrophobic tails away from water and 
begin to form micelles. Surfactants forming micelles show a strong tendency to do so above 
the critical micelle temperature, termed the Krafft point (Tk). A single surfactant molecule 
has limited solubility and below the Krafft point micellization is poor. As the temperature of 
the system increases however, the solubility increases until the CMC is reached and 
micelles are formed [152, 153]. Surfactant based micelles however tend to have a relatively 
high CMC rendering them unstable upon high dilution. For this reason they are sometimes 
unsuitable for use in biological systems as drug carriers.  
Polymeric micelles have therefore emerged as the micelles of choice for use in biological 
systems. Due to their low CMC values they are less prone to disintegration upon dilution 
and so make an ideal biomaterial which maintains its integrity in aqueous environments. 
They are formed from amphiphilic block copolymers that contain a hydrophilic and 
hydrophobic block which self-assemble to form micelles in aqueous solutions above their 
CMC [154] (Figure 2.4). As the CMC is reached, the hydrophobic segments of the copolymer 
associate to minimise contact with water molecules resulting in a hydrophobic core with an 
outward extended hydrophilic shell known as the corona [151]. Large core-forming 
segments of block copolymers exhibit strong aggregation tendencies and so high 
thermodynamic stability. High aggregation of core forming segments may result in high 
hydrophobic or electrostatic interactions within the core, resulting in lower CMC values 
making polymeric micelles kinetically stable [151, 155], it has also been suggested that 
polymeric micelles may not exist in equilibrium with their amphiphilic block copolymer 
monomers [156] retaining integrity even under high dilution. The hydrophobic cores of 
polymeric micelles are therefore able to encapsulate hydrophobic drugs with the 
hydrophilic corona offering the drug protection against an aqueous environment (Figure 
2.4). This aids poorly water soluble drugs to overcome bioavailability and solubility issues as 
well as drug aggregation problems in vivo [157]. The predominant shape of micelles is 
spherical although rods, tubules, needles and hexagonally packed hoops have been 
reported too [151, 158]. Amphiphilic diblock copolymers are most frequently used to 
prepare polymeric micelles although triblock and grafted copolymers are other options. 
The choice of amphiphilic copolymers determines the differences observed in micellar 
morphologies [159]. Block copolymers are linear polymers of the A-B (diblock) or A-B-A 
(triblock) arrangement (where A = a hydrophilic block and B = a hydrophobic block) 
whereas grafted copolymers consist of one copolymer side chain grafted to the main 
copolymer [160]. Appropriate choice of copolymers determines the physiological and 
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biological properties of polymeric micelles; this may include lower CMC values which 
improves stability, increased circulation times, evasion from RES, high drug entrapment and 
targeted delivery [161-165].  
Block copolymers that have been used in drug formulation include Poly(N-
vinylpyrrolidone)-block-poly(D,L-lactide) as a solubiliser for hydrophobic anticancer drugs 
[81], poly(ethylene glycol)-block-poly(ε-caprolactone-co-trimethylenecarbonate) as an 
encapsulation method for amphotericin B [26] and poly(ethylene glycol)-block-poly(D,L-
lactic acid) for the encapsulation of multiple poorly soluble drugs including paclitaxel, 
etoposide and docetaxel [161]. Methods of preparation can vary but for poorly soluble 
drugs the solid dispersion method, oil-in-water emulsion solvent evaporation method or 
the dialysis method can be used [165].  
 
Figure 2.4. Polymeric micelle construction from amphiphilic monomer units. Amphiphilic block 
copolymer units made of both hydrophilic and hydrophobic blocks self-assemble to form 
polymeric micelles entrapping hydrophobic drugs within their core, shielded from an aqueous 
environment by the outer corona shell. 
 
2.7.2.1 Polymeric Micelles in Toxicity Formulations 
Polymeric micelles are useful solubilising agents and as such have been used in the 
formulation of poorly soluble drugs. Furthermore they are now being studied as 
alternatives to the solubilising agents currently used in practice today, since the solubilising 
agents themselves can sometimes confer toxicity. Some of the most poorly soluble drugs in 
use today are the anticancer drugs for which suitable solubilising agents are difficult to find. 
Traditionally they are formulated using low molecular weight surfactant such as 
polyethoxylated castor oil (Cremophor EL) or polysorbate 80 (Tween 80). These surfactants 
however present clinical concerns of their own such as hypersensitivity and neurotoxicity 
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[166]. Polymeric micelles have therefore emerged as an alternative for the solubilisation of 
poorly water soluble drugs that have toxicity concerns. Polymeric micelles can achieve high 
drug loading and protect drugs from premature degradation in vivo due to their core shell 
structure that can shield drugs from metabolism.  
Diblock copolymers are particularly well suited for polymeric micelle construction and 
several studies have demonstrated their capability to solubilise paclitaxel, an anti-cancer 
drug of the taxene family. Kim et al (2001) developed a polymeric micellar system using the 
biodegradable amphiphilic diblock copolymer, monomethoxy poly(ethylene glycol)-block-
poly(D,L-lactide) (mPEG-PDLLA) to solubilise paclitaxel [80]. This polymeric micellar 
formulation of paclitaxel (PTX-mPEG-PDLLA) was compared to the current clinical 
formulation of Cremophor EL/ethanol (50:50), known as Taxol, for toxicity, 
pharmacokinetic and biodistribution differences.  
The MTD of PTX-mPEG-PDLLA was assessed in vivo in mice and determined to be 50 mg/kg, 
in comparison to Taxol which resulted in a MTD of 20 mg/kg. Similarly acute toxicity studies 
to establish the LD50 of the formulations in male rats showed PTX-mPEG-PDLLA to have an 
LD50 of 205.4 mg/kg, compared to 8.3 mg/kg for Taxol.  
To understand these toxicity differences the pharmacokinetic behaviour and 
biodistribution of these formulations was studied in vivo in mice bearing murine B16 
melanoma cells. Following a single i.v. injection of 50 mg/kg of PTX-mPEG-PDLLA or 20 
mg/kg of Taxol the pharmacokinetic profile was fitted by a two-compartment model (Table 
2.6). 
Table 2.6. Pharmacokinetic data following i.v. administration of PTX-mPEG-PDLLA formulation 
compared to Taxol in mice. Data adapted from [80]. 
 
Drug/Formulation 
Admin 
route 
Dose 
(mg/kg) 
AUC0-∞ 
(µg.h/mL) 
Cmax 
(µg/mL) 
Tmax 
(h) 
t1/2(β) 
(h) 
Cl 
(L/h/kg) 
Vd 
(L/kg) 
Taxol (non-
formulated) 
i.v. 20.0 94.38 
94.08 ± 
3.54 
0.05 0.34 0.22 0.27 
PTX-mPEG-PDLLA i.v. 50.0 69.75 
82.83 ± 
4.16 
0.05 0.21 0.72 0.88 
 
The pharmacokinetic data in Table 2.6 shows that despite the larger dose of administered 
PTX-mPEG-PDLLA, the AUC and Cmax values are in fact lower when compared to Taxol. The 
authors of the study also suggested that given an equivalent dose of 20 mg/kg, the AUC of 
PTX-mPEG-PDLLA was shown to be 10 to 20-fold lower than for Taxol, although organ 
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distributions remained comparable. These data however were not reported in the 
literature [80]. 
A similar study solubilising paclitaxel using polymeric micelles made of the diblock 
copolymer, poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) (PTX-PVP-PDLLA) reported 
similar findings when comparing their micellar formulation to Taxol. The authors 
determined the MTD of Taxol in mice to be 20 mg/kg whilst their micelle formulation, PTX-
PVP-PDLLA, resulted in a MTD of >100 mg/kg. The pharmacokinetic data reported in this 
study are from equivalent doses of 20 mg/kg, administered i.v. to mice bearing C26 
tumours. A non-compartmental open model was fitted (Table 2.7) [81]. 
Table 2.7. Pharmacokinetic data following i.v. administration of PTX-PVP-PDLLA formulation 
compared to Taxol in mice. Vd - at steady state, C0 - extrapolated peak plasma concentration. Data 
adapted from [81]. 
 
Drug/Formulation 
Admin 
route 
Dose 
(mg/kg) 
AUC0-∞ 
(µg.h/g) 
C0 (µg/g) t1/2 (h) 
Cl 
(L/h/kg) 
Vd 
(L/kg) 
Taxol (non-formulated) i.v. 20.0 91.8 ± 10.9 199.2 1.05 0.21 0.22 
PTX-PVP-PDLLA i.v. 20.0 18.6 ± 3.7 45.4 0.56 1.02 0.78 
 
The pharmacokinetic data in Table 2.7 show that at equivalent doses the micellar 
formulation (PTX-PVP-PDLLA) produces a lower AUC and extrapolated peak plasma 
concentrations (C0). Biodistribution data from this study also show that PTX-PVP-PDLLA is 
able to reduce the concentrations of the drug accumulating within various organs when 
compared to Taxol (Table 2.8). 
Table 2.8. Biodistribution study of PTX-PVP-PDLLA following i.v. administration of 20 mg/kg into 
mice. AUC0.25-24 - h.µg/g. Data adapted from [81]. 
 
Tissue Taxol (non-formulated) PTX-PVP-PDLLA 
Liver 301.9 ± 35.8 260.1 ± 25.0 
Spleen 83.8 ± 12.2 46.3 ± 55.4 
Kidney 162.3 ± 14.8 61.5 ± 8.6 
Lung 99.8 ± 14.7 58.1 ± 5.2 
Heart 94.8 ± 9.8 30.3 ± 3.3 
Muscle 35.4 ± 3.4 20.7 ± 1.4 
 
At an equivalent dose of 20 mg/kg, the PTX-PVP-PDLLA micellar formulation resulted in less 
paclitaxel accumulation within all the organs, in comparison to the clinical formulation 
Taxol. 
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The results from these studies suggest that a micellar formulation of paclitaxel (PTX-mPEG-
PDLLA or PTX-PVP-PDLLA) is able to reduce drug accumulation within organs, although the 
volume of distribution was reported to increase marginally when compared to Taxol. A 
reduction in AUC, peak plasma concentration and terminal half-life is observed with these 
formulations whilst the clearance of the drug is slightly increased. Although the 
pharmacokinetic and biodistribution data may suggest that the drug is removed quickly 
from systemic circulation and this naturally confers to an improved toxicity profile, in actual 
fact the changes in the pharmacokinetic and biodistribution of the drug through micellar 
formulation allow for a larger dose to be administered without observing any toxicities and 
would therefore improve the efficacy of the drug. Certainly in vitro the micellar formulation 
was shown to be equipotent against murine C26, EMT-6 and human OVCAR-3 cancer cell 
lines [81]. The gain in MTD must therefore result in better tolerability of the micellar 
formulation compared to the Cremophor EL/ethanol formulation. 
Other paclitaxel carrying micelles that have been developed include amphiphilically 
modified chitosan derivatives, consisting of hydrophobic alkyl chains and hydrophilic glycol 
groups conjugated to a chitosan backbone (PTX-OGC). These micelles were able to achieve 
a high drug loading capacity and produced no hypersensitivity reactions in guinea pigs 
when compared to an equivalent dose of Taxol which resulted in anaphylaxis upon 
administration. The MTD of PTX-OGC micelles in mice was reported to be 100 mg/kg 
compared to 25 mg/kg for Taxol and the LD50 reported as 123.1 mg/kg and 50.7 mg/kg for 
PTX-OGC and Taxol respectively. Intravenous administration of PTX-OGC at a dose that is 
half its LD50 value resulted in no histopathological changes in the heart, liver, spleen, lung, 
and kidneys of mice. In vitro cytotoxicity studies using human hepatoma HepG2 cells 
showed micelles without paclitaxel (OGC micelles) to be non-toxic however the Taxol 
formulation of Cremophor EL/ethanol without paclitaxel resulted in cytotoxicity. The 
cytotoxicity of drug loaded micelles (PTX-OGC) resulted in an IC50 value of 0.28 (± 0.14) 
µg/mL which was lower than that of Taxol whose IC50 was 0.79 (± 0.36) µg/mL. Although 
Taxol shows strong cytotoxicity it may be partially attributed to the formulation of 
Cremophor EL/ethanol but in contrast the cytotoxicity of PTX-OGC micelles is probably due 
to the drug alone [167]. 
Amphotericin B as discussed in section 2.7.1.1 is a polyene antifungal that presents local 
and acute toxicity concerns, such as phlebitis, fever, chills and nephrotoxicity. These 
toxicities are partly related to its affinity for cholesterol in mammalian cell membranes but 
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also due to its relatively poor aqueous solubility which results in a toxic aggregated form of 
the drug [168]. To overcome this toxicity due to aggregation, several polymeric micelle 
formulations have been developed to improve the solubility of the drug. Clinically, 
amphotericin B is administered in sodium deoxycholate (Fungizone), a bile acid that 
behaves as a detergent to solubilise the drug, although haemolytic behaviour has been 
associated with this formulation. Yu et al. (1998) [157, 169] developed polymeric micelles 
based on poly(ethylene oxide)-block-poly(b-benzyl-L-aspartate) (PEO-PBLA) which solubilise 
amphotericin B during self-assembly (AmB-PEO-PBLA). In vitro haemolysis studies using rat 
RBCs showed Fungizone to result in 100 % RBC lyses at a drug concentration of 3.0 µg/mL 
after 30 min of incubation. In contrast, AmB-PEO-PBLA micelles at a concentration of 3.0 
µg/mL resulted in no lyses for up to 24 hours, suggesting amphotericin B was gradually 
released from the micelles [157]. PEO-PBLA micelles without amphotericin B were shown 
to be non-haemolytic at a concentration of 0.7-1.0 mg/mL [157, 169]. To understand why 
this toxicity protection is afforded by the micelles, UV/VIS spectrum analysis revealed that 
AmB-PEO-PBLA micelles produced a spectrum that is characteristic of solubilising 
monomeric amphotericin B, whereas UV/VIS of Fungizone produced a spectrum that 
suggested amphotericin B was in an aggregated form [169]. Since the aggregated form of 
amphotericin B is partly related to its toxicity, the solubilisation of amphotericin B in PEO-
PBLA micelles maintains its monomeric form which translates to a reduction in toxicity. 
Cisplatin is a platinum based anticancer drug administered intravenously to treat various 
types of cancer. It consists of a central platinum atom, bonded to two ammonias and two 
chlorines. Tumouricidal activity results from the displacement of chloride by water during 
aquation, allowing the drug to interact with DNA and interrupt the mitotic phase of the cell 
cycle. Due to its low molecular weight, cisplatin is widely distributed into almost all tissue. 
The clinical use of cisplatin is however hindered by several toxicities associated with it, 
including ototoxicity, myelotoxicity, and in particular nephrotoxicity [94, 97]. Targeting 
cisplatin to a tumour site would therefore not only enhance efficacy but also reduce 
toxicity. 
To do this Mizumura et al. (2001) [170] bound cisplatin to the aspartic acid residues of 
poly(ethylene glycol)-poly(aspartic acid) (PEG-ASP) block copolymer via ligand substitution, 
which in aqueous media formed polymeric micelles containing cisplatin (PEG-ASP-Cis). They 
investigated the plasma clearance and biodistribution of PEG-ASP-Cis micelles or non-
formulated cisplatin by administering an i.v. dose of 150 µg into mice bearing Lewis lung 
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carcinoma cells. Whilst the plasma concentration of the non-formulated drug fell to below 
5 % of injected dose after 4 hours, the PEG-ASP-Cis injected dose only fell to 42 % after 4 
hours. The accumulation of PEG-ASP-Cis within the tumour was also significantly higher 
than that observed for non-formulated drug, however no difference in the kidney 
accumulation was observed between PEG-ASP-Cis and non-formulated drug.  
Toxicity assessments were made using body weight changes, clinical blood and pathological 
analysis. Following three 5 mg/kg i.v. injections of either PEG-ASP-Cis or non-formulated 
drug into mice the body weight changes observed on day 11 were reported. Body weight 
changes for PEG-ASP-Cis were in fact not significantly different to control animals, with a 
maximum loss of 3.3 %, whilst the non-formulated drug resulted in a 5 % body weight loss. 
Male rats were used for clinical and pathological assessments, following a 10 mg/kg 
injection of PEG-ASP-Cis or non-formulated drug. Table 2.9 shows the renal function of rats 
on day 7 after administration. 
Table 2.9. Renal function analysis of rats following administration of PEG-ASP-Cis and non-
formulated drug after 7 days. Data adapted from [170]. 
 
Drug/Formulation Species Admin route Dose (mg/kg) BUN (mg/mL) 
Creatinine 
(mg/mL) 
Cisplatin (non-formulated) Rats i.v. 10.0 67.3 ± 20.5 0.82 ± 0.23 
PEG-ASP-Cis Rats i.v. 10.0 24.0 ± 4.4 0.26 ± 0.09 
Control (saline) Rats i.v. - 20.6 ± 2.6 0.24 ± 0.06 
 
The data reported in Table 2.9 suggest that no nephrotoxic effects were apparent following 
administration of PEG-ASP-Cis, since the renal function parameters are in line with the 
saline control animals. Non-formulated drug however elevated levels of both BUN and 
creatinine 7 days after the administration of a 10 mg/kg dose. Renal pathological 
assessment revealed that rats administered non-formulated drug presented tubular cell 
degeneration which was not observed in the PEG-ASP-Cis treated rats. The data from this 
study show how PEG-ASP-Cis is able to accumulate to greater amounts within tumour sites. 
In vivo efficacy experiments reported in the study showed the tumouricidal effects of PEG-
ASP-Cis to be as effective as the non-formulated drug but with a reduced nephrotoxic 
burden [170]. 
From the data collected on polymeric micelles it is apparent that they achieve their toxicity 
reduction by strategies 3 and 4 discussed in section 2.7. That is they are able to actively 
target drugs to the site of disease as seen with cisplatin micelles that are able to 
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preferentially accumulate within a tumour, or they enhance the availability of the drug as 
seen with amphotericin B (monomeric vs aggregated form). 
2.7.3 Cyclodextrins 
Cyclodextrins (CD) are cyclic glucose oligosaccharides, consisting of (α-1,4)-linked α-ᴅ-
glucopyranose units. Common naturally occurring cyclodextrins consist of 6, 7 or 8 ᴅ-
glucopyranose units and are referred to as α-, β- and γ-cyclodextrin respectively (Figure 
2.5) [171].  
 
Figure 2.5. α, β and γ-cyclodextrin containing 6, 7 and 8 glucopyranose units respectively. 
 
From the steric arrangement of the glucose units, cyclodextrins form toroidal shaped 
structures that resemble a truncated cone. The inner side of the torus-like structure is less 
polar than the outer, resulting in a hydrophilic outer surface and hydrophobic inner core or 
cavity (Figure 2.6). In aqueous environments the hydrophobic cavity is occupied by water 
molecules which are energetically unfavourable and are readily substituted with “guest 
molecules” such as small hydrophobic drug compounds [172]. Ejecting the enthalpy rich 
water molecules from the cavity decreases the ring strain, producing a more stable energy 
state [171-173]. This complexation with hydrophobic compounds in aqueous media has 
been the basis behind the use of cyclodextrins for pharmaceutical applications. Inclusion 
complexes are formed provided the drug molecules are of the appropriate size and 
physiochemical properties. Covalent bonds are neither formed nor broken during 
complexation [174], with complexes readily dissociating in aqueous solution and free drug 
molecules remaining in equilibrium. Complexes can be formed with the entire drug or a 
specific portion in a typically 1:1 or 1:2 drug:cyclodextrin ratio [171, 173, 175]. The 
hydrophilic external hydroxyl groups remain exposed to the aqueous environment and so 
create a water soluble cyclodextrin-drug complex. Inclusion complexes offer profound 
effects to the physicochemical properties of the drug they carry. Most commonly they 
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enhance the solubility, permeability and bioavailability of drug molecules. Because 
cyclodextrins “lock” a drug within the complex they provide stability from degradation by 
UV light, heat and oxidation [172].  
In crystalline form only the surface molecules of the cyclodextrin can form inclusion 
complexes. This can be significantly enhanced by heating the cyclodextrin/drug mixture to 
encourage complexation. For poorly water soluble drugs it is possible to use solvents such 
as ethanol or diethylether which do not form inclusion complexes themselves, to solubilise 
drugs and aid complexation. 
 
Figure 2.6. Toroidal cyclodextrin shape with a hydrophobic inner core and hydrophilic outer 
surface (A). 1:1 Cyclodextrin:drug complexation (B). 
 
Since complexation is considered to be in equilibrium with the free drug, it may also be 
possible to increase the solubility of the drug through ionisation, salt formation and the 
formation of metal complexes to encourage complexation formation [176]. Several 
methods describing complexation preparation techniques are described in the literature 
and include co-precipitation, slurry complexation, and paste complexation [172]. Once a 
complex is formed and dried it is considered very stable with a long shelf life.  
Cyclodextrins are generally considered non-toxic although at sufficiently high 
concentrations they can cause haemolysis of erythrocytes [173, 177]. When given orally 
they are poorly absorbed through the gastrointestinal tract and practically resistant to 
salivary and pancreatic amylases [176, 178]. The chemical structure which contributes to a 
large number of hydrogen bond donors and acceptors, their molecular weight and very low 
octanol/water partition coefficient are all characteristics which result in poor membrane 
permeability [176]. Because of their poor gastrointestinal tract absorption they are 
considered non-toxic when administered orally [179]. Intra molecular hydrogen bonding 
between hydroxyl groups contributes to a lower solubility, which can be sufficiently 
enhanced by the introduction of functional groups at the 2-, 3- and 6-hydroxyl groups of 
46 
 
 
the glucose residue [173, 176, 179-181]. These changes improve the solubility by breaking 
the 2-OH-3-OH hydrogen bonds and by preventing crystallisation [173]. With 18 (α-CD), 21 
(β-CD) and 24 (γ-CD) substitutable hydroxyl groups there are many possible derivatives that 
can be made. Hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutyl-β-CD are two such 
derivatives with satisfactory toxicological profiles that are frequently used [171, 182]. 
2.7.3.1 Cyclodextrins in Toxicity Formulations 
Cyclodextrin complexation reduces toxicity mainly via the mechanisms described by 
strategies 2 and 4 (see section 2.7). One of the main applications of cyclodextrins in 
pharmaceutical formulations is to increase the solubility of a drug, although other studies 
have suggested cyclodextrins may also behave as permeation enhancers [183]. This 
increase in solubility improves the bioavailability of a drug which can then enter systemic 
circulation. The rate and extent of the bioavailability can be influenced by adjusting the 
factors which affect the dissociation equilibrium of the complex. Only the free form of the 
drug, which in solution will be in equilibrium with the complexed form, is able to penetrate 
lipophilic membranes to enter systemic circulation (Figure 2.7). Maximum absorption 
enhancement is therefore most likely to be achieved when the just the right molar 
concentration of cyclodetrin is used to dissolve the entire drug concentration in solution. 
An abundance of cyclodextrin would solubilise a drug in vitro well, but this abundance in 
vivo would prevent the free form drug dissociating for long enough that it could enter 
systemic circulation. 
 
Figure 2.7. Behaviour of cyclodextrin-drug complexation prior to absorption through biological 
membranes. 
 
Cyclodextrins therefore serve two purposes when used in formulations for toxicity 
reduction. 1) They entrap a poorly water soluble drug through complexation, thus 
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preventing precipitation and aggregation issues and 2) Through complexation they prevent 
large concentrations of drug interacting with local tissues. 
These two properties of cyclodextrins satisfy their mode of action as described by 
strategies 2 and 4 in section 2.7. 
To demonstrate these principles in practice there are several pieces of published work 
which show how the toxicity of a drug is ameliorated through cyclodextrin complexation. It 
is interesting to note that the majority of these studies used cyclodextrin formulations for 
the prevention of toxicities resulting from nonsteroidal anti-inflammatory drugs (NSAID).  
An in vitro study on the haemolysis of RBCs, demonstrated that complexation of 
chlorpromazine and flufenamic acid with β-cyclodextrin protected RBCs from lysis, 
accounting this protection to a reduced drug concentration within the cells [184]. 
Furthermore, in vivo, using rabbits it was shown that chlorpromazine complexed with β-
cyclodextrin resulted in a decrease in muscular tissue damage at the site of injection. This 
reduction in local toxicity was again ascribed to the reduction in the affinity of 
chlorpromazine for tissue membrane due to its affinity to preferentially form inclusion 
complexes [185]. 
The formulation of nonsteroidal anti-inflammatory drugs through cyclodextrin 
complexation has been studied and reported extensively in the literature. NSAIDs such as 
indomethacin, naproxen and diclofenac are known to cause adverse reactions in the 
gastrointestinal tract when administered orally, a condition that is exacerbated if the drug 
is poorly soluble or poorly permeable. As a consequence of poor absorption, levels of drug 
within the gut build up to a sufficient enough concentration to result in irritability and 
toxicity of the gastrointestinal mucosa [186]. Similar local toxicity issues are observed when 
NSAIDs are administered subcutaneously (s.c.) [187] or intramuscularly (i.m.) [188]. 
When administered orally, NSAIDs are reported to inhibit prostaglandin production 
through the inhibition of cyclooxygenases (COX-1 and COX-2). COX-1 is critical for 
maintaining healthy tissue and COX-2 is involved in the anti-inflammatory pathway of the 
gastrointestinal mucosa. These NSAIDs have been shown to significantly decrease the 
mucosal prostaglandin E2 concentration when administered orally to rats [189]. This 
deficiency leads to an increased gastric motility provoking severe gastric lesions and 
ulceration [189, 190]. Cyclodextrin complexation with NSAIDs would therefore seem a 
logical formulation given that complexation would prevent the NSAIDs from interacting 
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with the cyclooxygenases and enhance absorption into systemic circulation. Several studies 
have reported such findings in the literature. Indomethacin, etodolac, naproxen, rofecoxib, 
flurbiprofen and 4-Biphenylacetic Acid (felbinac) have all been formulated using various 
cyclodextrin derivatives and administered orally to rats. When compared to the non-
formulated drug, an enhancement in solubility, dissolution rate and bioavailability was 
reported. Gastrointestinal tolerability was also improved with lesions and ulcerations to 
gastrointestinal mucosa reduced in the formulated drugs [186, 191-195]. 
From these studies on NSAIDs we can conclude that cyclodextrins aid with the solubility of 
poorly soluble NSAIDs by reducing aggregation and prevent interaction with biological 
membranes such as the mucosa membrane thus preventing cyclooxygenases inhibition. To 
understand pharmacokinetic changes that result from cyclodextrin formulations several 
studies have reported their findings (Table 2.10). From these data it becomes apparent that 
regardless of the species used or the route of administration, a cyclodextrin formulation 
which reduces local toxicity does so because it is able to get the drug into systemic 
circulation quicker, indicated by the increase in AUC and Cmax of the cyclodextrin 
formulated drug compared to the non-formulated drug [186-188].  
Table 2.10. Pharmacokinetic changes through cyclodextrin formulation. AUC units - µg.h/mL* or 
ng.h/mL†. Cmax units - µg/mL* or ng/mL†. Administered dose amounts and AUC time periods 
have been omitted for simplicity reasons. Data adapted from [186-188]. 
 
Drug/Formulation Species 
Admin 
route 
AUC Cmax Tmax (h) t1/2 (h) Reference 
Ricobendazole (non-
formulated)* 
Sheep s.c. 
36.7 ± 
9.2 
1.34 ± 0.31 9.6 ± 2.9 8.5 ± 3.4 
[187] 
Ricobendazole-HP-β-CD* Sheep s.c. 
54.5 ± 
15.3 
2.90 ± 0.77 5.0 ± 0.6 5.5 ± 2.8 
Nimodipine (non-
formulated)† 
Rabbits i.m. 
31.90 
± 8.78 
9.13 ± 1.78 
0.78 ± 
0.21 
- 
[188] 
Nimodipine-2HP-β-CD† Rabbits i.m. 
82.55 
± 8.92 
23.18 ± 2.94 
0.35 ± 
0.06 
- 
4-Biphenylacetic Acid 
(non-formulated)* 
Rats Oral 10736 70.2 ± 1.1 - - 
[186] 
4-Biphenylacetic Acid- 
HP-β-CD* 
Rats Oral 14444 108.6 ± 2.5 - - 
 
This was attributed to the ability of cyclodextrin to inhibit precipitation post-administration 
allowing rapid drug absorption when compared to the non-formulated drug. Because of 
this rapid absorption, local toxicity at the site of administration was reduced. Interestingly 
the Tmax and t1/2 of these formulations are shorter, which is also a consequence of the rapid 
absorption in comparison to the non-formulated drug. Because the formulated drug will 
enter systemic circulation sooner it is therefore eliminated faster when compared to the 
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non-formulated drug which will enter systemic circulation slower due to precipitation at 
the site of administration [187, 188]. These pharmacokinetic data reinforce the reasoning 
behind how cyclodextrin formulations reduce the local toxicity concerns of NSAIDs. Similar 
pharmacokinetic changes have been reported for other classes of drugs when complexed 
with cyclodextrins [175]. 
2.7.4 Dendrimers 
Dendrimers are hyperbranched 3D tree-like molecules made up of polymers such as 
poly(amidoamine) (PAMAM) [196]. They possess a highly ordered structure with a high 
degree of molecular uniformity, narrow molecular weight distribution and multifunctional 
terminal surface properties. PAMAM dendrimers are synthesised from an alkyldiamine 
‘core’ such as ethylene diamine (EDA) reacted with methyl acrylate by nucleophilic addition 
(Michael addition) to form a branched intermediate. Subsequent reaction of this 
intermediate with EDA would produce a G0 (generation zero) dendrimer with four NH2 
surface groups (Figure 2.8) whilst the use of ethanolamine would produce a G0 dendrimer 
flanked by four OH surface groups. Higher generation dendrimers (G1, G2, G3 etc.) 
containing exponentially more branching points are possible with further methyl acrylate 
reactions terminating with an amine, resulting in a spherical nanomolecule with a high 
surface polycationic charge. Depending on the polymer used dendritic growth is limited 
from reaching higher generations due to the branching arms which lead to steric hindrance. 
Dendrimers are synthesised or grown in several ways. A core that is linear in structure will 
give rise to a rod like dendrimer whilst a tetrahedral core produces a more spherical 
dendrimer. Since dendrimers are made from polymers they are considered biologically safe 
[197], in particular ammonium core PAMAM generation 3, 4 and 5 dendrimers whose 
shape and structure is said to be mimicry of globular proteins such as insulin and 
haemoglobin [198]. Dendrimers additionally have a high degree of solubility and possess a 
large number of surface groups that can serve specific purposes such as carrying insoluble 
drugs to avert aggregation related toxicities [199]. 
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Figure 2.8. PAMAM G2 dendrimer showing ethylene diamine (EDA) core (red) reacted with methyl 
acrylate to produce G0 (red+blue), G1 (red+blue+green) and G2 dendrimer 
(red+blue+green+purple). 
 
2.7.4.1 Dendrimers in Toxicity Formulation 
The in vivo hepatotoxicity of methotrexate and 6-mercaptopurine was assessed by 
repeated dose toxicity assessment through formulation via melamine based dendrimers. 
After solubilising these anticancer drugs with dendrimers, a dose of 2 or 3.5 mg/kg of 
methotrexate or 6-mercaptopurine respectively was administered i.v. to mice for three 
consecutive days. 48 hours after the last dose the mice were sacrificed and blood samples 
assessed for hepatotoxic indications. The non-formulated administration of both 
methotrexate and 6-mercaptopurine elevated the serum ALT levels in mice when 
compared to a saline control, whilst the dendrimer formulated drugs resulted in lower ALT 
serum concentrations that were statistically different to the non-formulated groups but not 
significantly different to the saline controls. Dendrimers alone did not result in any serum 
ALT elevations either. These results suggest that dendrimers based on melamine are able 
to prevent the hepatotoxicity of methotrexate and 6-mercaptopurine. Although the exact 
cause of toxicity reduction is not reported it is thought that the noncovalent interaction of 
drug with the dendrimer prevents rapid diffusion of the free drug into systemic circulation 
thereby not exceeding a toxic threshold [200]. 
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The anthracycline doxorubicin is another candidate for toxicity reduction via dendrimer 
formulation. In a study using fifth generation polypropylene imine (PPI) dendrimers 
conjugated to folic acid, doxorubicin loaded formulations (PPI-FA-Dox) were assessed for in 
vitro and in vivo toxicity [28]. The haemolytic toxicity of the formulation was assessed in 
vitro using human RBCs and compared against non-formulated doxorubicin. At equivalent 
doses, PPI-FA-Dox resulted in 4.28 % RBC haemolysis whilst the non-formulated drug 
resulted in 16.37 % RBC haemolysis. Interestingly PPI dendrimer formulations without folic 
acid conjugates (PPI-Dox) resulted in 18.35 % RBC haemolysis, demonstrating that the folic 
acid conjugates played an important role in haemolytic protection. It was proposed that 
the folic acid conjugates shielded doxorubicin from interaction with RBC surfaces which 
resulted in reduced RBC lysis. 
Haematological studies of the PPI-FA-Dox formulation was also analysed in vivo using rats. 
Seven daily i.v. injections were administered of PPI-FA-Dox, non-formulated doxorubicin 
and PPI-Dox at a dose of 250 mg/mL. After 15 days, blood samples from the animals were 
collected and analysed for haematological cell counts. The analysis showed PPI-FA-Dox 
formulations were able to significantly reduce the reduction of RBCs and increase in WBCs 
that was typical of the non-formulated drug. An increase in monocyte and lymphocyte 
counts observed with non-formulated drug was also prevented with PPI-FA-Dox. PPI-Dox 
without folic acid conjugates was unable to prevent these toxicities. 
The in vitro drug release profiles of the two dendrimer formulations (PPI-FA-Dox and PPI-
Dox) were compared using PBS (phosphate buffered saline) at a pH of 7.4 and 6.4. PPI-Dox 
resulted in the release of 59.46 and 74.36 % drug from the formulation in PBS at pH 7.4 and 
6.4 respectively. PPI-FA-Dox produced a slower release profile resulting in the release of 
52.36 and 68.24 % drug release at pH 7.4 and 6.4 respectively. 
Cell inhibition studies also revealed an interesting mechanism of action for the PPI-FA-Dox 
formulations. Using MCF-7 human breast cancer cells the IC50 value of PPI-FA-Dox was 
reported as 0.45 µg/mL while PPI-Dox and non-formulated doxorubicin resulted in an IC50 
value of 0.75 and 0.70 µg/mL respectively. Fluorescence analysis showed a higher uptake of 
the PPI-FA-Dox formulation into MCF-7 cells which was accounted for due to the folate 
residues on the surface of PPI-FA-Dox dendrimer formulations. 
Together these results suggest that PPI-FA-Dox results in a higher uptake into MCF-7 cells 
due to the overexpression of folate receptors on these cells, suggesting a targeted 
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mechanism for the improved IC50 efficacy of the drug. The quicker release of drug from 
both PPI-Dox and PPI-FA-Dox formulations at a pH of 6.4 compared to pH 7.4 may also 
contribute to the improved efficacy of the drug. Since the microenvironment around 
tumour sites is generally below pH 7 this may confer improved drug targeting and efficacy 
in vivo. 
A dendrimer formulation bound to doxorubicin has been tested in vivo and reported by 
Kaminskas et al. They  prepared a polylysine based dendrimer conjugated with PEG and 
doxorubicin (PolyL-PEG-Dox) [52]. The MTD of the PolyL-PEG-Dox formulation in mice was 
reported as 10 mg/kg that resulted in no more than 10 % body weight loss. The MTD of the 
non-formulated doxorubicin was 4.5 mg/kg. The systemic toxicity and cardiotoxicity effects 
of non-formulated doxorubicin were also reduced by the PolyL-PEG-Dox formulation even 
when administered at a 2-fold higher dose in mice [52].  
Dendrimer formulations are therefore able to reduce the toxicity of a drug via the 
strategies 2, 3 and 4 discussed in section 2.7. 
2.7.5 Micro/Nano Formulations 
Micro and nanoformulations as their name implies are formulations in the micro (1-1000 
µm) and nano (1-1000 nm) size range. They are produced in much the same way although 
nano scaled formulations require much more robust methods. By convention, liposomes, 
cyclodexterins, polymeric micelles and dendrimers can be classed as nanoparticles given 
that their physical size is often in the nano range. This section however focuses on the 
micro/nano technologies that are formulated as emulsions, particles, suspensions, colloids 
and solid dispersions. Of these the micro/nano emulsions and particles are most widely 
used to formulate drugs for toxicity reduction. 
Microemulsions are formed by mixing oil, water and surfactants, forming phases that are in 
equilibrium with each other [201]. Microemulsions can be water-continuous, oil-
continuous or bi-continuous depending on the concentrations and drugs formulated [202]. 
An oil-in-water (o/w) microemulsion for example is a colloidal dispersion consisting of oil 
droplets and surfactant dispersed in a continuous water phase. As with micelles (see 
section 2.7.2), the surfactant’s hydrophobic tails associate to reduce the thermodynamic 
instability when in contact with water. The hydrophilic head groups then protrude and 
contact the aqueous phase. Oil droplets are carried within the hydrophobic interior of the 
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micelle and may contain a hydrophobic drug that becomes dispersed within the continuous 
aqueous phase. 
Nanoemulsions by contrast are considered to be in a non-equilibrium state making them 
thermodynamically unstable systems [202], However the destabilisation of nanoemulsions 
is slow, typically months [201] and they are resistant to moderate dilution and temperature 
changes [203], with their small size providing stability and avoiding Ostwald ripening and 
therefore emulsion degradation [201, 204]. A nanoemulsion can therefore be described as 
a conventional emulsion that contains particles of a nano size, typically 300 - 500 nm in 
diameter [201, 203]. Nano-emulsions can be oil-in-water (o/w) or water-in-oil (w/o) 
dispersions, depending on whether the water is the continuous phase and the oil is the 
dispersion phase or vice versa [204]. The major distinction between micro- and 
nanoemulsions is therefore the physical size of the dispersion phase and the 
thermodynamic stability of the system. Oil-in-water systems are used to formulate poorly 
water soluble drugs and disperse them into an aqueous media for administration. 
Lastly, nanoformulations are frequently produced as nanoparticles, which are described as 
solid colloidal particles in the nano scale range [203]. They are made from various 
macromolecules to which drugs are adsorbed, entrapped or covalently bound. Synthetic 
polymers, such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA) and their copolymer 
poly(lactide-co-glycolide) (PLGA) [205, 206] or Pluronic F127 [207] as well as natural 
macromolecules such as chitosan, polysaccharides and gelatin are frequently used to form 
nanoparticles [203]. PLA and PGA are considered biocompatible, have good stability and 
can sustain drug release. Nanoparticles have the added advantage that their sheer size also 
makes them ideal for intravenous delivery of drugs without the risk of forming aggregates 
causing an embolism or removal via the RES. Nanoparticles can be synthesised to deliver 
hydrophobic and hydrophilic drugs as well as proteins, vaccines and macromolecules.  
2.7.5.1 Micro/Nano Particles in Toxicity Formulation 
The platinum based anticancer drug cisplatin has been formulated using biodegradable 
poly(D,L-Lactic-co-glycolic) acid (PLGA) to form cisplatin bound nanoparticles (Cis-PLGA) 
(Figure 2.9) that were shown to be nephroprotective to the adverse effects of the drug 
[208]. This formulation was prepared by a water-oil-water emulsion solvent evaporation 
method.  
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The formulation was tested in mice bearing the DHD/K12PROb adenocarcinoma colon cell 
line. Following a 5 mg/kg i.p. dose once per week for two cycles, of formulated and non-
formulated drug administered to mice the study showed Cis-PLGA was able to reduce 
elevations in BUN that were recorded with the non-formulated drug. 
 
Figure 2.9. Scanning electron micrograph of cisplatin-PLGA nanoparticles prepared by a water-oil-
water emulsion solvent evaporation method. Image reproduced from [208]. 
 
Table 2.11 shows that on the 8th day the BUN levels of the non-formulated drug reached 
42.1 ± 3.2 mg/dL, compared to Cis-PLGA levels of 19.9 ± 1.9 mg/dL which were comparable 
to control animals. The changes in body weight were also favourable for the Cis-PLGA 
group with no body weight loss measured, whereas for the non-formulated drug result in 
approximately 10 % body weight loss when compared to the control group. 
Table 2.11. BUN plasma levels (mg/dL) following 5 mg/kg i.v. administration of Cis-PLGA and non-
formulated cisplatin. Data represents the mean ± SD of 6 animals. Data adapted from [208]. 
 
Time (Days) Control (saline) 
Empty PLGA 
nanoparticles 
Cisplatin (non-
formulated 
Cis-PLGA 
Basal 20.1 ± 1.6 19.8 ± 3.3 21.1 ± 1.2 20.0 ± 0.6 
7 20.3 ± 1.5 21.7 ± 1.9 18.5 ± 2.6 19.6 ± 1.7 
7.25 21.3 ± 2.9 22.2 ± 0.7 27.5 ± 1.2 20.0 ± 0.6 
8 20.1 ± 2.5 21.8 ± 2.1 42.1 ± 3.2 19.9 ± 1.9 
9 21.5 ± 2.4 21.4 ± 2.3 35.7 ± 3.9 20.3 ± 2.1 
11 21.3 ± 1.3 21.5 ± 0.8 20.9 ± 1.5 19.6 ± 0.4 
 
Both the non-formulated drug and Cis-PLGA reduced the growth of the developing tumour 
with no significant difference between them, suggesting the efficacy of the Cis-PLGA 
formulation was maintained yet nephrotoxicity was reduced. No statistical difference on 
the tumour growth was observed between the control and empty nanoparticle groups 
either, suggesting PLGA nanoparticles alone have no tumouricidal properties. A statistical 
55 
 
 
difference was found between the two cisplatin groups and the two non-cisplatin groups in 
terms of tumour growth. 
The biodistribution and pharmacokinetics of the Cis-PLGA formulation were also reported 
and highlighted some interesting changes that result from nanoparticle formulation.  Table 
2.12 shows the change in the pharmacokinetics that becomes apparent with a Cis-PLGA 
formulation when compared to the non-formulated drug. 
Table 2.12. Pharmacokinetics of cisplatin formulated in PLGA nanoparticles and non-formulated 
free drug. Data adapted from [208] 
 
Drug/Formulation Species 
Admin 
route 
AUC0-21 
(mg.day/L) 
Cmax (mg/L) Tmax (min) 
Cisplatin (non-formulated) Mice i.p. 3.77 ± 0.33 10.83 ± 0.95 5 
Cis-PLGA Mice i.p. 2.80 ± 0.02 0.33 ± 0.05 60 
 
The changes in pharmacokinetics that result from a PLGA nanoparticle formulation are 
striking, a statistical difference was found in the AUC, Cmax and Tmax values when compared 
to the non-formulated drug. Of particular interest is the Cmax value of the Cis-PLGA 
formulation that was only 3 % of the Cmax of the non-formulated drug. The Tmax was also 
prolonged to 60 min from 5 min for the Cis-PLGA formulation and non-formulated drug 
respectively. 
Biodistribution profiles of Cis-PLGA and non-formulated drug showed the main organ for 
uptake of Cis-PLGA was the spleen, whilst a reduced uptake was observed in the lungs and 
liver when compared to non-formulated drug. Drug uptake into the kidneys was similar for 
both Cis-PLGA and non-formulated drug but the reduced nephrotoxicity of Cis-PLGA may 
be reflected by the slow release of the drug from PLGA nanoparticles that accumulate 
within the spleen. The significantly lower Cmax and prolongation of Tmax demonstrate that a 
sustained release of the drug from the Cis-PLGA formulation from within the spleen is the 
most likely reason for the nephroprotective properties of the nanoparticle formulation. 
Microemulsions are an alternative to the nano-formulations that have been shown to be 
successful at ameliorating toxicity. For example Brime at al. [209] has reported on lecithin-
based oil-in-water microemulsions of amphotericin B that demonstrated a reduced toxicity 
profile of the drug. A lecithin based microemulsion that incorporated amphotericin B was 
administered to mice at a dose of 1 mg/kg i.v. for 5 consecutive days and compared to the 
clinical sodium deoxycholate formulation of amphotericin B (Fungizone). Histopathological 
examinations of mice administered Fungizone showed tubular lesions of the kidneys, 
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including focal necrosis of the epithelial cells that occurred in the Henle loop and distal 
convoluted tubules. No significant histopathological changes were observed in animals 
treated with the microemulsion formulation. Furthermore, no significant changes were 
recorded at a dose of 3 mg/kg for the microemulsion formulation either, demonstrating a 
higher tolerability of this formulation. A 3 mg/kg dose of Fungizone was not tested. At the 
tested dose of 1 mg/kg no significant changes in the blood creatinine levels between the 
microemulsion and Fungizone were reported, although histopathological reports confirmed 
nephrotoxicity, creatinine may not be a sensitive enough biomarker for the detection of 
renal injury at low doses. Pharmacokinetic parameters assessed in rabbits demonstrated 
the differences between the formulations, with the microemulsion formulation producing a 
lower AUC, Cmax, MRT and Vss than that of Fungizone. The Cl was reported to be slightly 
higher for the microemulsion than for Fungizone (Table 2.13). This may demonstrate a 
faster elimination of the microemulsion incorporated amphotericin B from the plasma via 
RES uptake, followed by redistribution as seen with other lipid-based amphotericin B 
formulations [140, 210]. 
Table 2.13. Pharmacokinetic profiles of a microemulsion amphotericin B formulation and 
Fungizone administered at 1 mg/kg i.v. into rabbits. All values are mean ± SD. *Non-
compartmental analysis.  † Two-compartmental analysis. Data adapted from [209]. 
 
Drug/Formulation Species 
Admin 
route 
AUC0-∞ 
(mg.h/L)* 
Cmax 
(mg/L)* 
MRT 
(h)* 
t1/2 (h)* 
Cl 
(L/h)† 
Vss (L)† 
Amphotericn B 
(Fungizone) 
Mice i.v. 
32.280 ± 
7.310 
3.890 ± 
0.480 
27.100 
± 4.800 
19.840 ± 
3.140 
0.082 ± 
0.010 
2.035 ± 
0.170 
Amphotericn B 
Microemulsion 
Mice i.v. 
21.890 ± 
5.170 
2.920 ± 
0.540 
16.230 
± 0.200 
12.320 ± 
0.480 
0.113 ± 
0.006 
1.890 ± 
0.160 
 
This lipid based microemulsion formulation of amphotericin B may offer toxicity protection 
in a similar manner to other lipid based formulation of amphotericin B, principally by 
reducing the exposure of the drug to mammalian membranes as discussed in section 
2.7.1.1. 
Mitoxantrone is an antineoplastic agent that results in local systemic toxicity issues at 
therapeutic doses with intraperitoneal injections reported to cause abdominal pain and 
bowel obstruction. The effects reported on the abdominal cavity are thought to develop as 
a result of high local drug concentrations at the site of administration. Luftensteiner et al. 
therefore developed albumin loaded mitoxantrone microspheres (Mxn-Alb) with high 
stability, biocompatibility and controlled release properties. Rats administered 30 mg/m2 
surface area i.p. at 3-weekly intervals with Mxn-Alb were shown to survive significantly 
longer than rats administered the non-formulated drug. Mxn-Alb administered animals 
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were also shown to gain weight over a period of 21 days whilst animals administered non-
formulated drug slightly lost weight [211]. 
The pharmacokinetic profiles of the Mxn-Alb formulation were compared to the non-
formulated drug following a single i.p. dose of 30 mg/m2 surface area (Table 2.14). The 
data show that following i.p. administration of Mxn-Alb the plasma AUC and Cmax are 
reduced compared to the non-formulated drug. The Tmax is also prolonged to 8 hours for 
the Mxn-Alb formulation, compared to 1 hour for the non-formulated drug [212]. These 
data show that albumin microspheres achieve a reduction in toxicity by controlling the 
release of the drug from the formulation. 
Table 2.14. Pharmacokinetic profile of mitoxantrone in albumin microspheres and non-formulated 
drug at an i.p. dose of 30 mg/m2 surface area. Data adapted from [212]. 
 
Drug/Formulation Species 
Admin 
route 
Dose (mg/m
2
 
surface area) 
AUC0-72 
(ng.h/mL) 
Cmax 
(µg/mL) 
Tmax (h) 
Mitoxantrone (non-
formulated) 
Rats i.p. 30 463.5 70.2 1 
Mitoxantrone albunim 
microspheres 
Rats i.p. 30 442.8 20.3 8 
 
Lastly, lipid based nano-particles are an alternative approach to nano-based formulations, 
that have been widely reported in the literature. Lipid nanoparticles form a hydrophobic 
core made from a monolayer of phospholipids and can entrap poorly soluble drugs, 
modulating their release behaviour in vivo and improving their therapeutic index [29]. Jung 
et al. formulated several lipid based nanoparticles using a spontaneous emulsification, 
solvent evaporation method to entrap amphotericin B (LNP-AmpB); plain, anionic and PEG 
based lipid nano-particles were developed and compared to the clinical formulation of 
amphotericin B in sodium deoxycholate (Fungizone). 
In vitro haemolysis studies performed on rat erythrocytes showed that all the LNP-AmpB 
formulations showed very little haemolysis up to a concentration of 50 µg/mL amphotericin 
B, whereas Fungizone resulted in 100 % haemolysis at an equivalent concentration. These 
results suggest that the lipid matrices of LNP-AmpB formulations reduce the direct 
interaction of the drug with erythrocytes resulting in less haemolysis, a similar finding is 
reported with liposomal based amphotericin B formulations (see section 2.7.1.1). 
Furthermore due to the reported nephrotoxic implications of amphotericin B the study also 
tested the in vitro cytotoxicity of these LNP-AmpB formulations against human kidney cells 
(293 cells). At a concentration of 100 µg/mL Fungizone lowered cell viability to 
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approximately 20 %, whereas the anionic and PEG based LNP-AmpB formulations resulted 
in no effect on cell viability. 
The in vivo pharmacokinetic profiles of these formulations were compared against 
Fungizone using rats. LNP-AmpB formulations and Fugizone were administered i.v. at a 
dose of 3 mg/kg body weight. A one-compartment model was fitted and showed that LNP-
AmpB formulations increased the AUC and Cmax of amphotericin B when compared to 
Fungizone (Table 2.15). The PEG LNP-AmpB formulations however significantly increased 
the AUC and Cmax of amphotericin B, suggesting that the PEG stabilised amphotericin B in 
systemic circulation and reduced opsonisation or RES uptake due to low plasma protein 
binding. The extended half-life of PEG LNP-AmpB formulations in vivo also suggests that 
amphotericin B is slowly released from the lipid nanoparticles. 
Table 2.15. Pharmacokinetic properties of lipid based nanoparticle formulations entrapping 
amphotericin B, administered at a dose of 3 mg/kg i.v. into rats. Data adapted from [29]. 
 
Drug/Formulation Species Admin route 
AUC0-24h 
(µg.h/mL) 
Cmax (ng/mL) t1/2 (0-24h) (h) 
Amphotericn B (Fungizone) Rat i.v. 1.084 0.224 3.825 
Anionic LNP-AmpB Rat i.v. 2.598 0.907 1.526 
PEG LNP-AmpB Rat i.v. 19.448 4.021 5.591 
 
It is worth noting that these pharmacokinetic results are in contrast to the lecithin based 
microemulsion formulation [209] discussed earlier in this section. Although the 
pharmacokinetics was assessed in rabbits the microemulsion formulation reduced the 
plasma AUC and Cmax values. This may be accounted for by the different animal models 
used or the differences in micro and nano formulation properties. Both studies however 
reported a toxicity reduction that was accounted for by the reduced interaction of 
amphotericin B with its site of toxicity. 
Nano/micro formulations are therefore able to reduce the toxicity of a drug through 
strategy 2 as discussed in section 2.7. By controlling the release of a drug the formulation is 
effectively preventing a toxic dose from interacting with its site of toxicity. 
2.7.6 Antidotes 
Antidote formulations do not generally involve drug encapsulation, solubilisation, polymer 
attachment or targeting techniques for toxicity reduction. Rather they are co-
administrative agents that aid in ameliorating a drug’s toxicity. They achieve this by 
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interfering with or interrupting adverse outcome pathways, out competing ligands for 
active sites, thereby preventing molecular initiating events (MIE), promoting endogenous 
cellular defences, up/down regulating biochemical pathways or acting as scavengers of 
reactive species.  
Antidote formulations are interesting since they impact the pharmacodynamic toxicity 
aspects of a drug. Although pharmacokinetic modulation through antidote formulation may 
be possible [213], the majority of the antidotes modulate some aspect of a drug’s adverse 
outcome pathway (AOP). These antidotes can therefore be integrated into the AOP profile 
of a drug providing an understanding of the mechanism for their reduction in toxicity. 
Understanding the toxicity pathway of a drug may additionally help translate antidotes that 
are effective with one drug to another provided they share some commonality in their 
toxicity pathway. 
Antidotes cover a vast range of compounds that cannot be described collectively. They 
comprise vitamins, plant extracts, seed oils and other drugs. Since the pharmacokinetic 
profile of a drug is largely unaffected by antidote formulations, these formulations most 
probably reduce the toxicity manifestation of a drug through strategy 1 discussed in section 
2.7. 
2.7.6.1 Antidotes in Toxicity Formulation 
To understand how antidotes achieve their toxicity reductions it is important to understand 
in some detail the toxic pathway of a specific drug. For this reason this section will focus on 
the antidote formulations that have successfully reduced the hepatotoxicity of 
acetaminophen. 
 Acetaminophen (paracetamol) has a well-documented metabolism pathway, with new 
additions continuously discovered and reported in the literature. The major parts of 
acetaminophen’s toxic pathway are shown in Figure 2.10. Briefly, at therapeutic doses 
acetaminophen undergoes extensive hepatic metabolism with about 85 % of a therapeutic 
dose undergoing phase II metabolism and safely excreted via glucuronidation and 
sulphation. The remaining drug undergoes phase I metabolism via a direct two electron 
oxidation step and is converted into the toxic metabolite N-acetyl-p-benzoquinone imine 
(NAPQI) by cytochrome P450 enzymes [214, 215]. The principal enzyme in this metabolism 
is CYP2E1 although others such as CYP1A2, CYP3A4 and CYP2D6 have been reported in the 
literature [88, 214, 216]. At therapeutic doses, NAPQI is detoxified by reduced glutathione 
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(GSH), an endogenous antioxidant and excreted via the kidneys. At toxic doses however or 
at times of impaired liver function, GSH becomes rapidly depleted leaving NAPQI to bind 
with cellular proteins resulting in the formation of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). NAPQI is also implicated with mitochondrial protein 
binding which depletes mitochondrial GSH resulting in further ROS production. As 
intracellular ROS increases it activates ASK-1 (Apoptosis signal-regulating kinase 1), a 
mitogen-activated protein kinase kinase kinase (MAP3K), which in turn activates JNK (c-Jun 
N-terminal kinases). The translocation of JNK to mitochondria induces mitochondrial 
permeability transition (MPT) pore opening which diminishes mitochondrial integrity 
resulting in cell death [216-218]. 
 
Figure 2.10. Metabolism of acetaminophen. At toxic doses, NAPQI is not sufficiently detoxified 
allowing biomolecule binding which leads to toxicity (red outline). 
 
Understanding the adverse outcome pathway of a drug can prove critical in formulating for 
toxicity reduction but understandably this may not be a luxury afforded to a formulator 
working with NCEs. The pathway for acetaminophen described in Figure 2.10 provides an 
ideal platform for understanding the mechanism of action of antidote formulations. The 
red outline of Figure 2.10 shows the pathway undertaken during acetaminophen induced 
liver toxicity. Antidote formulations that interrupt this pathway or promote the non-toxic 
pathway (green outline) could therefore act as potential hepatoprotectants. 
Several studies have shown this principle to work in practice. Lee et al. demonstrated the 
use of the drug chlormethiazole, an active inhibitor of the P450 enzyme CYP2E1 which was 
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able to completely attenuate the toxicity of acetaminophen. Pretreatment of 
chlormethiazole via i.p. administration 30 min before an i.v. dose of acetaminophen into 
mice was able to maintain serum AST and ALT levels, comparable to that of control 
animals. Furthermore chlormethiazole was also effective when administered 2 hours after 
acetaminophen, resulting in less elevated AST and ALT levels compared to that of the non-
formulated drug [219]. The drug cimetidine is reported to show similar hepatoprotective 
properties via the same mechanism of action of preventing P450 acetaminophen oxidation 
[220]. Dimethylsulfoxide (DMSO) is known to promote the activity of CYP2E1 and would 
potentially not be a suitable protectant for acetaminophen. However studies by Yoon et al. 
showed that although CYP2E1 activity is upregulated through DMSO administration, the 
solvent is also a substrate for CYP2E1 and actively competes for the enzyme thereby 
preventing the formation of NAPQI when both are administered i.p. into mice [69]. 
The current therapeutic treatment for acetaminophen overdose is through the 
administration of N-acetylcysteine (NAC). NAC is an L-cysteine analogue that serves as a 
precursor to GSH [221] the main endogenous defence against the reactive acetaminophen 
metabolite NAPQI (see Figure 2.10). To provide cellular protection during times of 
acetaminophen toxicity, levels of GSH or other suitable antioxidant must be maintained. 
Several studies in the literature report co-administrative efforts that provide antioxidant 
benefits during acetaminophen toxicity. Sesame oil administered orally to rats was able to 
maintain GSH levels, reduce ROS generation and inhibit lipid peroxidation, preventing 
increases in serum transaminase levels without affecting acetaminophen oral absorption. 
Histological analysis showed sesame oil prevented centrilobular necrosis within liver tissue 
possibly due to the various antioxidants contained within it [222]. Many plant based 
extracts are known to offer hepatic protection against acetaminophen toxicity. The 
literature reports on extracts of garlic, Phyllantus niruri and the fruit of Cornus officinalis as 
hepatoprotectants of acetaminophen injury [66, 102, 223]. 
2.8 Building Toxicity Protection Pathways 
From the data discovered through the literature that detail the pharmacokinetic and 
pharmacodynamic modulating formulations for toxicity reduction, it is possible to construct 
toxicity protection pathways. These pathways show how different formulation techniques 
are effective at reducing the toxicity of a drug at specific points of an AOP profile. The 
pathways are partly built on the AOP framework but provide more detail at the cellular 
level of toxicity to accommodate the pharmacodynamics modulating formulations. 
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Consider the aminoglycoside antibiotic gentamicin, used to treat gram-negative bacterial 
infections. As with all aminoglycosides, gentamicin’s use is limited by its nephrotoxicity. 
Pharmacokinetic studies show that gentamicin is principally excreted via the kidneys in a 
largely un-metabolised form [224]. This serves as the first step of the drug’s AOP profile 
with high kidney exposure in vivo. Once within the kidneys the drug accumulates within the 
epithelial cells of the proximal tubule [99] largely by megalin/cubilin mediated endocytosis 
[225, 226] and governed by the electrostatic interaction of gentamicin to negatively 
charged membrane phospholipids [101, 225, 227], resulting in the loss of brush border 
which leads to tubular necrosis. Intracellular, gentamicin mostly accumulates within 
lysosomes but also interacts with the Golgi complex and endoplasmic reticulum (ER). 
Within lysosomes, gentamicin is responsible for membrane destabilisation, lysosomal 
aggregation, alterations in lipid metabolism and phospholipidosis [100, 228]. ER stress 
inflicted by gentamicin activates the unfolded protein response, which, depending on 
intensity drives the cell towards apoptosis [229]. Free cytosolic gentamicin is then able to 
attack mitochondria inhibit ATP production, amplifying oxidative stress and initiating the 
intrinsic apoptosis pathway [230, 231] through mitochondrial permeability transition pore 
opening and cytochrome c release into the cytosol. Activation of the extracellular calcium 
sensing receptor (CaSR) by gentamicin has also been suggested as a cause of tubular cell 
death [232]. Subsequently the glomerular mesangial cells are affected which manifests as a 
reduction in the glomerular filtration rate (GFR) and renal blood flow (RBF) contributing to 
proteinuria augmented by gentamicin-induced tubular damage [132, 233]. 
Understanding the basic principles of gentamicin’s AOP and integrating the data collected 
from the literature allows a toxicity protection pathway to be built. Figure 2.11 
conceptualises the toxicity protection pathway for gentamicin, which is briefly discussed 
below. 
Liposomal formulations of gentamicin as discussed in section 2.7.1.1 have been shown to 
reduce the volume of distribution of the drug, thereby retaining the drug within the central 
compartment which prevents kidney accumulation and toxicity [124, 135, 137]. Liposomal 
formulations act on the pharmacokinetic profile of the drug. There are many formulations 
which act on the pharmacodynamics of the drug to prevent toxicity many of which are 
shown in Figure 2.11. Receptor mediated endocytosis of the drug can be prevented using 
cytochrome c fragments which act as an antagonist to the receptor megalin [225]. 
Cyclodextrin sulphates have been shown to prevent lysosomal degradation by displacing 
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gentamicin from the negatively charged lysosomal membranes [234, 235]. Promoting the 
exocytosis of gentamicin is another effective toxicity reduction approach which has been 
demonstrated by Beauchamp et al. (1997) [236]. Using the bactericidal drug fleroxacin, co-
administered with gentamicin the group were able to show a significant reduction in 
nephrotoxicity in rats. Morales et al. (2010) [231] used the drug metformin to stabilise 
mitochondrial permeability and respiration, normally disrupted through the use of 
gentamicin. The administration of metformin was able to maintain mitochondrial 
homeostasis, reduce lipid peroxidation and maintain cellular antioxidant mechanisms all of 
which prevented cell necrosis. Metformin has also been shown to prevent the elevation of 
BUN and creatinine in rats [237]. Lastly the use of various agents that behave as 
antioxidants are frequently reported in the literature, gentamicin toxicity results in an 
increase of reaction oxygen species and reactive nitrogen species, furthermore the 
depletion of endogenous defences such as GSH, Superoxide dismutase and catalase are 
frequently reported [238]. Antioxidant agents such as vitamin C & E [238], melatonin [239], 
trapidil [240], lycopene [241], curcumin [242, 243], probucol [244], eugenol [243, 245] and 
sesame oil [246] have all been demonstrated to ameliorate gentamicin nephrotoxicity. 
 
Figure 2.11. Toxicity protection pathway for gentamicin. Formulations that prevent a particular 
toxicity pathway are shown in red.  
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The toxicity pathway for gentamicin shown in Figure 2.11 is by no means a complete 
toxicity profile of the drug. Rather it only includes the parts for which formulations that 
reduced its toxicity were discovered from the literature. Furthermore when new 
information becomes available it can also be incorporated into the toxicity protection 
pathway. If the toxicity pathways for other drugs are known then it may be possible to 
construct networks for which common pathways overlap. Thus a formulation successfully 
tried with one drug may be successful with an untested drug if there is some overlap in 
their toxicity pathways. For example, the literature reports that the nephrotoxicity of 
cisplatin can also be ameliorated using the vitamins C and E [33, 247]. This suggests that 
both gentamicin and cisplatin deplete endogenous antioxidant defences as part of their 
toxicity pathways. Moreover the other antioxidants used with gentamicin such as, 
lycopene, sesame oil or melatonin could be tried with cisplatin also. 
Discovering pathways for drugs however is a labour intensive process, most frequently 
achieved by piecing together individual bits of information extracted from the literature. 
Formulating for NCEs may prove to be extremely difficult as very little is often known about 
their AOPs.  
2.9 Summary 
This chapter has provided an overview of the scientific aspects of drug formulation for 
toxicity reduction. To fully understand a drugs toxic pathway, it is important to understand 
the major aspects of its pharmacokinetic and pharmacodynamic profile. Several different 
types of formulations have been discussed that are able to affect a drug’s pharmacokinetic 
profile as well as interfere with a drug’s pharmacodynamic profile. Although the current 
technologies which affect a drug’s pharmacokinetic profile are limited, they are effective in 
achieving significant toxicity reductions in vivo. The formulations available for modifying a 
drug’s pharmacodynamic response are more varied but frequently tend to be, other drugs, 
vitamins, oils or antioxidants. Collectively the pharmacokinetic and pharmacodynamic 
modulation formulations achieve their toxicity reduction in one of four proposed strategies 
discussed in section 2.7 of this chapter. 
Using information extracted from the literature, it is possible to construct toxicity 
protection pathways based on an AOP framework which maps formulations to specific 
points of an AOP pathway. If two or more drugs overlap in their toxicity pathway then 
potentially the formulations along that pathway can be effectively used for both drugs. 
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Although this has not been demonstrated through experimentation it may be possible to 
discover examples from the literature that reinforce this theory. Literature searches 
revealed that the most frequently formulated drugs for toxicity reduction are the cytotoxics 
and anti-infectives, making them an ideal choice to begin building toxicity protection 
pathways for. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
 
 
3 
3  Machine Learning 
Approaches in Predictive 
Toxicology 
 
This chapter provides an informative discussion of how experimental toxicity data are 
processed and prepared for use with machine learning techniques in predictive toxicology. 
More specifically, details are provided of the procedures required to successfully build 
classification models and the pitfalls encountered with such work. Information on data 
gathering, data curation, chemical structure handling and descriptor generation are 
discussed, as well as the various machine learning techniques currently available, with 
examples provided of their application in toxicity prediction problems reported in the 
literature. The chapter ends with a discussion of how predictive classification models are 
validated and assessed for performance. 
3.1 Predictive Toxicology 
Predictive toxicology is concerned with the development of in silico non-experimental 
models that make use of existing data for the assessment of chemical toxicity. Whilst a shift 
away from experimentation sounds ideal, in reality this is not the case. Rather, a welcomed 
change from assessing adverse effects at high doses in experimental animals has been 
replaced by a requirement to understand the underlying principal mechanisms of toxicants 
on organisms at the molecular, cellular and organ level. This type of data can in principle be 
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gathered using in vitro experiments negating or reducing the requirement of animal 
experimentation and thereby continuing to support the ongoing efforts of the 3Rs. 
Predictive toxicology can therefore be considered as the application of mathematical 
interpretations and computational approaches to predict the toxic potential of a new 
compound.  More significantly these approaches are based on information processing (data 
gathering, curating and mining) to arrange data in an appropriate manner for 
computational approaches to be used effectively. Although this thesis is not concerned 
with the prediction of compound toxicities it does make effective use of many of the 
approaches used in predictive toxicology to achieve the objectives set out in chapter 1. It is 
therefore useful to provide a brief overview of some of the techniques and approaches 
commonly used in this field of study. 
3.1.1 In silico Approaches to Predictive Toxicology  
In silico predictive toxicology can be considered as one alternative to animal testing for 
which several different approaches have been developed. There are many advantages 
associated with the use of in silico approaches which include the reduction of animal use, 
cost-effectiveness and fast turn-around of results. These in silico toxicity approaches are 
based on the premise that the toxic manifestation of a drug is related to its chemical 
structure. Therefore if the chemical structure of a new drug is known, it should in principle 
be possible to predict a toxic outcome, by relating its structure to a similar structure of 
known toxicity [248]. Such relationships are termed (quantitative) structure-activity 
relationships ((Q)SARs) [249]. Whilst this definition of QSAR fits with the description of 
QSARs recently presented by Tropsha et al. (2010) [250], some authors specifically refer to 
the term QSAR when SAR relationships become quantified [251]. In this thesis the term 
QSAR is used to refer to chemical structures whose activity (toxicity) can be reported as 
continuous (e.g. LD50) or categorical (e.g. toxic and non-toxic) values.    
Generally there are two main strategies to building predictive toxicology models; Expert 
systems and data-driven QSAR methods; 
Expert systems are based on human reasoning approaches which rely on an underlying 
knowledge base containing rules from which toxicity endpoints are derived. The knowledge 
base is unlikely to contain the exact answer to a particular new problem, but instead the 
expert system must utilise this knowledge and infer new information from it. Rules are 
compiled from experimental data of compounds that result in one or more toxic 
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manifestations within a biological system [249, 252]. DEREK is one such commercially 
available expert system developed by Lhasa Limited [253]. It utilises a knowledge base 
derived from human expertise, with structural alerts associated with toxicological effects. 
Some of the endpoint predictions DEREK is able to provide include, mutagenicity, 
carcinogenicity and skin sensitisation. OncoLogic [254] and HazardExpert Pro [255] are 
other examples of expert systems that contain human derived knowledge [256]. A 
significant advantage of these systems is that they are highly mechanistically based through 
a thorough analysis of the information, which means the reliability of the knowledge 
derived rules can be assured [249]. Other expert systems derive their rules for the 
association of a fragment structure with toxicity automatically. TOPKAT [257] uses 
statistical methods such as linear multiple regression equations, whilst CASE [258] uses a 
Bayesian approach to present a probable toxicity endpoint with confidence levels. These 
systems have the ability to analyse large datasets but provide no mechanistic information 
[249]. 
Data-driven QSAR methods develop predictive models from experimental data. Such 
methods utilise statistical and machine learning approaches to build models from the input 
data to make data-driven predictions or decisions, without any prior knowledge of the 
underlying mechanisms (toxicity mechanisms). Machine learning approaches can be split 
into supervised and unsupervised approaches. Supervised learning approaches include 
Naïve Bayes, neural networks, decision trees and random forests which are used with 
labelled data (for example, toxic or non-toxic) to train the models. In supervised learning 
the data contains an input (X) or set of inputs and an output (Y) label. The task of machine 
learning approaches is to learn and predict the output for a given set of inputs. 
Unsupervised approaches include techniques such as clustering or principal component 
analysis that use unlabelled data to fit models. Since the data used are unlabelled, there is 
no error or prediction evaluation provided. The aim of unsupervised learning is to assess 
data distribution, reduce high dimensionality or find patterns hidden amongst the data.  
The remainder of this chapter will focus on supervised machine learning techniques that 
derive QSAR data-driven predictions of toxicology endpoints. Such models use labelled data 
containing a set of inputs (derived descriptors) and related them to an output (toxicity 
endpoint). An overview of how such models for toxicity predictions are built and examples 
reported in the literature is provided. 
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3.2 Developing Machine Learning Approaches for 
Toxicity Predictions 
One of the main challenges of building predictive toxicity models is information reuse. The 
aim of such in silico approaches is to make use of the vast numbers of experimentally 
generated data currently available to learn and develop knowledge from. The following 
sections of this chapter discuss some of the main requirements for building predictive 
QSAR models using machine learning techniques. Several key steps are discussed, which 
include; establishing toxicity endpoints, gathering data, curating data, chemical data 
representation, identifying appropriate machine learning techniques, model validation and 
performance measurements.  
Although other significant factors in developing in silico classification models can be 
mentioned, these key points are relevant to the work in this thesis and are collectively 
discussed in the sections below. 
3.2.1 Toxicity Endpoint and Data Collection 
To begin building predictive QSAR models a toxicity endpoint must first be established. 
Chapter 2 discusses several toxicity types that are often reported in experimental studies, 
although this is not an exhaustive list it provides some insights into the kinds of toxicity 
endpoints which may be considered. Although picking an endpoint first may appear rather 
counter intuitive, it helps determine the nature of the data required for any supervised 
machine learning techniques to be applied.  
Data can be gathered through a variety of sources that pertain to the toxicity endpoint to 
be modelled. In-house sources may be available to laboratories that generate such data, 
alternatively publicly available resources can also be considered. Several online databases 
have been developed for such purposes, many of which are discussed by Toropov et al. 
(2014) [259]. Searching for specific compounds or toxicity endpoints can also be 
considered. Gathering individual pieces of data is extremely labour intensive although 
anomalies can be easier to identify. Using in-house data is also sometimes advantageous if 
they represent the chemical space for which predictions are sought. Where specific data 
collections result in scarce data it may be necessary to broaden the search criteria, for 
example collecting data on one specific species may result in few data, which can be 
resolved by collecting data on species from the same taxa [260]. Alternatively where data 
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are plentiful it may be appropriate to reduce the data size, for instance filtering data 
pertaining to a single sex of an animal for in vivo data. 
Acquiring data from multiple data sources will inevitably require some element of data 
integration, in particular when the acquired data are held in multiple formats. Integration 
techniques will vary according to the complexity of the data being gathered. The many 
different integration approaches are beyond the scope of this thesis but the literature 
contains several published reports on the current techniques available [261, 262]. Once 
suitable data sources are found, capturing these data into a suitable format is critical, for 
many cases a text or Excel file will suffice and enables modelling software to easily read the 
data. 
The data must then be assessed for suitability, if the information contained does not allow 
for machine learning approaches to be applied then can any additional data be obtained 
and added. For instance if data are gathered for the aquatic toxicity to Daphnia but it only 
contains chemical names and no chemical structures, it is possible to obtain structures 
from alternative sources which can then be integrated. If sufficient structures cannot be 
obtained, then this will limit the amount of data with which QSAR models can be built. A 
large data size does not necessarily result in better models; rather the size, scope and 
chemical space of the data play a significant role in defining the applicability domain of the 
model i.e. the constraints to which is model is considered reliable [263]. 
It is worthwhile mentioning here that, for a dataset gathered in a table format (e.g. Excel) 
the layout of the data in its simplest form should contain chemical information, i.e. a 
chemical structure and a toxicity endpoint (referred to as the class for classification 
modelling) corresponding to each chemical structure. For example if the toxicity endpoint 
being considered was nephrotoxicity, then the class of each chemical could be considered 
as toxic or non-toxic. For toxicity endpoints such as LD50, the endpoint information may be 
a continuous value. It is also important to remember that whilst data on compounds which 
are nephrotoxic may be relatively easy to come by, data reported on the non-nephrotoxic 
potential of a compound are sometimes more difficult to obtain. For classification models it 
is imperative that compounds are known to be toxic or non-toxic and not just assumed so 
because there are no data to suggest otherwise [17]. 
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3.2.2 Data Curation 
Whilst a large number of data are desirable, it may contain noise that prevents effective 
learning. It is imperative to deal with such instances as part of a data curation step. For 
example if outliers within the data are observed or identical instances resulting in two very 
different outcomes, for instance one compound labelled as non-toxic whist in a separate 
record the same compound is labelled as toxic then some form of pre-processing to deal 
with such occurrences is vital for effective model learning. For classification purposes it is 
important that two identical instances are not classified differently. Not recognising and 
dealing with such situations can result in poor predictive performance with results that 
become unexplainable. Several methods have been developed to assess the quality of the 
data being used and frequently look at factors such as; the reliability of the data to 
represent the toxicity endpoint, the consistency of the data to ensure low statistical 
variance and the reproducibility of the data to ensure the data are independent of any bias 
[264, 265]. 
Finally, the chemical structures contained within the data are linked to an activity (toxicity) 
presented in the data. If a chemical structure is available, but a toxicity endpoint for that 
chemical is not established then that datum point becomes unusable for modelling. The 
aim is to establish a link between any structural and/or physico-chemical properties of a 
chemical and an effect. If mechanistic knowledge is available about structural features then 
this can be used as a basis for parameter selections that are likely to influence toxicity 
endpoint. 
3.2.3 Chemical Data Representation 
Data representation of a toxicity endpoint is relatively straightforward and has been 
mentioned above and in chapter 2, so is not discussed again in this section. This section 
rather focuses on the representation of chemical data before QSAR models can be 
developed. 
Whilst there are many chemical structure representation models (Kekulé structure, Lewis 
structure and condensed structure) with widely established nomenclature processes that 
provide systematic names such as that created and developed by the International Union 
of Pure and Applied Chemistry (IUPAC) [266], for computational machine learning 
approaches a more sophisticated machine readable representation is required. There are 
essentially two classes of chemical properties that are described from the constituent parts 
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of a molecule’s atoms and bonds; explicit and derived properties. Explicit properties are 
those required to specify the mathematical graph of a molecule; that is the ordering of the 
set of atoms (nodes) and bonds (edges) that make up a molecule’s structure. Derived 
properties are those which can then be computed from the graph. 
For computational modelling the chemical representation must therefore be such that 
mathematical calculations can be made to develop descriptors (derived properties) that are 
able to describe the molecular entity in some way. A descriptor may simply be the 
molecular weight or atom counts of a compound which can be calculated from the 
condensed representation of a molecule, for example C2H6O, ethanol, whose molecular 
weight would be calculated as 46.07 g/mol is made up of 2 carbon atoms, 6 hydrogen 
atoms and 1 oxygen atom. Constitutional descriptors as such are useful but do not provide 
information about the molecular geometry or atom connectivity. For more complex 
descriptor calculations a better chemical representation in electronic format is therefore 
required.  
Many chemical file formats have been developed for computational use, which relate a 
molecule’s chemical structure to enable detailed descriptors to be calculated. Most of 
these formats are based on the physical valence model, which represents molecules based 
on mathematical graph theory. The usefulness of each format varies with limitations 
associated with each type. Three of the most commonly used formats, SMILES, InChi and 
Molfiles are described below: 
3.2.3.1 SMILES 
SMILES (simplified molecular-input line-entry system) are line notation strings that 
represent molecules. Typically a number of number of variations can be used to write 
SMILES which are all equally valid, for example ethanol can be represented as CCO, OCC, 
C(O)C and C(C)O. Canonicalization algorithms can be used to generate unique SMILES 
amongst all valid possibilities. Atoms in SMILES are represented by the standard chemical 
element abbreviation in square brackets, such as [Ag] for silver. Hydrogen atoms are 
assumed to fill the valence spaces with adjacent atoms connected by single bonds, double 
and triple bonds are represented as an equal sign (=) and number sign (#) respectively. 
SMILES carry the same information as connection tables but its advantage is that it is 
linguistically constructed which can be human-interpreted rather than a computer data 
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structure. One final advantage of a SMILES string is that it is digitally small and so does not 
require vast amount of hard disk space to store multiple structures [267-269].  
3.2.3.2 InChi 
InChi (IUPAC International Chemical Identifier) is a unique line notation string 
representation of a chemical structure, derived from the structural graph representation of 
a structure that is independent of the way the structure was drawn. A single molecule will 
therefore always produce the same InChi, which is a unique identifier for a particular 
compound. InChi uses hierarchical layers (encoded by a forward slash, /) based on a core 
parent structure to represent various levels of chemical complexity that can include bond 
connectivity, isotope information, tautomeric information, stereochemistry and electrical 
charge information. Not all layers are necessarily required, for example the stereo 
information layer can be omitted if that information is not relevant to the application. 
Omitting this information means the same InChi will be produced for the source structure 
and all of its stereo isomers [266, 270, 271]. The InChi string for ethanol is represented by 
InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3. 
3.2.3.3 Molfile 
Molfiles are based on connection tables (CTAB) that contain a table detailing the atoms of a 
molecule and another table detailing the bonded atom connections and bond types. 
Connection tables represent a single molecular structure that is divided into several blocks 
that carry information pertaining to the molecule. The header block carries the name of the 
molecule, the atom and bond counts and 3D coordinates (x, y, z). The CTAB for ethanol is 
shown in Figure 3.1. SDF file formats (structure-data files) wrap molfiles and multiple 
compounds are delimited by four dollar ($$$$) signs. SDF files have the ability to include 
associated data [272]. 
 
 
Figure 3.1. Molfile CTAB for ethanol. 
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The atom block specifies the atomic symbol with mass differences, charge, stereochemistry 
and any associated hydrogens for each atom. Finally the bond block contains one line per 
bond and specifies which two atoms are connected by a bond, the bond type along with 
bond stereochemistry and topology [272].  
3.2.3.4 Molecular Descriptors and Fingerprints 
Producing informative data from molecular structures/representations is important in 
computational applications and in particular for QSAR models. Molecular descriptors and 
fingerprints are alternative ways to encode and represent chemical data; their purpose is to 
capture the salient aspects of a chemical structure for application with machine learning 
approaches. The purpose of producing molecular descriptors and fingerprints (derived 
properties) is to derive a relationship between one or more properties of a compound and 
the toxicity endpoint being assessed. Thus if a new chemical possesses similar or identical 
properties then predictions about its toxicity can be made. 
A critical step in building predictive QSAR models is to determine which properties are 
linked causally to the toxicity endpoint being modelled. Some properties will show no 
correlation, whilst it is possible that some may coincidently result in a superficial 
relationship, which require identifying and removing if the models are to be correctly 
interpreted later. For successful modelling it is important to use the properties for which a 
rationale to the toxicity endpoint can be justified. In many cases however a mechanistic 
understanding of this relationship is poorly understood which may therefore require the 
inclusion of chemical properties which are not easily explainable [260]. 
Molecular descriptors are calculated from the chemical representations discussed above. 
Various physicochemical properties of a chemical compound are output as numerical 
values that can be correlated against a compounds activity/toxicity. It is estimated that 
thousands of descriptors now exist many of which have been extensively reviewed and 
reported by several authors [273-275]. Most descriptors can be calculated using 
commercially available software such as CODESSA [276] or DRAGON [277] which also offers 
a web based service, E-DRAGON [278]. Of the many descriptors available they can be 
categorised into four main categories as, constitutional, topological, electrostatic and 
geometrical. 
Constitutional descriptors provide relatively simple information of the chemical structure, 
such as the molecular weight, number of atoms, number of carbon atoms, number of 
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double bonds to name a few. Such descriptors are useful when the activities of a series of 
compounds are thought to be correlated to the size of the molecule [279]. 
Topological descriptors are single valued descriptors that are calculated from the 2D graph 
of a molecule, and characterise the size, shape or degree of branching of a structure. The 
Wiener Index is one such example of a topological descriptor which sums the lengths of the 
shortest paths between pairs of atoms of all the heavy atoms within the graph structure. 
The Randić index, Zagreb index and Chi connectivity indices are other topological 
descriptors [280]. 
Electrostatic descriptors provide information about the molecular charge distribution. 
Electrical charges in compounds dictate electrostatic interactions that are fundamental to 
biological interactions. The topological polar surface area (TPSA) descriptor for instance, is 
a measure of a compound’s molecular surface area. The octanol-water partition coefficient 
(ClogP) is another example of a descriptor with an electrostatic component as are atomic 
charge and net orbital charge descriptors [275]. 
Finally geometrical descriptors are derived from the x, y, z spatial coordinates of a structure 
and describe the size and shape of a structure. Since geometric descriptors require prior 
knowledge of the atoms in 3D space they can provide more detailed information and 
discriminating potential over topological descriptors. However the drawbacks of such 
calculations are that geometry optimisation of chemical structures is required and for 
flexible molecules, several conformations may exist. Exploring the relationship between a 
molecular structure and biological activity is often effective through the use of geometrical 
descriptors since they are often better at describing the 3D interactions of a ligand to a 
receptor. Some examples of geometrical descriptors include, moments of inertia, molecular 
surface area, shadow indices, WHIM descriptors and 3D MoRSE descriptors [275]. 
Molecular fingerprints provide an alternative means of describing the structure of a 
chemical compound. They work on the basis of encoding the structure of a chemical 
compound as a binary bit string with each bit representing the presence (1) or absence (0) 
of a particular group, atom or other structural fragment. Fingerprints are therefore based 
around a dictionary of existing chemical fragments that are designed to pick out features 
which may be of interest in chemical structures. There are many different fingerprint 
generation tools, of which the MACCS keys fingerprints is frequently used [281]. MACCS 
fingerprints code 166 structural keys into a bit vector. An example of some of the MACCS 
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fingerprints generated for the drug diazepam is shown in Figure 3.2, which has been 
adapted from [282].  
 
Figure 3.2. MACCS keys fingerprint for the drug diazepam. Image adapted from [282]  
 
The sample fingerprint generated in Figure 3.2 shows the MACCS key positions, the key 
descriptions and the key code generated for diazepam. Positions in the key code that 
contain a 1, indicate the presence of that substructure, whereas a 0 indicates absence. For 
diazepam, the key code shows that a 7-membered ring (7M RING) a C=N bond, a OC(N)C 
group and a 6-membered ring (6M RING) are present. Whereas a 4-membered ring (4M 
RING) an S-S bond and a C=CN group are absent. It is important to note that diazepam 
contains two 6-membered rings, however using a bit vector fingerprint will only indicate 
the presence or absence and not quantify. 
Comparing the bit string of two compounds can therefore provide a measure of “similarity” 
between their chemical structures. To compare the similarity there are various coefficient 
metrics which have been developed; examples include the Cosine coefficient, the Dice 
coefficient, the Hamming distance and the Euclidean distance, which are all extensively 
reported in the literature [283, 284]. One of the most frequently used similarity measures 
for binary fingerprints is the Tanimoto coefficient, which is defined as: 
𝑇𝐴𝐵 =  
𝑐
𝑎 + 𝑏 − 𝑐
 (1) 
 
where a is the number of bits set to 1 in molecule A, b is the number of bits set to 1 in 
molecule B and c is the number of bits common to both. The output range is 0 to 1, 
although a value of 1 does not necessarily mean the molecules are the same. Another issue 
with using fingerprints is that some compounds may result in a fingerprint with very little 
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information or possibly none at all, if any of their sub-structural properties do not occur 
within the dictionary. 
3.2.4 Model Selection 
Through prior knowledge of the type of data available an appropriate machine learning 
modelling technique can then be chosen. It is important to consider that some machine 
learning techniques such as neural networks are difficult to interpret with limited 
transparency whilst techniques such as decision trees are considered more transparent 
given a pathway to a prediction can be logically followed.  
To remain within the scope of this thesis a brief overview with examples is provided for the 
various machine learning techniques available that have been used to develop QSAR 
classification models for toxicity predictions and reported in the literature. For the purpose 
of categorical toxicity endpoints (i.e. toxic or non-toxic) classification algorithms tend to be 
the obvious choice of machine learning techniques used. Whilst there are a host of 
different techniques available this section focuses on those most commonly used in 
predictive toxicology modelling. 
3.2.4.1 Artificial Neural Networks 
Artificial neural networks (ANN) are models based on the architecture of biological neural 
networks. They consist of three or more layer which consists of an input layer, a hidden 
layer or layers and an output layer (Figure 3.3). When training, ANNs carry a weight 
between each neuron which are varied as the network learns how to form a relationship 
between the input and output layers. When constructing models the number of number of 
hidden layers and elements can be varied to optimise the model [285]. Although inspired 
by the structure of biological brains, an ANN is not capable of simulating higher brain 
functions. In actual fact a typical ANN is smaller than the brain of a 302 neuron 
Caenorhabditis elegans [286]. 
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Figure 3.3. Artificial neural network, consisting of an input layer (blue), one hidden layer (green) 
and an output layer (yellow). 
 
ANNs have been applied to a wide range of problems which include predicting bioactivity 
of oestrogen receptor agonists [287], and kinase inhibitors [288]. In relation to toxicity 
predictions, ANNs have been applied in aquatic toxicity studies [289, 290], hERG blockade 
studies [251] and for the prediction of toxicity of benzene analogues administered as an 
oral dose to rats [291]. Interestingly the authors of the benzene analogue study reported 
that the performance of the model was dependent on the molecular representation of 
their chemical structures and the choice of training set [291]. This supports the theory that 
ANNs suffer from overfitting and are susceptible to learning noise that is present in the 
training set, making them less able to generalise for the test data [292]. 
3.2.4.2 Decision Trees and Random Forests 
Decision trees (DT) form a model of decisions which result in a tree like structure. At each 
node of the tree a branch is split based on the actual values within the training set applied 
sequentially. A DT begins at the root node, which contains all the training data, as it splits 
into intermediate nodes each of these nodes contain the sum of the samples connected 
below it, until a terminal node is reached (Figure 3.4). Intermediate nodes carry the 
information of the training set whilst a terminal node results in a “decision” (e.g. toxic or 
non-toxic). Once a DT has been established a query compound is channelled to a terminal 
node through decisions based on the properties of its structure.  
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Figure 3.4. Decision tree layout, showing the root node (red), intermediate nodes (green) and the 
terminal nodes (purple). 
 
There are many DT algorithms which have been developed, of which the CART [293] and 
C4.5 [294] are particularly popular [295].  
Random forest (RF) is an ensemble method based on a forest of decision trees [296]. It 
works on the principle that many decision trees collectively, will predict better than a single 
tree. For each tree built, RFs continually split the training data into two randomly chosen 
sets, a local set to grow trees with and an out-of-bag (OOB) set to assess the goodness of 
fit, this process is known as the bootstrap phase. The OOB set may contain approximately 
37 % of the training set data selected randomly [285]. Independent decision trees are then 
constructed from the random selection of variables (compound properties) sampled 
independently from a subset of variables. As the tree grows each node becomes 
increasingly more homogenous until a terminal node is reached. The Gini criterion is used 
to ensure each node of a tree is partitioned in the best possible way [297]. Each tree is 
grown to the largest possible size with no pruning. The output of a RF is the mode of the 
prediction of the individual trees. The number of trees that a random forest builds is a 
parameter set by the user, with Svetnik et al. (2003) [298] demonstrating that 500 trees is 
usually sufficient for many models. It is useful for binary classification purposes that an odd 
number of trees are chosen so the mode prediction cannot be evenly split. In any case if an 
even number of trees is chosen for a binary class a random selection between the two 
predictions is made. RFs are generally better adapted to overfitting and are considered 
more robust to parameter changes, unlike that seen with ANNs [298]. 
DTs and RFs have been successfully used in many predictive toxicity studies. Using 
molecular descriptors of phenols Ren et al. (2003) [299] used DT models to predict the 
aquatic toxicity mechanism of this group of compounds, whilst Martin et al. (2013) [300] 
demonstrated the ability of RF models to predict aquatic toxicity mechanisms of action 
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using a dataset of 924 compounds for which they achieved overall accuracies of 84.5 to 
87.7 %. Cheng et al. (2003) [17] utilised an ensemble recursive partitioning approach to 
predict dose-dependent human hepatotoxicity, using only 2D structural information they 
achieved accuracies of greater than 80 %. RF models have also been successfully validated 
against external datasets for the prediction of the aquatic toxicity of Tetrahymena 
pyriformis [301]. The nephrotoxicity data of 41 well-characterized compounds that are 
toxic or non-toxic to human primary renal proximal tubular cell (PTCs) were used to build 
RF predictive classifiers. This study correlated the expression of the biomarkers interleukin-
6 and 8 to the toxicity of a compound. They found that their RF model produced a balanced 
accuracy of 87.8 %, whilst an SVM model resulted in a balanced accuracy of 81.6 %. 
Interestingly the authors reported interleukin-8 alone to result in higher accuracies than 
interleukin-6 alone [19]. A range of other toxicities have also been investigated using RF 
models which include mutagenicity [302] and skin sensitisation [303]. 
3.2.4.3 Support Vector Machines 
Support vector machines (SVM) work on the basis of identifying a separation line of some 
hyperplane which separates molecules of a dataset represented as an instance in the 
“feature space” of their descriptors. SVMs aim to map the data into this dimensional space 
using a linear or non-linear function, such that each instance of a binary class lies on 
opposite sides of the hyperplane. Many linear hyperplanes are potentially possible, but an 
SVM will attempt to maximise the margin between two classes. A good SVM model is one 
that achieves the maximum margin between the closest data points (known as support 
vectors) and the hyperplane (Figure 3.5).  
 
Figure 3.5. Support vector machine, showing maximum margin hyperplane and support vectors for 
a binary class. 
 
The benefit of finding the maximum hyperplane margin means the model can offer the best 
generalisation possible allowing plentiful room for the correct classification of a test 
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compound [295]. Misclassified compounds of an SVM model will most probably lie close to 
the hyperplane [263]. SVMs can be adapted to multiclass problems or regression [304, 
305]. 
For prediction classification problems SVMs have been used for a range of different toxicity 
endpoints. Lowe et al. (2010) [306] demonstrated a superior predictive accuracy of SVMs 
when compared to an RF model for the prediction of phospholipidosis. They also reported 
on the improved performance of their model through the use of circular fingerprints 
(representing structures by atom neighbourhoods [307]) when compared to descriptors 
generated by the E-DRAGON software. Cardiotoxicity studies that predicted hERG inhibition 
have also been successful using SVM models. Li et al. (2007) [308] showed their SVM binary 
classification models were able to distinguish between hERG channel blockers and non-
blockers up to an accuracy of 94 %, with a similar study reporting accuracies of 80 % using 
an external validation test set [309]. Mutagenicity is another toxicity endpoint extensively 
studied using predictive QSAR classification models, Liao et al. (2007) [310] developed SVM 
classifiers and tested their models on two publicly available datasets and an in-house 
agrochemical dataset for which they reported predictive accuracies of 80 % or greater for 
all datasets. Interestingly a study reported by Low et al. (2011) [18] replaced chemical 
descriptors with toxicogenomic biological descriptors and reported predictions for rat 
hepatotoxicity, using SVMs and RFs, which produced better predictions than could be 
achieved using conventional chemical descriptors. Furthermore, through this approach 
they were able to identify 85 transcripts relevant to the mechanism of drug-induced liver 
injury which were then linked to chemical structural alerts [18]. 
3.2.4.4 k-Nearest Neighbour 
The k-nearest neighbour (kNN) algorithm is one of simplicity; its principle being that a 
prediction (classification) is made based on the number (k) of its nearest neighbours within 
a specified feature space. In a QSAR model the training compound descriptors described as 
position vectors would constitute the feature space, which can be of a high dimensionality. 
Neighbours are therefore measured within this feature space using a distance measure, 
typically the Euclidean distance, although alternative metrics can be considered. Since 
kNNs do not relate the descriptors directly to an activity (toxicity) there is relatively low risk 
of under- and overfitting. Rather kNNs work on the hypothesis that similar chemical 
structures will result in similar toxicity profiles. Under this premise however they can be 
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prone to active cliffs, for which similar structures do not constitute to similar toxicity 
profiles [311]. 
If k=1 then the prediction is simply the single nearest instance to the test compound. 
Generally the value of k in kNN models is set low, although this makes them susceptible to 
noise. If the k value is set too large however, then instances from other classes may be 
included into its neighbourhood [295]. Consider the example shown in Figure 3.6. For a test 
compound (purple), if k is set to 1 it is simply predicted within the same class to which the 
yellow compounds belong. If k is set to 2 then it will still be predicted as the same class to 
which the yellow compounds belong given it is out voted 2:1 (yellow:green). If however k is 
set to 3, then the test compound is now near 3 green compound and 2 yellow compounds 
it is therefore out voted 3:2 (green:yellow) and will be classified into the same class as what 
the green compounds belong to.  For binary classification problems it is sometimes useful 
to select an odd number for k, to avoid the chance of tied votes.  
 
Figure 3.6. k-nearest neighbour model. Classification of the purple compound will depend on the k 
value set by the user.  
 
kNNs work well with localised data which form distinct clusters within the feature space, 
with global coverage possible if the feature space is evenly distributed. Since kNNs rely on a 
distance to a neighbour(s), in principle this value could be used as a measure of prediction 
confidence. 
Due to their simplicity kNN models are frequently used with classification toxicity 
problems. A kNN QSAR model predicting the algal toxicity of 91 compounds against 
Chlorella vulgaris revealed three descriptors related to the hydrophobicity, electrophilicity 
and a function of molecular size corrected for the presence of heteroatoms resulted in an 
effective model, whilst a multiple linear regression approach was unable to model the data 
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[312]. A hybrid SVM-kNN model for kinase inhibition was shown to produce effective 
predictions on an in-house dataset used by Briem et al. (2005) [288].  
Using a relatively small dataset of 26 compounds, Honorio et al. (2005) were able to model 
the psychoactivity of cannabinoid compounds, successfully validating the model with an 
external validation set of 8 cannabinoid compounds with known activity [313]. This study 
demonstrates the effective use of kNNs with small datasets of localised data, although it 
may be limited when applied to larger or more diverse datasets. Furthermore, Gadaleta et 
al. (2014) [314] developed kNN models using repeated dose toxicity data of rats for which 
their model was only able to predict correctly a small number of compounds, showing the 
limited capability of kNNs when the feature space complexity is high. 
3.2.4.5 Naïve Bayes 
Naïve Bayes classifiers use a branch of mathematics known as probability theory to find the 
most likely classification. An estimation of the posterior probabilities of class is determined 
based on feature information. It assumes that the features, fi, are conditionally 
independent of each other given the output classification, c, which results in the formula: 
𝑃(𝑐|𝑓1, 𝑓2, … 𝑓𝑛)  =  𝛼 𝑃(𝑐) ∏ 𝑃(𝑓𝑖|𝑐)
𝑛
𝑖=1
 (1) 
A prediction results in a class being assigned with the highest estimated probability. For 
QSAR models however, the assumption of the conditional independence of the features 
(descriptors) is not always valid, but can be obtained through feature selection procedures. 
Naïve Bayes are prone to false predictions if over-weighted or irrelevant features are 
selected and more so if the training set contains a different distribution of toxic/non-toxic 
compounds to the test set.   
Nevertheless many successful classification models for toxicity predictions have been 
demonstrated using naïve Bayes classifiers. A study [315] reported on the use of naïve 
Bayes and RF classifiers to map in vitro toxicity results of pesticide compounds into an in 
vivo effect. Although many different classifiers were tested the most effective results were 
produced by the naïve Bayes and RF models, interestingly they also demonstrated that 
using a lower number of trees in their RF models improved their results. Whilst the authors 
were generally able to predict toxicity they were unable to successfully predict a specific 
endpoint, determined by the various in vitro toxicity assays that the pesticides were tested 
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against. Unfortunately the study did not take into account a descriptor reduction step 
which resulted in a sparse feature space and may be the cause of their RF models 
producing better results with a lower number of trees. 
3.2.5 Model Validation 
Models that fit data are only useful if they are able to accurately predict for the general 
case. A model must therefore be able to generalise from the data used to train it and make 
predictions for an unknown instance(s). To assess a trained model’s ability to do this it 
must be validated. The most common approach used is to randomly split the originally 
collected dataset into two sets; a training set and a test set. The split is typically 80:20 or 
70:30, training:test, although other splits can be used. This method is useful since it does 
not require a second round of data collection and curation which is a lengthy time 
consuming process. The training set is then used to train the model to learn from the 
information contained within it. The classification properties of the training set are known 
to the model. Once trained, the model is then run against the test set, for which the 
classification values are hidden and not known to the model. The concordance of these 
predicted values, against the hidden actual values is measured to assess the accuracy of the 
model. This form of validation is considered an “external validation,” provided any feature 
selection or model parameter settings are not based on the test set and it is solely used to 
assess model predictions once training is complete. Some authors argue that a true 
external validation set is compiled of data from an alternative source to the original dataset 
[316-318]. Data contained in the originally collected dataset may contain compounds 
within the same chemical space, in particular if in-house data is used. Splitting this data 
into a training set and test set is therefore likely to result in good predictions given the test 
set is similar to the training set. 
A counter argument however, can also be made against using a test set that is chemically 
very diverse to the training set. For effective predictions to be made the test set must fall 
within the applicability domain of the training set [263]. A test instance that has no similar 
instance to it within the training set is less likely to be predictable, resulting in poor model 
performance. 
More efficient ways to split the dataset into a training set and test set have been developed 
which arguably allow better training to occur. Of these the cross validation method is 
frequently used. An n-fold cross validation involves splitting the data randomly or in a 
85 
 
 
stratified way to result in n different folds. One fold is used as the test set while the 
remaining n-1 folds are used as the training set. Each fold is then cyclically permutated so 
that every fold is used as the test set once with the remaining n-1 folds used to train the 
model. Using this method, n models are created which sequentially train on all the data, 
whilst also providing predictions for each of the instances within the dataset [319].  
Careful consideration must be taken when using a cross validation process; any feature 
selection techniques or model parameters used should be independent of the n test sets 
and any information regarding the test set must not find its way into the model building 
process. Typically a 5- or 10-fold cross validation technique is employed although a special 
case of this validation, termed Leave-One-Out (LOO) cross validation is sometime used. 
LOO, as the name suggests involves leaving one instance for model validation while training 
on the remaining data set. This process is recursively looped until all instances within the 
dataset are predicted for. 
Another approach to testing the reliability of a model is known as y-randomisation or y-
scrambling. In this approach the class (or y values) are randomly assigned to instances 
within the dataset and the models are run according to the settings and parameters 
previously tested. Randomising the class, disrupts any link between property descriptors 
(features) and the class so no possible correlation remains. If the models are still able to 
produce equivalent accuracy measurements then the models are considered unreliable as 
they are most likely modelling noise rather than signal [318]. 
3.2.5.1 Measuring Classification Model Performance 
For QSAR classification models, the predictive accuracy of a model can be measured by the 
number of correct predictions divided by the total number of predictions made. For 
example, if a model was asked to predict 10 compounds for which it was correct 7 times, 
the accuracy could be considered to be 70 %. For classification problems however this is an 
inadequate measure of model performance.  
Consider a binary classification model for which the classes are disproportionately split, 
say, 90:10. A model which favoured the major class, every time it made a prediction, would 
inadvertently seem to be highly predictive. However in reality due to the unbalanced 
dataset the model is unable to discriminate between the classes. An alternative measure is 
therefore required. 
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Considering a single class of a binary classification model, predictions can be considered as 
correctly recognised class examples (true positives (TP)), correctly recognised examples 
that do not belong to the considered class (true negatives (TN)), examples incorrectly 
assigned to the class (false positive (FP)), and examples not recognised as class examples 
(false negatives (FN)), satisfying; TP+FP+TN+FN = N, with N being the total size of the test 
set [320]. A confusion matrix of the observed against the predicted would look like (Table 
3.1): 
Table 3.1. Confusion matrix for a binary classifier. 
 
  Observed 
  Positive Negative 
P
re
d
ic
te
d
 
Positive TP FP 
Negative FN TN 
 
From the confusion matrix shown in Table 3.1 the accuracy discussed above can be 
represented as: 
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝑇𝑃 + 𝑇𝑁
𝑇𝑃 + 𝐹𝑃 + 𝑇𝑁 + 𝐹𝑁
 (2) 
 
The precision of a model can be defined as a measure of the accuracy of the number of 
elements in a specific class, regardless of whether they should be present or not. It is given 
by: 
𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 =  
𝑇𝑃
𝑇𝑃 +  𝐹𝑃
 (3) 
 
Using the confusion matrix it is possible to calculate the sensitivity, sometimes referred to 
as the recall and is considered as the true positive rate, i.e. the number of true predictions 
divided by the total number that should be true. For a binary classification this can be 
considered as the correct classification rate of one of the two classes and is given by: 
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =  
𝑇𝑃
𝑇𝑃 +  𝐹𝑁
 (4) 
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Furthermore the correct classification rate of the other class is given by the specificity, 
which is a measure of the true negative rate, i.e. the number of negative predictions 
divided by the total number that should be negative. This is given by: 
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =  
𝑇𝑁
𝐹𝑃 +  𝑇𝑁
 (5) 
 
For an unbalanced binary dataset, for which the accuracy is not a true reflection of model 
performance, a mean of the correct classification rates of the two classes can be calculated 
to give the balanced accuracy of a model. The balanced accuracy is able to avoid inflated 
accuracy rates on unbalanced datasets, it is given by: 
𝐵𝑎𝑙𝑎𝑛𝑐𝑒𝑑 𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =  
𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 + 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦
2
 (6) 
 
Similarly, the Matthews Correlation Coefficient (MCC) can be used to assess the overall 
discriminative ability of a binary classifier. As with the balanced accuracy, the MCC takes 
into account all the values from the confusion matrix and is particularly suited with highly 
unbalanced datasets [321, 322]. The MCC is given by: 
𝑀𝐶𝐶 =  
𝑇𝑃 𝑥 𝑇𝑁 −  𝐹𝑃 𝑥 𝐹𝑁
√(𝑇𝑃 + 𝐹𝑃) (𝑇𝑃 + 𝐹𝑁) (𝑇𝑁 + 𝐹𝑃) (𝑇𝑁 + 𝐹𝑁)
 (7) 
  
The MMC value is always between -1 and +1. A value of -1 indicates total disagreement (i.e. 
all predictions were incorrect) and a value of +1 which indicates total agreement (i.e. all 
prediction were correct). A value of 0 (zero) suggests predictions are made randomly [322]. 
For binary classification models, the performance measurements described above are the 
ones most frequently reported in the literature. Whilst other statistical measures can be 
explored [320], they are not discussed here as this thesis is concerned with classification 
models only. 
3.2.5.2 Applicability Domain 
The concept of an applicability domain is considered as the chemical space in which a 
model makes reliable accurate predictions. Therefore the output of the model is only valid 
if the compound being predicted lies within the applicability domain [323]. This domain can 
be defined as a theoretical multidimensional chemical space [318], where each dimension 
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can represent the structural, biological, or physico-chemical properties of a compound 
[324]. Since the training set used to train the model represents a small proportion of the 
chemical space, it seems reasonable to set the domain from the compounds used to train 
the model. Most methods reported in the literature provide a numerical value such as a 
similarity measure between the test and training set [324]. This value can then be used as a 
threshold for further predictions. Predictions made outside of the domain can be high but 
considered unreliable, on the other hand predictions made within the domain can be low 
but deemed reliable [318, 323].  
3.3 Summary 
In this chapter the development of QSAR models using machine learning techniques for 
classification problems has been discussed. A stepwise approach which begins with 
establishing a toxicity endpoint prior to data collection and curation is explained. 
Information regarding chemical structure handling and chemical representation in terms of 
descriptor and fingerprint generation is explained. An understanding of the importance of 
descriptor/fingerprint generation and potential correlation against activity (toxicity) is one 
of the key concepts of predictive toxicity models. An overview has been provided of some 
of the popular machine learning techniques used with classification problems and their 
relative abilities have been discussed. Furthermore, examples of ANNs, DTs, RFs, SVMs, 
kNNs and Naïve Bayes models reported in the literature and their success rates as reported 
in the literature have been discussed. Reasons for model validation and the approaches 
used have been described and the statistical methods used to assess classification model 
performances have been discussed. Finally the applicability domain of a model has been 
discussed with a brief overview of its definition and how the domain parameters can be 
set. 
Whilst a comprehensive in-depth detailed discussion of all the methods used in 
computational toxicology problems is beyond the scope of this thesis, this chapter aims to 
provide an informative discussion of the methods used and explored in subsequent 
chapters. 
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4 
4 Graphs for Visualising 
and Extracting Data 
 
This chapter is concerned with the application of graph theory for scientific data 
representation, visualisation and the quick identification of drug-vehicle relationships, 
which show significant changes in patterns of toxicity. A novel bipartite graph preparation 
methodology is proposed and discussed for the rapid extraction of interesting relationships 
within large datasets that require minimal data curation.  
Furthermore, the toxicity differences afforded by two different vehicles for a specific drug 
or group of drugs can be arranged into a Venn diagram to identify multiple vehicle 
relationships and identify the number of data points that are available for these 
relationships. This methodology therefore allows the rapid visualisation and identification 
of data a scientist may consider interesting to work with. A practical example of how this 
methodology can be applied to real scientific data is demonstrated in this chapter. 
4.1 Graph Theory 
Graph theory is an area of discrete mathematics that uses complex networks to solve 
practical problems. In the domain of science alone, graph theory has been used for brain 
networks, gene networks, protein side chain predictions, molecular descriptor calculations 
and cellular functional organisations [275, 325-328]. 
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A graph G comprises a pair of sets (V, E) where V is the set of vertices or nodes (v1…vn) and 
E is the set of edges or arcs formed between pairs of vertices. E is considered a multiset 
given that its element can occur more than once. Any two vertices in G are said to be linked 
if there exists an edge that connect vertices vi to vj given that both vi and vj are elements of 
V (vi V and vj V). The edge connecting vertices vi and vj is denoted as (vi, vj). The total 
number of vertices within a graph is denoted as |V| and the set of vertices adjacent to 
vertex vi, are referred to as the neighbours of vi. The number of edges connecting to the 
vertex vi, is referred to as the degree of vi. Whereas the number of vertices connected to 
edge ei, is referred to as the degree of ei. Edges can be weighted or carry additional 
information which may represent the relationship of the two vertices it connects. For a 
subgraph G’ to be formed from graph G it must satisfy the relationships of V’  V and E’  
E. A graph is considered undirected if there is no start or endpoint between two connected 
vertices. Similarly a directed graph or digraph is therefore a graph whose vertices are 
connected via directed edges.  
A bipartite graph is a graph whose vertices’ set V can be divided into two disjoint sets X and 
Y, with each edge e , connected at one end to a vertex in X and at the other end to a 
vertex in Y. Vertices that are elements of X or Y cannot be connected to one another by an 
edge for bipartite to hold true. A directed bipartite graph would therefore contain directed 
edges which connect the two disjoint sets (see Figure 4.1). 
  
Figure 4.1. Directed bipartite graph showing two disjointed sets of V (X and Y) connected by 
directed edges E. 
 
If all the vertices of a graph V are ordered (v1…vn), then the edge connection between any 
two vertices (vi and vj) can be give given by the adjacency matrix A of G: 
aij = {
1   𝑖𝑓   𝑣𝑖𝑣𝑗  ∈ 𝐸
 0   𝑖𝑓   𝑣𝑖𝑣𝑗 ∉ 𝐸
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4.2 Data for Graph Representation Methodology 
The dataset used for the work in this chapter (NIH dataset) was obtained from the National 
Institutes of Health’s Developmental Therapeutics Program (DTP) [20]. The dataset is 
publicly available and has been collected over a period of approximately 30 years, 
beginning in the 1950’s up until the 1980’s. The dataset contains experimental records 
from their in vivo screening program against animals inoculated with cancer cell lines to 
assess the effectiveness of the compounds against the developing tumour. The dataset 
contains 2,724,199 records detailing the in vivo experimental screening results of 227,093 
unique compound identification numbers (NSC). Each compound was tested by one or 
more laboratories (screener) at various doses against different cancer cell lines in various 
animal models. Experiments were most commonly conducted in mice, rats and hamsters 
using different dosing schedules and administration routes. Test compounds were 
administered using a range of different vehicles, which facilitates the administration of the 
compound. There are 39 different vehicles used throughout the dataset for which some 
vehicles had been used more frequently than others (Figure 4.2) 
 
Figure 4.2. Vehicle distribution frequency of the NIH dataset. A total of 39 different vehicles are 
present, of which some vehicles have been used more frequently than others. The six most 
frequently occurring vehicles in the dataset are shown in the pie chart with the remaining grouped 
into the ‘Other’ category. 
 
Although the primary objective of the DTP was to discover antineoplastic compounds, the 
work in this chapter aims to visualise these data through the methodology proposed below, 
to demonstrate how large numbers of data can be rapidly processed and interesting 
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relationships extracted for scientific purposes. For each experiment detailed in the dataset 
the survival rate on a specified day was recorded as a measure of toxicity. This information 
is used to construct bipartite graphs which allow for rapid identification of interesting drug-
vehicle relationships that show significant changes in patterns of toxicity. 
The NIH dataset is made available in appendix A as an electronic file. 
4.3 Data Pre-Processing 
The methodology proposed in this chapter requires a minimal amount of curation for 
interesting drug-vehicle relationships to be visualised and extracted. All data curation and 
visualisation was handled using a Knime workflow [329]. The NIH dataset was downloaded 
as a 63 x 2,724,199 data table, and interpreted using a document referred to as 
“instruction_14,” available for download from the DTP website [20]. 
For each of these 2,724,199 experiments within the NIH dataset, a number of animals, 
typically 6, 8 or 10 were used per dosing schedule. At a specified experimental endpoint 
(TOXDAY) the toxicity outcome of these experiments in terms of animal survival was 
reported. The dataset therefore contains a record of the animals at the start of an 
experiment (SURVIVOR_NUMBER_START) and also a record of the animals remaining at the 
end of an experiment (SURVIVOR_NUMBER_TOXDAY).  
To compare two individual experiments that used identical experimental conditions but 
different starting animal counts, the % survival of each experiment was calculated as: 
% survival =  
SURVIVOR_NUMBER_TOXDAY
SURVIVOR_NUMBER_START
 x 100 (1) 
 
Any records which resulted in a % survival rate of > 100 % were removed from the dataset. 
These are clearly errors as the surviving animals at the end of an experiment cannot exceed 
the number of animals at the start of an experiment. To improve computational processing 
times, columns carrying information deemed unnecessary for the purpose of this work 
were removed, although this is not considered necessary as part of this methodology. For 
example the column labelled TREATMENT_TIME, recorded the time at which dosing began. 
This information was considered not to have an influence on experimental outcome 
(toxicity) and so was entirely removed from the dataset. Other columns that were removed 
included, but were not limited to, the date of the experiment (TEST_DT) and the laboratory 
(SCREENER) in which the experiments were conducted. Attempts to identify any correlation 
93 
 
 
between the columns removed, for example, SCREENER, and the survival outcome were 
unsuccessful and so removal of these columns was considered acceptable. Other columns 
were removed based on the limited information that they carried. For example a column 
that recorded the sex (SEX_CD) of an animal was present. However of 2,724,199 records 
available, 463,450 were recorded as male, 448,483 were recorded as female, 259 as mixed 
sex and 1,812,007 fields were missing. If the records that were missing were entirely 
removed from the dataset, this would significantly reduce the number of data available to 
build graphs and extract interesting relationships from. For this reason it was decided to 
aggregate the data in this column, i.e. experiments were not separated by sex. 
It is important to note at this point however that an inoculated tumour growing on an 
animal host can affect the survival outcome of the animal, if a tumour grew rapidly then 
there is a possibility it will lead to lethality. The decision to aggregate on the tumour code 
column (TUMOR_CD) was taken since the survival outcomes of animals were recorded on 
day 0 (zero) or day 5 (TOXDAY) after the first dose was administered and as such the 
toxicity outcome would be largely influenced by the drug administered rather than the 
developing tumour. 
The columns which remained were considered important to experimental outcome and are 
listed in Table 4.1 below: 
Table 4.1. List of columns retained after data curation of the NIH dataset for data visualisation. 
The columns listed were considered influential on experimental toxicity outcome i.e. survival rate. 
 
Original column heading Description of column 
NSC Identification number of compound tested (NSC- National Service Number) 
HOST_GROUP_CD Type of animal 
HOST_CD Species/strain of animal 
ADMIN_ROUTE Route of administration of drug 
INTERVAL Time between treatment (dosing) in terms of interval unit 
INTERVAL_UNIT Minutes (M), hours (H) or days (D) 
VEHICLE_CD Vehicle used 
NUMBER_INJECTIONS Total number of injections administered 
FIRST_INJECTION_DAY Day of first administered injection relative to day zero (inoculation) 
REPETITION Repetition of injection cycle 
RESTART_DAYS Days on which repetition occurs 
DOSE_AMOUNT Dose in mg/kg unless otherwise stated 
TOXDAY Day toxicity is measured 
SURVIVOR_NUMBER_START Animal count at start of experiment 
SURVIVOR_NUMBER_TOXDAY Animal count on toxday 
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Once the % survival for each of the 2,724,199 individual experiments is calculated a % 
mean survival value is calculated for any replicate experiments that are present. To do this 
all records that contained identical experimental conditions were grouped together and a 
mean of their % survival values is calculated. The experimental conditions that were 
aggregated include: NSC, HOST_GROUP_CD, HOST_CD, ADMIN_ROUTE, VEHICLE_CD, 
NUMBER_INJECTIONS, FIRST_INJECTION_DAY, INTERVAL_UNIT, INTERVAL, 
DOSE_AMOUNT_UNITS, DOSE_AMOUNT, TOXDAY, REPETITION and RESTART_DAYS. 
4.4 Methodology of Graph Construction 
To build graphs for the visualisation of interesting relationships and data extraction, the 
challenge is therefore to arrange the NSC, DOSE_AMOUNT, VEHICLE_CD and % mean 
survival into a graph’s vertices such that the toxicity differences offered by different 
vehicles can be easily visualised and relevant information readily extracted. A further 
aspect of graph representation in this study was to show that minimal data pre-processing 
is required from which interesting data relationships can be extracted. 
A rather discernible observation is that the drug (NSC), dose (DOSE_AMOUNT) and vehicle 
(VEHICLE_CD) are considered the causality of % mean survival. The opposite (i.e. % mean 
survival causing drug, dose amount and vehicle) cannot hold true, therefore the first point 
to be made is that the graph to be created must be a directed graph (digraph) which has a 
direction from the drug, dose amount and vehicle leading to the % mean survival. 
Initially a directed graph (G1) was constructed with the NSC, DOSE_AMOUNT, VEHICLE_CD 
and % mean survival represented as vertices with directed edges connecting one vertex to 
another. The digraph G1 can therefore be represented as; G1 = (V1, E1), where set V1 
consists of the four elements shown in Table 4.2 below. 
Table 4.2. Elements of set V1 for digraph G1 = (V1, E1). 
 
Vertices (V1) Elements of V1 
Connecting to 
element of V1 
NSC (Drug) N D 
DOSE_AMOUNT D VE 
VEHICLE_CD VE S 
% mean survival S - 
 
The digraph G1 is therefore a directed graph which forms a set of edges (E1) with the 
elements of set V1 in the order N → D → VE → S. A mock example of graph G1 is shown in 
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Figure 4.3 below which is produced from the mock data shown in Table 4.3. For illustrative 
purposes actual values from the NIH dataset have been replaced with mock values, 
although the heading titles of each field have been retained. 
Table 4.3. Data table for digraph G1. Although the data headings are retained from the NIH 
dataset, the values for each instance are arbitrary.   
 
Row Number NSC DOSE_AMOUNT VEHICLE_CD % mean survival 
1 Drug X 10 Vehicle 1 100 % 
2 Drug X 10 Vehicle 2 80 % 
3 Drug Y 10 Vehicle 1 80 % 
4 Drug Y 20 Vehicle 1 100 % 
5 Drug Y 20 Vehicle 2 80 % 
 
Digraph G1 (Figure 4.3) provides a simple visualisation of the mock data showing the 
relationship between drug, dose, vehicle, and survival represented by the elements N, D, 
VE and S respectively of set V1. The digraph is arranged so that it shows a drug used at a 
specific dose and vehicle leading to a toxicity outcome. For example rows 1 and 2 of Table 
4.3 show Drug X at a dose of 10 mg/kg being used with Vehicle 1 and Vehicle 2 resulting in 
a % mean survival of 100 and 80 % respectively. These two relationships can be visualised 
from graph G1 shown in Figure 4.3.  
 
Figure 4.3. Digraph G1 showing vertices V1 connected by edge set E1 (arrows). V1 contains the 
elements N, D, VE and S shown as purple, yellow, blue and green vertices respectively. 
 
A major concern related to this form of graph layout however is that the individual 
relationships can be difficult to follow without further information being included into the 
graph or by referring back to the original data table. For instance, at the vertex 
representing Vehicle 1 there are 3 directed out-degree edges that leave this vertex. Two 
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edges lead to the vertex 100 % and one edge leading to the vertex 80 %. Since the in-
degree edges of the vertex Vehicle 1 can come from three possible sources (Drug X/10 
mg/kg, Drug Y/10 mg/kg or Drug Y/20 mg/kg) it is difficult to ascertain from the graph 
which out-degree edge belongs to which of the three possible in-degree permutations. 
Given the issues associated with graph G1 an alternative solution was required. To maintain 
the simplicity of graph representation it was not ideal to add more information to the 
graph making it overtly complex to visualise and analyse. 
An alternative graph representation could therefore remove element S of set V1 from graph 
G1 and add this information as a weighted edge label. The proposed graph G2, can 
therefore be represented as G2 = (V2, E2) where set V2 contains the elements N, D and VE 
ordered as N → D → VE and set E2 now contains the element S (S E2). Edges that connect 
vertex D to vertex VE can now be labelled with element S of set E2. Using the data 
presented in Table 4.3 graph G2 can be visualised as shown in Figure 4.4 below. 
Graph G2 shows the set V2 containing the elements N, D and VE and edge set E2 containing 
element S (red text). Using the % mean survival (S) as a weighted edge that connects vertex 
D to vertex VE makes visualising the data much easier. For example it is much easier to see 
that Drug Y at a dose of 20 mg/kg has been tested with two different vehicles, Vehicle 1 
and Vehicle 2 which resulted in the % mean survival rates of 100 and 80 % respectively. 
Such information is much less apparent from graph G1. 
  
Figure 4.4. Weighted digraph G2 showing set V2 connected by edge set E2 which contains element S 
(red text). V2 contains the elements N, D and VE shown as purple, yellow and blue vertices 
respectively. 
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Graph G2 does however still carry some inherent problems. For example, at the vertex 10 
mg/kg, the number of out-degree edges is 3 and the number of in-degree edges is 2. This 
suggests that at a dose of 10 mg/kg, Drug X or Drug Y has only been tested with one of the 
vehicles, as confirmed by the data in Table 4.3, however from the layout of graph G2 it is 
impossible to determine this and therefore this weighted graph is also not an optimal 
solution. 
Multiple elements contained within the set V, result in graphs that are difficult to visualise 
and follow. To overcome these issues a directed bipartite graph may be the optimal 
solution. A bipartite graph contains two disjointed elements within its vertices set. The data 
in Table 4.3 would therefore require further processing to create two elements that can be 
represented by the vertices set V. Removing one or more of the elements (data instances) 
would result in losing critical information that enables differences in toxicity to be 
visualised and extracted. For example if the dose amount column was removed from Table 
4.3 it would seem as if two records (rows 3 and 4) produced two different toxicity 
outcomes for the same drug and vehicle combination, when in actual fact the differences 
are related to the dose of the drug. Similar misleading information would result from the 
removal of the other columns carrying vital information listed in Table 4.3.  
Since the removal of critical data or the inclusion of additional data, are not ideal solutions, 
the approach taken in this study was to combine data columns and use non-numerical 
values as edge weights or labels. 
Since the drug (NSC) and dose amount (DOSE_AMOUNT) are important factors of toxicity 
which need to be kept constant when comparing two or more different vehicles it was 
decided that these values could be combined into a single data value which would make up 
one element (N-D) of the vertices set V. The other element would simply be the % mean 
survival value (S). Graph G3 can therefore be represented as G3 = (V3, E3), where V3 contains 
the elements N-D and S ordered as N-D → S and E3 now contains the element VE (VE E3). 
The NSC and DOSE_AMOUNT columns in Table 4.3 must therefore be combined before G3 
can be constructed; this processed data for graph G3 is shown in Table 4.4 below. 
With the drug (NSC) and dose (DOSE_AMOUNT) now combined as a single value (NSC-
Dose) it is possible to construct a directed bipartite graph (G3) as shown in Figure 4.5 
below. 
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Table 4.4. Data table for graph G3 showing drug (NSC) and drug dose (DOSE_AMOUNT) combined 
into a single value. 
 
Row Number NSC-Dose (N-D) VEHICLE_CD (VE) % mean survival (S) 
1 Drug X-10 Vehicle 1 100 % 
2 Drug X-10 Vehicle 2 80 % 
3 Drug Y-10 Vehicle 1 80 % 
4 Drug Y-20 Vehicle 1 100 % 
5 Drug Y-20 Vehicle 2 80 % 
 
From graph G3 it becomes immediately apparent that arranging a graph in this manner 
allows quick visualisation of data from which interesting relationships can be easily singled 
out. From this graph we can see that Drug X at 10 mg/kg and Drug Y at 20 mg/kg have both 
been tested with Vehicles 1 and Vehicles 2 and that a difference in survival outcome 
related to the difference in vehicles used is easily observed from the graph (G3). The graph 
also enables data that is not considered useful to be rapidly removed. For example graph 
G3 shows that Drug Y at a dose of 10 mg/kg was only tested using one vehicle (Vehicle 1) 
and so a relationship to another vehicle cannot be made. This dataum value therefore does 
not present any interesting toxicity comparisons and can be entirely removed from the 
graph. 
 
Figure 4.5. Directed bipartite graph G3 showing set V3 connected by edge set E3 which contains 
element VE (red text). V3 contains the elements N-D and S shown as purple and green vertices 
respectively. 
 
To quickly filter graph G3 so that any drug-dose (NSC-Dose) combinations that have only 
been tested with a single vehicle are removed from the graph, we apply an out-degree 
filter to the N-D element of set V3. Filtering all the vertices of element N-D which possess 
an out-degree of <2 removes all instances of a drug-dose combinations (NSC-Dose) for 
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which only one vehicle has been used. Applying this filter produces the graph shown in 
Figure 4.6 below. 
 
Figure 4.6. Directed bipartite graph G3 filtered for drug-dose relationships that have more than 
one vehicle associated with them. 
Arranging the data as a directed bipartite graph (G3) where vertex V3, contains the 
elements drug-dose (NSC-Dose (N-D)) and % mean survival (S) in the arrangement N-D → S 
with the edges, E3, containing the element VE, provides an elegant and unique way of easily 
visualising the data for interesting toxicity relationships. The graph quickly helps identify 
the two drug-dose combinations for which two different vehicles have been used both 
resulting in a difference in toxicity outcome. Furthermore single data values, for which 
interesting relationships are not present, can be quickly removed through vertex filtering 
criteria. 
Using graph extraction techniques it may also be possible to extract subgraphs showing 
only the connecting elements of a specific drug-dose, or all the connections made by a 
specific vehicle or pairs of vehicles. This arrangement of bipartite graph representation 
makes the extraction of several different data arrangements possible. 
4.5 Graphs for Data Visualisation 
For data visualisation, graphs can be arranged and organised in several different ways. The 
type of data that is chosen to be displayed in a graph can have a significant impact on the 
way a graph is then mined for knowledge extraction. For the NIH dataset that has been pre-
processed for graph visualisation, several possibilities were explored and are discussed in 
the methodology section above.  
So that only records of identical experimental conditions were compared the largest subset 
of identical experimental conditions was filtered for from the pre-processed NIH dataset. 
To do this the following experimental conditions were grouped; HOST_GROUP_CD, 
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HOST_CD, ADMIN_ROUTE, NUMBER_INJECTIONS, FIRST_INJECTION DAY, INTERVAL_UNIT, 
INTERVAL, TOXDAY, REPETITION and RESTART_DAYS.  
This resulted in the grouping together of many experimental records containing different 
drugs, dose amounts, vehicles and % mean survival rates. The largest subset of identical 
experimental records that resulted from this grouping contained 387,662 records with 
63,783 unique drug numbers (NSC number). This single subset was chosen to demonstrate 
the methodology of this chapter in practice. All the records within any one grouping are 
considered to be identical in experimental protocol and therefore can be directly compared 
for toxicity outcome, provided the same drug and dose were used with two or more 
different vehicles. The experimental conditions can thus be removed, leaving behind a 
dataset which contains the following columns; NSC, DOSE_AMOUNT, VEHICLE_CD, and % 
mean survival. 
The application of the methodology provided in section 4.4 was then used to extract 
interesting drug-vehicle toxicity relationships from the pre-processed NIH dataset. For the 
illustrative purposes of this thesis some minor changes to the above methodology were 
made to make reporting of the data easier to demonstrate and visualise. These changes will 
be discussed below as they become relevant.  
The NIH dataset recorded dose amounts (DOSE_AMOUNT) as a seven digit figure. A dose of 
250 mg/kg would thus be recorded as 0000250. To make visualisations less cluttered the 
leading 0 (zeros) of the dose amounts were removed. The drug number (NSC) and dose 
amounts (DOSE_AMOUNT) were then combined as discussed in the methodology (section 
4.4) to produce one single value separated by a hyphen (-), so for the NSC number, 740, 
dosed at 0000330 mg/kg, the combined value would look like; 740-330. This was done for 
all drug-dose combinations in the pre-processed dataset. 
Since the % mean survival rates have been calculated from replicate experiments, this 
resulted in a range of continuous values within the dataset. To simplify matters a decision 
was taken to bin the % mean survival values into 10 bins as follows (Table 4.5); 
Binning is performed for the purpose of ease of visualisation although the % mean survival 
rate continuous values could equally have been used. The dataset now contains the 
following three columns; NSC-Dose, VEHICLE_CD and Bin. 
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Table 4.5. Bin values for % mean survival rates. 
 
% mean survival range Bin 
0 – 10 % 10 % 
11 – 20 % 20 % 
21 – 30 % 30 % 
31 – 40 % 40 % 
41 – 50 % 50 % 
51 – 60 % 60 % 
61 – 70 % 70 % 
71 – 80 % 80 % 
81 – 90 % 90 % 
91- 100 % 100 % 
 
A directed bipartite graph can then be created from this dataset. The vertices set V 
therefore contains the two disjointed elements, NSC-Dose (N-D) and % mean survival rates 
which are now represented by the bin values. For continuity purposes, the bins will be 
referred to as the % survival set and this element can therefore be labelled as S. Edges in 
the graph are represented by the edge set E which contain information regarding the 
vehicles (VE) used with a particular drug and dose amount (N-D).  
A graph representing the 387,662 records of identical experimental conditions is not 
visually useful as this graph contains all possible associations of data i.e. interesting and 
non-interesting relationships. To demonstrate this, Figure 4.7 shows the graph G4 = (V4, E4), 
produced from a subset of the data and contains 10,000 of the 387,662 records. Elements 
of N-D are shown in purple, and elements of S are shown in green (which are obscured by 
the purple N-D elements). These two disjoined elements of set V4 are connected by the 
edge set E4 which contains the element VE (which again is obscured by the purple of the N-
D elements). 
The purpose of graph representation is to visualise drug-vehicle relationships where the 
use of two different vehicles, results in a change in toxicity outcome. Elements of N-D can 
therefore be filtered using an out degree filter. A filter setting of >1 would mean each 
element of N-D must have two or more elements of VE connected to it. This would mean 
two or more different vehicles are associated with that vertex (N-D). If this is not the case 
those vertices will be removed from the graph. 
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Figure 4.7. Graph, G4, representing a subset of 10,000 records. Elements of the vertices set V4, are 
shown in purple (N-D) and green (S), which are connected by edge set E4 which contains the 
element VE.  
 
The filter also serves a second important purpose. As mentioned earlier, this methodology 
requires minimal data curation. As part of this curation, missing records were not dealt 
with in any way and not removed from the dataset. Consider the data in Table 4.6, which 
contains 4 mock records, for which the vehicle and % mean survival, have not been 
recorded for the 4th instance of this table. 
Table 4.6. Mock graph data containing missing vehicle (VE) and % mean survival (S) information. 
 
NSC-Dose (N-D) Vehicle (VE) % mean survival (S) 
740-250 Saline 80 % 
740-250 HPC 100 % 
14762-50 Saline 60 % 
178-25 - - 
 
A graph produced from the information in Table 4.6 would result in the vertex, 178-25 (N-
D), containing no out degree connections since no vehicle (VE) information is available to 
connect it to a % mean survival rate (S) which is also not available. This vertex represented 
as a graph would contain a circular reference, i.e. an edge connecting the vertex to itself. 
This vertex therefore contains no out degrees as it does not connect to any elements of the 
set S. The out degree filter of >1, used to filter out elements of N-D with only a single 
vehicle associated with it will also therefore filter out elements of N-D for which data were 
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missing from the dataset. This is considered a unique advantage of this type of data 
representation and methodology as datasets are most often curated thoroughly before any 
kind of processing occurs. 
Once all elements of N-D that contain only one out degree have been removed, the graph 
now only contains drug-doses (N-D) that have two or more different vehicles tested with 
them. This is still however 23,793 records (each containing pairs or more of data) of the 
387,662 initial records of the pre-processed dataset. 
Another filter is therefore applied to the data of the graph. This time a filter for the 
element VE of edge set E4 is used. VE represents the different vehicle types contained 
within the dataset. A subset of the edge set E4 can therefore be extracted with all 
connecting vertices attached. As this chapter focuses on visualisation as well as data 
extraction it was decided to extract the subgraph containing the three most commonly 
occurring vehicles of the NIH dataset. These are; Saline, Saline with Tween-80 and 
hydroxypropylcellulose (HPC) (see Figure 4.2). Filtering the graph for these three vehicles 
results in 16,911 records of data for which each vertex of element N-D contained 2 or more 
of the three different vehicles selected, connected to it. 
All elements of N-D therefore potentially carry interesting relationships which may show a 
difference in toxicity outcome with the use of different vehicles. This information can now 
be easily visualised for any of the drug names (NSC) in the dataset which remains. For 
example, consider the NSC number 180259. The elements of vertex N-D can be searched 
for all instances of this drug number using a wildcard pattern search to account for the 
hyphenated dose that is combined to the drug number. Searching the elements of N-D for 
180259 produces the following subgraph, G4a (Figure 4.8). 
Subgraph G4a = (V4a, E4a) shows the data extracted for drug number (NSC) 180259 from the 
parent graph G4, for the various doses shown. The graph is a directed bipartite graph, since 
elements of the vertices set V4a, N-D (purple) and S (green) are not connected to 
themselves. Elements of the edge set E4a, VE, have been coloured red and blue which 
represent the vehicles saline and saline with Tween-80 respectively. 
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Figure 4.8. Subgraph G4a for drug number (NSC) 180259, showing elements of the vertices set V4a, 
N-D (purple) and S (green), with elements of the edge set E4a, VE, shown in red (Saline) and blue 
(Saline with Tween-80). 
 
If the subgraph G4a is rearranged, so that the two elements of set V4a, N-D and S, are 
aligned opposite each other, the visualisation and relationships become more clear (Figure 
4.9). 
 
Figure 4.9. Subgraph G4a with elements rearranged for ease of visualisation. 
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From Figure 4.9, the elements of N-D shown in purple all pertain to the drug number (NSC) 
180259 for which each vertex of N-D (purple) has a dose attached to it. For example the 
value 180259-4 represents drug number (NSC) 180259 at a dose of 4 mg/kg. The elements 
of N-D in Figure 4.9 have intentionally been arranged with an increasing dose amount as 
you move from top to bottom. Similarly the survival element, S (which represents the 
binned survival values) are shown in green, they too have been arranged so the % mean 
survival values decrease as you move from top to bottom. The edge set E4a which contains 
the element VE contains coloured edges to represent the vehicles saline (red) and saline 
with Tween-80 (blue). Arranging the graph in this way makes visualisation and exploring 
the graph much easier.  
From Figure 4.9 the first thing that becomes apparent is that dose amounts for drug 
number (NSC) 180259, range from 4 to 112 mg/kg, roughly doubling each time except for 
the very highest dose. What is also apparent from this graph representation is that for 
every drug-dose combination the vehicles saline (red edges) and saline with Tween-80 
(blue edges) have both been used to administer the drug. For the two lowest drug doses of 
4 and 8 mg/kg (180259-4 and 180259-8), the survival outcome for both vehicles is identical 
(100 %). However from the visualisation it is easy to see that at a dose of 18 mg/kg 
(180259-18), the vehicle saline is more protective than the vehicle saline with Tween-80, 
resulting in survival outcomes of 100 and 90 % respectively. At the 37 mg/kg dose (180259-
37), the survival rate observed for both vehicles is identical, at 90 %. For the two highest 
doses however, of 75 and 112 mg/kg (180259-75 and 180259-112), there is a difference in 
the survival outcome between the two different vehicles, with saline (red) always offering 
more toxicity protection than saline with Tween-80 (blue). The same information can also 
be extracted from the graph in Figure 4.8, only it is not as easy to visualise. 
Similarly other subgraphs can be extracted from graph G4. A search for the drug number 
(NSC) 143015, resulted in the extraction of subgraph G4b = (V4b, E4b), which is shown in 
Figure 4.10 below.  
As with subgraph G4a shown in Figure 4.9, the subgraph G4b shown in Figure 4.10 and 
extracted from the parent graph G4, shows that drug 143015 has been tested at three 
different doses (purple) with the vehicles saline (red) and saline with Tween-80 (blue). For 
all three doses the visualisation shows that the vehicle saline always results in better 
toxicity protection than the vehicle saline with Tween-80. 
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Figure 4.10. Subgraph G4b for drug number (NSC) 143015, showing elements of the vertices set V4b, 
N-D (purple) and S (green), with elements of edge set E4b, VE, shown in red (Saline) and blue 
(Saline with Tween-80). 
 
As a final example of data visualisation, consider the subgraph G4c = (V4c, E4c), shown in 
Figure 4.11, which has been extracted from the parent graph G4.  
 
Figure 4.11. Subgraph G4c for drug number (NSC) 154948, showing elements of vertices set V4c, N-D 
(purple) and S (green), with elements of edge set E4c, VE, shown in red (saline), blue (saline with 
Tween-80) and yellow (HPC). 
 
This graph shows the drug number (NSC) 154948 having been tested at 6 different doses 
(156, 312, 625, 1250, 2500 and 5000 mg/kg). Furthermore, at all doses the drug was 
administered using 3 different vehicles, saline (red), saline with Tween-80 (blue) and HPC 
(yellow). From the subgraph it is quick to visualise the differences in toxicity protection that 
the each vehicle provides. At the two lowest doses (154948-156 and 154948-312) all three 
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vehicles provide the same level of toxicity protection resulting in an animal survival rate of 
100 %. At a dose of 625, 1250 and 2500 mg/kg (154948-625, 154948-1250 and 154948-
2500) however, the vehicles saline (red) and HPC (yellow) result in survival rates of 100 %, 
but the vehicle saline with Tween-80 (blue) consistently results in lower survival rates, thus 
offering lower toxicity protection. At the highest dose of 5000 mg/kg (154948-5000) the 
three vehicles all offer different levels of toxicity protection. Saline (red) resulted in the 
best survival rate of 90 %, followed by HPC (yellow) with a survival rate of 70 % and lastly 
saline with Tween-80 (blue) which resulted in a survival rate of 50 %. 
4.6 Graphs for Extracting Toxicity Relationships 
Visualising the data using subgraph extraction techniques allows patterns in toxicity related 
to the use of different vehicles for a specific drug to be easily visualised from a large 
dataset with minimal pre-processing. However it would be useful if the drug numbers (NSC) 
within the dataset could be grouped together depending on how their toxicity profiles are 
influenced by different vehicles. For example from the subgraphs G4a, G4b and G4c (see 
section 4.5) the drugs shown in the graphs all seem to result in better toxicity profiles when 
used with the vehicle saline rather than the vehicle saline with Tween-80. Furthermore, for 
the drug number (NSC) 154948 shown in subgraph G4c, HPC also seems to offer better 
toxicity protection than saline with Tween-80, and on one occasion at a dose of 5000 
mg/kg it is also apparent from subgraph G4c that the vehicle saline can be considered more 
protective than the vehicle HPC. Therefore from the subgraph G4c, for drug number (NSC) 
154948 the following relationships can be deduced; 1) saline is more protective than saline 
with Tween-80, 2) saline is more protective than HPC and 3) HPC is more protective than 
saline with Tween-80. 
If sufficient numbers of these relationships for different drugs can be extracted then it 
would be useful to see how many data (i.e. number of compounds) exists for each group, 
and more specifically if any of the drugs overlap between groups. For example if a set of 
drugs show that the use of saline provides better toxicity protection than saline with 
Tween-80 then do these same drugs also show that HPC offers better toxicity protection 
than saline with Tween-80? This will not be possible to demonstrate for all the drugs as 
some drugs will not have been tested with some of the vehicles, as is the case with the data 
shown in subgraphs G4a, G4b and G4c. It would nevertheless be useful if as many 
comparisons as possible can be made and demonstrated. 
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4.6.1 Mining Graphs for Data Relationships 
To extract groups of drugs for which one vehicle offers more protection than another the 
graph G4 was mined for such relationships. This graph contains data relating to 3 different 
vehicles (saline, saline with Tween-80 and HPC) as discussed in section 4.5.  
These vehicles were first treated in a pairwise manner, so that the following comparisons 
could initially be made; 
1) Saline is better than saline with Tween-80 
2) Saline with Tween-80 is better than saline 
3) Saline is better than HPC 
4) HPC is better than saline 
5) Saline with Tween-80 is better than HPC 
6) HPC is better than saline with Tween-80 
For every vertex of the element N-D of graph G4 (see section 4.5) it is therefore possible to 
extract the difference in toxicity outcome for each of the vehicles connected to it. At the 
very least this can be done in a pairwise manner since each vertex of the element N-D 
contains at least two different vehicles connected to it. 
If the outcome for two or more vehicles is equivalent, these points are discarded as they do 
not show any differences in toxicity. Such instances are most likely to occur at very low 
doses where the survival rates may be 100 % or at very high doses where survival rates may 
be 0 % regardless of vehicles used. 
Consider the mock plot shown in Figure 4.12, for a particular drug at a range of doses used 
with two different vehicles (saline and saline with Tween-80). A difference in toxicity 
outcome is observed for the two vehicles, however at a dose of 10 and 20 mg/kg (low 
doses) the toxicity outcome is the same (100 %) and at the very high dose ranges, of 90 and 
100 mg/kg again the toxicity differences between the two vehicles is the same (0 %). These 
data points do not show any interesting relationships (toxicity differences) and so are not 
considered. For the purpose of forming drug groupings, only the data points where there is 
a toxicity difference, is of interest (data points between vertical green lines) and only those 
data points are considered in the data extraction process. 
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Figure 4.12. Mock plot of vehicles saline (red) and saline with Tween-80 (blue) showing differences 
in toxicity outcome for a given drug. Data points between the vertical green lines are of interest. 
 
 
Figure 4.13. Mock plot of saline (red) and saline with Tween-80 (blue) showing conflicting 
differences in toxicity outcome for a given drug. Data points between the vertical green lines 
suggest the vehicle saline is offering better toxicity protection than saline with Tween-80, 
however the opposite relationship is suggested for the data points between the vertical purple 
lines. 
 
Furthermore, one assumption is made for the purpose of this work; if a specific vehicle 
used with a particular drug shows a better toxicity outcome than another vehicle used with 
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the same drug, then this should be the case at all the dose ranges tested where a 
difference is measurable. If for a specific drug the vehicles cross over in toxicity protection 
over a range of doses then this drug is removed completely from any groups as it suggests 
conflicting toxicity outcomes. 
For example consider the mock plot shown in Figure 4.13, which shows the toxicity profiles 
of the vehicles saline (red) and saline with Tween-80 (blue) for a particular drug. The plot 
suggests that the vehicle saline offers better toxicity protection between the doses of 20 
and 70 mg/kg (vertical green lines), whereas between the doses of 70 and 100 mg/kg the 
vehicle saline with Tween-80 seems to offer the better toxicity protection (vertical green 
lines). 
The toxicity pattern of the two vehicles is conflicting for this particular drug and as such this 
kind of data extracted from the graphs will be removed as an uncertainty arises as to which 
group this drug would belong to. 
To begin with, all the drug-doses (elements of vertex N-D of graph G4) showing the 
relationship of saline being better than saline with Tween-80 were extracted and any 
conflicting or equivalent data points regardless of dose for a specific drug removed. The 
binned % survival values were converted to integers so toxicity differences could be 
established numerically. This leaves behind a list of drug numbers (hyphenated doses 
removed) for which the vehicle saline offers better toxicity protection than the vehicle 
saline with Tween-80, for which no conflicting data for the drugs in this list existed in the 
graph. Only unique drug numbers are retained in the list i.e. only one instance of any 
replicate drug numbers is retained. 
Next all the drug numbers which showed the opposite relationship, saline with Tween-80 is 
better than saline, were extracted with any conflicting or equivalent data points removed. 
This resulted in the extraction of two groups, with each group containing a list of drug 
numbers (NSC) without any hyphenated doses attached. Both these lists should in theory 
contain no overlapping drug numbers. 
This pairwise extraction process was performed for the other 4 relationships shown in the 
numbered list at the beginning of this section. The number of unique drugs extracted from 
the graph for each of the 6 groups is shown in Table 4.7 below. 
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Table 4.7. Total number of compounds per group for the various vehicle pairings of saline, saline 
with Tween-80 and HPC. 
 
Row Number Group Number of drugs 
1 Saline is better than saline with Tween-80 212 
2 Saline with Tween-80 is better than saline 238 
3 Saline is better than HPC 214 
4 HPC is better than saline 163 
5 Saline with Tween-80 is better than HPC 220 
6 HPC is better than saline with Tween-80 157 
 
From these 6 lists, which have conflicting data removed, for any two vehicles which form a 
pairing, say saline and saline with Tween-80, which is shown in the first two rows of Table 
4.7, the list of drugs contained in the two opposing groups should be unique, i.e. the list of 
drugs in the lists of rows 1 & 2 (opposing groups) of Table 4.7 should be unique. Similarly 
the lists of row 3 & 4 and 5 & 6 should be unique. 
This can be demonstrated by producing Venn diagrams for each opposing vehicle pairing 
(i.e. rows 1 & 2, 3 & 4 and 5 & 6) resulting in the three Venn diagrams shown below in 
Figure 4.14. 
 
Figure 4.14. Venn diagrams showing no overlap between any two opposing vehicle pairings. 
 
For all three Venn diagrams the overlapping segment contains zero data points, therefore 
the drug lists isolated from the graph G4 are unique to each opposing group with no 
conflicts. 
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Using the Venn diagrams, it is now possible to isolate the number of interesting 
relationships that are shown across more than two groups to identify the number of data 
points that may be available for any future work considered. So for example, consider the 
relationship saline is better than saline with Tween-80 (row 1, Table 4.7) and saline with 
Tween-80 is better than HPC (row 5, Table 4.7) A Venn diagram of these two lists is shown 
in Figure 4.15. 
The Venn diagram shown in Figure 4.15 shows the relationship of the number of drugs for 
which the vehicle saline is better than saline with Tween-80 and for saline with Tween-80 is 
better than HPC.  
 
 
Figure 4.15. Venn diagram of saline is better than saline with Tween-80 and saline with Tween 80 
is better than HPC. 
 
From the Venn diagram we can see that there are 10 drugs that form an overlap, therefore 
for those 10 drugs the following two statements hold true; 
1) Saline is better than saline with Tween-80 and 
2) Saline with Tween-80 is better than HPC 
Given these two statements, can the presumption that saline is better than HPC be made 
for those 10 drugs?  
To find out how many of the 10 drugs this holds true for we simply add the data from the 
list containing drugs for saline is better than HPC (row 3, Table 4.7) to see if any overlap 
occurs. This is shown in the Venn diagram shown in Figure 4.16 below. 
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Figure 4.16. Venn diagram showing the overlap of saline is better than saline with Tween-80, 
saline with Tween-80 is better than HPC and saline is better than HPC. 
 
This Venn diagram shows that of the 10 drugs from Figure 4.15 which show an overlap and 
for which the deduction that saline is better than HPC could questionably be made. In 
actual fact that deduction holds true for 8 of those 10 drugs, as shown by the central 
overlap of the Venn diagram in Figure 4.16. The remaining two drugs would therefore have 
either showed an equivalence in toxicity protection between saline and HPC and were 
removed from the data or were not tested with the vehicle HPC. 
The Venn diagram can be further enhanced by adding the other vehicle relationships of 
Table 4.7, from which, other overlaps of data can be seen. Due to the constraints of the 
Venn diagram library (gplots) used with the R package in Knime, a maximum of 5 lists can 
be added to form a Venn diagram. For this reason the grouping with the lowest number of 
drugs in Table 4.7 (row 6) has been omitted from the Venn diagram shown in Figure 4.17. 
From the Venn diagram of Figure 4.17 the overlaps of 5 different vehicle pairings which 
offer better toxicity protection over the other are shown. The overlaps of the Venn diagram 
help to quickly pick out the relationships for which there is data available. For example, 
from Figure 4.17 the overlap which shows the relationship saline is better than saline with 
Tween-80, saline with Tween-80 is better than HPC and saline is better that HPC is shown 
by the green circle in the Venn diagram. This is the same relationship that was shown in 
Figure 4.16. From the Venn diagram of Figure 4.17 it is also possible to extract the 
relationship saline with Tween-80 is better than HPC, HPC is better than saline and saline 
with Tween-80 is better than saline. This relationship is circled red in the Venn diagram and 
is made up of 6 different drugs. 
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Figure 4.17. Venn diagram showing the overlay of 5 different vehicle pairings. 
 
The numbers in the overlaps of the Venn diagram of Figure 4.17, show the number of 
unique drugs in the lists extracted from the graphs. Where crossovers suggest a conflict of 
vehicle relationships these all contain zeros (0) in the Venn diagram. If it was possible to 
add more lists to the diagram other relationships could be readily extracted. 
The red and green circles of the Venn diagram in Figure 4.17 represent the drugs for which 
patterns in toxicity relating to three different vehicles is observable and for each of those 
drugs in the list the pattern is identical. This makes those drugs interesting to study from a 
drug-vehicle toxicity reduction perspective. 
4.7 Summary 
The work presented in this chapter has demonstrated the application of graphs for data 
visualisation and extraction of useful information. A methodology has been proposed and 
developed for the arrangement of data into graphs which allows drug-vehicle relationships 
to be quickly visualised with minimal data curation. Several graph representations were 
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explored before a directed bipartite graph was considered to be the optimal solution. 
Furthermore, to represent data on the vertices of the graph some data values (drug and 
dose) had to be combined. The methodology also uses labelled edge data since the 
common practice of using weighted edges were not feasible for the intended application. 
The methodology has been successfully demonstrated using the NIH dataset from which 
interesting drug-vehicle relationships which show differences in toxicity were visualised. 
Extracting these drug-vehicle relationships from the graphs resulted in lists of drugs 
generated for which a particular vehicle offered better toxicity protection than another. 
These lists were then plotted using Venn diagrams from which multiple vehicle 
relationships could be deduced. This helped identify the number of data points (unique 
drugs) that would be available to study should any further analysis be desired. Due to the 
limitations of the Venn diagram library of the R package, larger Venn diagrams containing 
more lists could not be created. However substituting one list for another may still offer 
further insights into the data. 
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5 
5 Modelling Drug-Vehicle 
Relationships 
This chapter is concerned with the work based on building drug-vehicle relationships for 
the prediction of a drug vehicle for toxicity reduction. It demonstrates the use of data 
mining techniques to extract, curate and organise scientific information into a framework 
that can be utilised for knowledge gain. From these principles successful predictive models 
are built based on machine learning techniques (decision trees and random forests). The 
work in this chapter provides a unique example of how experimental scientific data are 
transitioned from in vivo experimental results to useful in silico information. 
The main focus of this chapter is to describe the methodology that has been developed, 
based on the area under a curve concept to validate and build predictive models, the 
principles of which can be easily applied to other scientific data to produce similar models. 
The methodology discussed, provides a means of making pairwise comparisons between 
two functional variables, in this case two vehicles, which offer different levels of toxicity 
protection that can then be successfully modelled. The results are reported in the 
subsequent chapter. 
Finally the concepts of “big data” and “data repurposing” are explored with respect to the 
dataset used and the challenges encountered are discussed. 
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5.1 Dataset 
The dataset used for the work in this chapter is the NIH dataset discussed in chapter 4. 
Whilst a description of the dataset has previously been provided there are significant 
differences in the methodologies used and so some information may be repeated during 
the data curation and extraction information provided in section 5.4. 
The work in this chapter aims to repurpose these data for an alternative goal. The aim is to 
mine the dataset to establish drug-vehicle relationships with respect to toxicity. These 
relationships are then explored to assess whether a vehicle has any influence on the 
compound’s toxicity 
5.2 Principles of Big Data 
Although the NIH dataset used in this chapter does not meet all the requirements that are 
generally accepted to describe big data [330] it does meet some of the criteria and 
therefore the challenges that come with it. Big data is not simply a large volume of data or 
a substantial sized database with millions of records. There are currently several proposed 
definitions of big data, of which the three V’s (Volume, Velocity & Variety) seem to be the 
most prominent [330], they are discussed below with reference to the NIH dataset: 
Volume – refers to the size or volume of data being large. Although no minimum size limit 
exists, the data frequently come from multiple autonomous sources and are considered 
heterogeneous in nature. The size of the NIH dataset is certainly large with approximately 
2.7 million records and these data have been compiled from different sources, given that 
various laboratories (known as screeners) contributed to the screening program. This 
brings about its own challenges given that the complexity of the data gathered from 
multiple sources will carry different error rates which are difficult to measure. Cross 
comparisons of the same experiment from different laboratories also becomes difficult, in 
particular if conflicting outcomes have been reported. The term veracity is sometimes 
associated with big data [331]; it refers to the quality or trustworthiness of the data. 
Techniques that handle the veracity of data help filter out “noise” to leave behind reliable 
trustworthy data that can be used with some element of confidence. 
Velocity – is related to the speed at which data are generated, making datasets dynamic 
due to the absorption of additional complementary data. Although the NIH dataset is large, 
it is not changing dynamically or increasing in size since complementary data are not being 
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added. However all datasets can be added to if additional suitable data become available. 
The data can be compiled and structured accordingly before some form of integration is 
applied. The NIH dataset used here is as it was when acquired from the source [20] and no 
additional data were added. Most of the data have been compiled from experimentation 
that covers an era spanning some time from the 1950’s up until the 1980’s. It covers a 
period where computers were not common place in industry and so a substantial effort has 
been made retrospectively to make the data electronically available. This is something to 
bear in mind when considering the reliability of the data since errors in transcription can be 
made, which eventually translate into any models that are built.  
Variety – expresses that data is gathered in different forms or via different means. This 
stands true to some extent for the NIH dataset, since different laboratories (screeners) 
contributed to the data that have been compiled into this dataset. The form and structure 
of the data contributed however have remained constant across all screeners. A constant 
structure from multiple sources is beneficial for the ease of manipulating and handling data 
through any data mining techniques. The ease of working with structured data saves 
considerable time and effort and should be considered beforehand when generating or 
gathering big data. 
Since the three V concept for big data was first proposed [330] a range of other Vs have 
since been suggested by experts working in the big data analytics field. Two additions Vs of 
particular interest to the work in this chapter are Value and Visualisation. 
Value – pertains to the knowledge that can be extracted from the data and the usefulness 
of this information, the ultimate goal being the discovery of something new, novel and of 
value. For scientific data, that useful information may lead to new discoveries or scientific 
principles that were previously unknown. For predictive analysis models it allows informed 
decisions to be made based on large volumes of scientific data that would ordinarily be 
unprocessable by the human mind. 
Visualisation – can be considered one of the end points of big data mining, although as 
demonstrated in chapter 4 it can be used in parallel to quickly extract useful information 
also. As an endpoint, visualisation deals with the concept of being able to visualise the data 
that have been extracted in a format that is easily comprehensible. This can be in the form 
of charts and graphs or summarised data tables that present some statistical relevance of 
the data extracted. 
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5.3 Methodology 
The methodology developed as part of this work was to use the area under a curve 
approach to compare the output of two variables, in this case two vehicles. This approach 
is widely applicable for comparing the functional relationship of two variables. Chapter 2 
discussed some of the methods used experimentally to measure toxicity. The NIH dataset 
reported toxicity as the survival count of animals per dose administered. Typically groups of 
6 or 10 animals were used per dosing schedule from which a % survival rate outcome could 
be calculated. It is therefore possible to extract survival versus dose relationships for 
compounds that were administered using different vehicles. The methodology of this 
proposed approach is discussed in this section. 
For any given drug administered separately over a dosage range into animal subjects using 
any given vehicle, 𝑉𝑘, the dosage range and survival outcome can be represented by two 
arrays 𝐷𝑘 and 𝑆𝑘, which are of equal size, n (n>1) where: 
   𝐷𝑘 = [𝑑1
𝑘 … 𝑑𝑛
𝑘] (dosage amount array) 
   𝑆𝑘 = [𝑠1
𝑘 … 𝑠𝑛
𝑘] (survival rate array) 
and n is the number of doses given in the experiment. 
The relationship of the vehicle 𝑉𝑘 to the toxicity of the drug is therefore represented by 
the two arrays as: 
   𝑉𝑘 = [𝐷𝑘, 𝑆𝑘] 
Elements of the array 𝐷𝑘 are ordered ascendingly so that 𝑑1
𝑘< 𝑑𝑛
𝑘 where n>1. Given this, 𝑠1
𝑘 
represents the % survival rate for the smallest dose amount of drug administered using 
vehicle 𝑉𝑘, and value 𝑠𝑛
𝑘 would then represent the % survival rate for the largest dose 
amount of drug administered using vehicle 𝑉𝑘. 
For making pairwise comparisons of two different vehicles (𝑉1 and 𝑉2) given the same 
drug, a plot of arrays 𝑆1 against 𝐷1 would produce a survival versus dose curve for vehicle 
𝑉1 and similarly a plot of the arrays 𝑆2 against 𝐷2 would produce a survival versus dose 
curve for vehicle 𝑉2. A mock survival versus dose curve for vehicle 𝑉1 and 𝑉2 is shown in 
Figure 5.1. The survival outcome difference between that offered by vehicle 𝑉1 in 
comparison to that offered by vehicle 𝑉2 can then be determined by calculating their 
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respective area under the curve (AUC). The differences between their AUCs provides a 
measurement that distinguishes between the toxicity reductions afforded by the vehicles. 
From Figure 5.1 it is apparent that the toxicity of the drug administered with vehicle 𝑉2 is 
lower, due to a higher survival rate than for that offered by vehicle 𝑉1. The AUC of vehicle 
𝑉2 would therefore be larger than the AUC of vehicle 𝑉1. 
Although the elements in the arrays for 𝑉1 may not be equivalent in length or value to that 
of the elements in the arrays for 𝑉2 it is important that the maximum number of data 
points which span the largest area possible under the survival versus dose curve are used 
to compare the toxicity differences between the two vehicles. Using this approach ensures 
comparisons across as many doses as possible thus providing a utility framework that 
enables predictive models to be built from as much of the available data as possible. The 
advantage of this approach is that it reduces the chance of experimental variability 
influencing the predictive models, since experimental variability is more influential over a 
single data point compared to data spanning a range of doses. 
 
Figure 5.1. Mock survival versus dose curves for vehicles 𝑉1 and 𝑉2 showing the survival outcome 
differences as dose increases. The survival curve of vehicle 𝑉1 at lower doses is obscured by the 
curve of vehicle 𝑉2. 
 
An additional problem is encountered when comparing two vehicles used for the same 
drug which is dosed at different concentrations. These comparisons require further 
processing steps that ensure the maximum number of data points is used; these 
approaches are discussed below. 
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5.3.1 Extrapolation 
Extrapolation of data points was considered beyond the maximum and/or below the 
minimum dose for each vehicle array. Consider the following set of arrays for vehicles 𝑉1 
and 𝑉2 below: 
Dose amount (mg/kg) for 𝑉1 (𝐷1):  [15, 20, 30, 40, 50, 60] 
% survival for 𝑉1 (𝑆1):    [100, 100, 100, 70, 30, 0] 
Dose amount (mg/kg) for 𝑉2 (𝐷2):  [10, 20, 30, 40, 50, 60, 70] 
% survival for 𝑉2 (𝑆2):    [100, 100, 100, 80, 50, 30, 10] 
Extrapolation of the survival versus dose curve below the minimum recorded dose amount 
is considered if the minimum dose amount for 𝑉1 is greater than the minimum dose 
amount for 𝑉2 and the survival related to the minimum dose amount, 𝑠1
1, is 100 %. 
Similarly if the maximum dose amount of 𝑉1 is less than the maximum dose amount for 𝑉2 
and the % survival rate at the maximum dose, 𝑠n
1, is 0 % then extrapolation was also a 
possibility. Given that the minimum dose amount for 𝑉1 (15 mg/kg) is greater than the 
minimum dose for 𝑉2 (10 mg/kg) and the % survival rate for 𝑉1 at its minimum dose is 100 
% then it is reasonable to assume that the % survival rate of 𝑉1 at a lower, extrapolated 
dose of 10 mg/kg would also result in a 100 % survival, since a lower dose would naturally 
correspond to a lower toxicity. At the high dose end of the array a similar assumption can 
be made. With the maximum dose of 𝑉1 (60mg/kg) being less than the maximum dose for 
𝑉2 (70 mg/kg) and the survival rate for 𝑉1 at its maximum dose being 0 % it is therefore 
reasonable to assume that the survival rate of 𝑉1 at a higher extrapolated dose of 70 
mg/kg would also result in a 0 % survival rate. The extrapolated arrays for 𝑉1 would then 
look like (extrapolated values underlined); 
Extrapolated dose amount (mg/kg) for 𝑉1 (𝐷1): [10, 15, 20, 30, 40, 50, 60, 70]  
Extrapolated % survival for 𝑉1 (𝑆1):  [100, 100, 100, 100, 70, 30, 0, 0] 
In the example above, if extrapolation is not used then the 15 mg/kg dose for 𝑉1 and the 
10 and 70 mg/kg doses for 𝑉2 and their respective % survival rates would have to be 
discarded since they cannot be directly compared. Extrapolation is possible at both ends of 
an array, one end of the array or neither end of the array depending on the dose amounts 
and only if the % survival rate values for the minimum and maximum doses corresponded 
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to 100 and 0 % respectively. The pre- and post-extrapolation curves for 𝑉1 and 𝑉2 are 
shown in Figure 5.2 and Figure 5.3 respectively. 
 
Figure 5.2. Pre-extrapolated curve for vehicles 𝑉1 and 𝑉2. 
 
 
Figure 5.3. Post-extrapolated curve for vehicles 𝑉1 and 𝑉2. Extrapolated data points for vehicle 𝑉1 
are shown in green. 
 
Figure 5.3 shows the extrapolated survival values for 𝑉1 at the doses of 10 and 70 mg/kg. 
The AUCs of the two curves can now be compared across a wider range of doses, which 
provides more reassurance that the differences between the AUCs of the two vehicles (𝑉1 
and 𝑉2) are real and not due to experimental noise. Using the extrapolation method the 
percentage differences between the two AUCs will change, which plays a significant role 
when classifying the data (see section 5.5). 
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5.3.2 Interpolation 
Interpolation of data is considered if extrapolation is not possible. Interpolation of data is 
therefore used when the minimum and maximum doses of an array of one vehicle result in 
a <100 or >0 % survival rate respectively. With such arrays the assumptions made during 
extrapolation are not possible (see section 5.3.1). Therefore to maximise the number of 
datum points over which AUCs can be calculated, interpolation of data is employed. 
Consider the following set of arrays for vehicles 𝑉3 and 𝑉4 below, and shown graphically in 
Figure 5.4: 
Dose amount (mg/kg) for 𝑉3 (𝐷3):  [5, 20, 30, 40, 50, 80] 
% survival for 𝑉3 (𝑆3):    [90, 80, 70, 60, 30, 10] 
Dose amount (mg/kg) for 𝑉4 (𝐷4):  [10, 20, 30, 40, 50, 60, 70] 
% survival for 𝑉4 (𝑆4):    [100, 100, 80, 70, 40, 30, 25] 
The arrays for vehicles 𝑉3 and 𝑉4 are comparable over a common dose range of 20 to 50 
mg/kg, with extrapolation not a possibility, this would result in the loss of two datum 
points from 𝑉3 (5 and 80 mg/kg and their respective survival rates) and the loss of three 
datum points from 𝑉4 (10, 60 and 70 mg/kg and their respective survival rates). To 
overcome some of these issues linear interpolation between datum points can be used. 
Given that the minimum dose for 𝑉4 is 10 mg/kg, linear interpolation can be used to 
generate a datum point at a mock dose of 10 mg/kg for 𝑉3 using the 𝑉3 data points of 5 
and 20 mg/kg and their respective % survival rates. 
To interpolate a % survival rate for 𝑉3 (𝑠i
3) at a mock dose of 10 mg/kg (𝑑i
3), the two dose 
amounts of 5 (𝑑1
3) and 20 mg/kg (𝑑2
3) and their respective % survival rates (𝑠1
3 and 𝑠2
3) are 
used. The value of 𝑠i
3 along the straight line is given by: 
 
𝑠𝑖
3 = 𝑠1
3 + (𝑠2
3 − 𝑠1
3)
𝑑𝑖
3 −  𝑑1
3
𝑑2
3 −  𝑑1
3 (1) 
    
where 𝑑1
3 = 5 mg/kg, 𝑑2
3 = 20 mg/kg, 𝑠1
3 = 90 %, 𝑠2
3 = 80 %, 𝑑𝑖
3 = 10mg/kg, then 𝑠𝑖
3 = 86.6 %. 
Similarly if extrapolation at the high dose end of 𝑉3 is not possible then an interpolated 
mock datum point for a common dose value contained within 𝑉4 can be calculated. In the 
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example above, a mock dose value of 70 mg/kg can be added between the 50 and 80 
mg/kg values present in the array 𝑉3 with its respective % survival rate interpolated and 
added into the array 𝑆3. The interpolated arrays for 𝑉3 would then look like (interpolated 
values underlined): 
Interpolated dose amount (mg/kg) for 𝑉3 (𝐷3): [5, 10, 20, 30, 40, 50, 70, 80] 
Interpolated % survival for 𝑉3 (𝑆3):  [90, 86.6, 80, 70, 60, 30, 16.6, 10] 
The pre- and post-interpolated curves for 𝑉3 and 𝑉4 are shown in Figure 5.4 and Figure 5.5 
below. 
 
Figure 5.4. Pre-interpolated curve for vehicles 𝑉3 and 𝑉4. 
 
 
Figure 5.5. Post-interpolated curve for vehicles 𝑉3 and 𝑉4. Interpolated data points for vehicle 𝑉3 
are shown in green. 
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Using the extrapolation and interpolation methods maximises the common dose range 
over which vehicles can be compared and so utilises as many of the data available as 
possible. This technique therefore provides a method of comparing data when not all 
experimental parameters are consistent. 
5.3.3 AUC Calculation 
Once extrapolation and interpolation procedures are complete the area under the % 
survival rate versus dose curve (AUC) for the two vehicles can be calculated, over the 
largest common dose range possible. Given a dose range of [𝑑1
𝑘 … 𝑑𝑛
𝑘] that corresponds to a 
% survival rate array of [𝑠1
𝑘 … 𝑠𝑛
𝑘], the AUC is calculated as follows: 
𝐴𝑈𝐶 =  ∑(𝑑𝑥+1
𝑘 − 𝑑𝑥
𝑘)
𝑛−1
𝑥=1
(
𝑠𝑥
𝑘 − 𝑠𝑥+1
𝑘
2
) (2) 
 
The AUCs for two different vehicles used for the administration of the same drug can then 
be compared to see which offers the greater toxicity protection. The greater the difference 
in AUCs between two different vehicles, the greater in the confidence that the difference in 
toxicity is real. Using this methodology enables a threshold to be set where an AUC 
difference above the threshold is considered significant and AUCs which differ below the 
threshold can be deemed equivalent. For example if the AUC difference threshold was set 
to 10 %, then any AUC differences of ≥10 % are deemed significant and AUCs with a 
difference of <10 % are considered equivalent. 
The threshold is set according to how reliable the data are deemed to be. In particular the 
signal-to-noise ratio of the data is important to consider, if the data being processed 
contain a large amount of noise a larger AUC threshold may be considered. If however the 
data are considered very reliable then a lower AUC threshold may be used. The 
consequence of setting a high threshold however is fewer data available to model. 
5.4 Data Curation and Extraction 
Before survival versus dose plots can be extracted, the NIH dataset required pre-processing 
and curating which was accomplished using a Knime workflow [329]. The NIH dataset was 
downloaded as a 63 x 2,724,199 data table and  interpreted using a document referred to 
as “Instruction_14,” available for download from the DTP website [20]. Initial data curation 
involved removing entire columns from the dataset that were irrelevant to the purpose of 
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this work. For example the column labelled TREATMENT_TIME, was the time at which 
dosing began. The information in this column was considered not to have an influence on 
animal survival rate and so was entirely removed from the data set. Furthermore this 
column only contained data for 1661 of the 2,724,199 instances and so was incomplete. 
Other such columns that were deleted included, but were not limited to, the date of the 
experiment (TEST_DT) or the laboratory (SCREENER) in which the experiments were 
conducted. Attempts to identify a difference in toxicity outcome by comparison of 
SCREENER or TEST_DATE were unsuccessful and therefore aggregation was considered 
acceptable. Several columns carried information about the inoculated cell lines that 
animals carried. Since the dataset comes from an in vivo screening program, compounds 
were tested for their ability to reduce tumours. These columns were removed from the 
data since they were not relevant to the drug-vehicle relationships being modelled. It is 
important to note at this point however that an inoculated tumour growing on an animal 
host can affect the survival outcome of the animal, if a tumour grew rapidly then there is a 
possibility it will lead to lethality. The decision to aggregate on such columns was taken 
since the survival outcomes of animals were recorded on day 0 (zero) or day 5 (TOXDAY) 
after the first dose was administered and as such the toxicity outcome would be largely 
influenced by the drug administered rather than the developing tumour. 
When repurposing data, which was initially intended for a particular use, the challenges 
faced are complex and deciding what information to use and what to discard is an 
interesting problem. Large datasets such as the NIH dataset can rapidly shrink in size after 
pre-processing and curation. To minimise this impact careful consideration must be given 
to how the data are handled. For the NIH dataset these issues have been solved by logical 
reasoning. Whilst the removal of columns was a relatively straightforward process, deciding 
which columns could be aggregated on was more challenging. For example, a column 
containing information about the sex of the animals in each experiment was reported in 
the NIH dataset. Of the 2,724,199 records, 463,450 were recorded as male, 448,483 were 
recorded as female, 259 as mixed sex and 1,812,007 fields were missing. If each of these 
were treated separately, then extracting any relevant data sufficient enough to build 
models would be extremely difficult. Furthermore the 1,812,007 records that were missing 
would have to be discarded since there is no way of satisfactorily assigning a value to them. 
The impact of this would mean 66.5 % of the data is immediately lost. For this reason it was 
decided to aggregate the data in this column, i.e. individual experiments were not 
separated by sex. 
127 
 
 
The columns that were retained were considered relevant enough to affect the toxicity 
outcome of the experiments. These key columns are listed in Table 5.1 with their original 
heading name and a brief description of their value. 
Table 5.1. List of columns retained after data curation of the NIH dataset for building predictive 
models. The columns listed were considered influential on experimental toxicity outcome i.e. 
survival rate. 
 
Original column heading Description of column 
NSC Identification number of compound tested (NSC- National Service Number) 
HOST_GROUP_CD Type of animal 
HOST_CD Species/strain of animal 
ADMIN_ROUTE Route of administration of drug 
INTERVAL Time between treatment (dosing) in terms of interval unit 
INTERVAL_UNIT Minutes (M), hours (H) or days (D) 
VEHICLE_CD Vehicle used 
NUMBER_INJECTIONS Total number of injections administered 
FIRST_INJECTION_DAY Day of first administered injection relative to day zero (inoculation) 
REPETITION Repetition of injection cycle 
RESTART_DAYS Days on which repetition occurs 
DOSE_AMOUNT Dose in mg/kg unless otherwise stated 
TOXDAY Day toxicity is measured 
SURVIVOR_NUMBER_START Animal count at start of experiment 
SURVIVOR_NUMBER_TOXDAY Animal count on toxday 
 
Once all unnecessary columns are removed, individual records within the dataset must be 
curated. Records which are considered erroneous are removed from the dataset. For 
example, the dataset recorded the toxicity outcome of an experiment as the number of 
animals surviving at the end of an experiment (SURVIVOR_NUMBER_TOXDAY). If this 
number was greater than the number of animals at the start of an experiment 
(SURVIVOR_NUMBER_START) this is clearly an error in the recording of the data and 
without any way of confirming the information the only option was to remove the entire 
record from the dataset. Other individual instances that were missing from important fields 
were also entirely removed from the dataset. Fields that were considered important 
include the vehicle field (VEHICLE_CD) or the dose amount (DOSE_AMOUNT). This initial 
curation reduced the dataset from 2,724,199 records to 2,297,845.  
The in vivo experiments recorded in this dataset largely used 6 or 10 animals per dosing 
experiment. To compare the experimental outcome of an experiment using 6 animals with 
those using 10, a percentage survival rate (% survival) was calculated as follows: 
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% survival =  
SURVIVOR_NUMBER_TOXDAY
SURVIVOR_NUMBER_START
 x 100 (3) 
 
Since the dataset contained some records of replicate experiments which would naturally 
on occasions result in differences in experimental outcome it was necessary to calculate a 
mean of the % survival values across all replicate experiments (% mean survival). Not all the 
records contained replicate experiments and the difference in the number of replicate 
experiments between compounds was sometimes large. For example some compounds 
contained several hundred replicate experiments whilst others only reported a single 
experiment.  
Dealing with multiple replicate experiments by meaning the outcome value is a relatively 
common statistical approach which can help minimise the error of the measured values. 
The variance and standard deviation of these multiple data points could also be reported 
although this was not done since some experiments only carried a single datum point. 
Having multiple datum records from replicate experiments additionally carries the 
complexity of dealing with any outlier values that may have been produced. An outlier is 
considered an observation of the multiple measurements taken for a particular experiment 
that results in a value or values that deviates greatly from the other observed observations. 
There are many literature publications on outlier detection in datasets, with many methods 
proposed to deal with such cases [332-338]. Such methods are certainly useful but often 
specific to a given problem, methods that deal well with continuous data may not perform 
as well with categorical data. A simple yet effective approach here would be to remove any 
identified outliers from the dataset which would minimise the noise. However other 
literature reports argue that what may seem as apparent outliers are in fact part of real 
data and should not be handled in any special way since it may introduce bias into the data 
[339, 340]. Furthermore, Gottmann et al. (2001) [341] reported on the reproducibility of 
rodent data for carcinogenicity SAR studies and found a concordance of only 57 % between 
the data from two sources reporting on the same compounds tested. Their results suggest 
that the low concordance of in vivo rodent studies is in fact part of the real data. 
Considering these findings together with the NIH dataset which contained some 
experiments with multiple records and others with only a single record reported, it was 
decided for this study that no processing of outliers would be performed and all replicate 
experimental outcome values (regardless of suspected outliers) would be used to calculate 
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an average % survival. The mean % survival was used in preference to the median to give 
equal weight to all the data points therefore not treating any data points as outliers. 
To construct % mean survival versus dose curves from the processed dataset, experiments 
were grouped on identical experimental conditions, that is: NSC, HOST_GROUP_CD, 
HOST_CD, ADMIN_ROUTE, INTERVAL_UNIT, INTERVAL, NUMBER_INJECTIONS, 
FIRST_INJECTION_DAY, REPETITION, RESTART_DAYS and TOXDAY. By grouping experiments 
on these fields, array lists could be constructed of the DOSE_AMOUNT, % mean survival 
and VEHICLE_CD fields. These lists could then be used to plot % mean survival versus dose 
curves for two different vehicles that were used with a particular compound. An example 
of the array lists extracted from the NIH dataset for compound NSC 63479 for two different 
vehicles, saline and carboxymethylcellulose (CMC) is shown below: 
DOSE_AMOUNT (mg/kg): [300, 1000, 3300, 10000, 300, 100, 3330, 10000] 
% mean survival:  [100, 100, 33, 0, 100, 100, 100, 67] 
VEHICLE_CD:   [Saline. Saline, Saline, Saline, CMC, CMC, CMC, CMC] 
Once these array lists were extracted from the NIH dataset they can be used for the 
pairwise comparison of the two vehicles. The array lists in the example above are split into 
their corresponding vehicle arrays as detailed below: 
DOSE_AMOUNT (mg/kg) (saline): [300, 1000, 3300, 10000] 
% mean survival (saline):  [100, 100, 33, 0] 
DOSE_AMOUNT (mg/kg) (CMC): [300, 100, 3330, 10000] 
% mean survival (CMC):   [100, 100, 100, 67] 
The spilt arrays for the two different vehicles used with compound NSC 63479, at the 
various dose amounts can then be used to produce % mean survival versus dose plots as 
shown in Figure 5.6. 
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Figure 5.6. % mean survival versus dose plots for compound NSC 63479 used with the vehicles 
saline and carboxymethylcellulose (CMC). 
 
The % mean survival versus dose plot for compound NSC 63479 shows that at the two 
lower doses of 300 and 1000 mg/kg , there is no observable difference between the 
vehicles, with both producing a 100 % mean survival. As the dose increases however to 
3300 and 10,000 mg/kg, it becomes clear that the vehicle CMC provides better toxicity 
protection against compound NSC 63479 than the vehicle saline. 
5.5 Classification Through Pairwise Comparisons 
Using the calculated AUC values for two different vehicles used with the same compound, 
over a common dose range, allows a pairwise comparison to be made that distinguishes 
whether one vehicle is more protective against the drug’s toxicity over another vehicle. 
Whilst the example in Figure 5.6 clearly shows a large difference between the two curves of 
saline and CMC, not all differences are as clear to see. For this reason a threshold of 30 % 
or greater was set. For a vehicle to be more protective over another, it would have to result 
in an AUC value of 30 % or greater than the vehicle it was being compared against. Given 
the significant challenges faced with the NIH dataset, which was un-curated and contained 
noise that was difficult to measure, a large threshold of 30 % is used to ensure the 
differences observed are related to the vehicles and not due to noise or experimental 
variation.  
Using the AUC data and the 30 % threshold value, compounds in the dataset were classified 
as follows. For any given compound used with two different vehicles, for instance saline 
and CMC, if saline resulted in an AUC value that was 30 % or greater than the AUC for CMC, 
this compound would be assigned to the class termed saline>CMC. Likewise if CMC had 
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resulted in an AUC of 30 % or greater, then that compound would be assigned to the class 
termed CMC>saline. For any AUC comparisons that produced difference of less than 30 %, 
these vehicles were considered equivalent and not assigned to a class. 
In this study, AUC thresholds of 40 and 60 % were also considered to see how this could 
influence model performance. 
During compound classification, there were occasions which resulted in a compound being 
assigned to more than one class. This occurred when one set of experiments suggested 
that the vehicle saline for instance was more protective than CMC but for the same 
compound under a different set of experiments the opposite was found to be true. To 
ensure compounds are only assigned to a single class, any compounds that resulted in 
conflicting information were removed entirely from the data. This naturally reduced the 
number of compounds that could be modelled but this final curation step was critical for 
building successful predictive models. The classification assigned to the data (compounds) 
for each of the models is available in Appendix A as an electronic file. 
5.6 Chemical Structure Curation 
For QSAR models to be built chemical structure information is required for interpretation 
of the compounds within the dataset. Several chemical structure files (.sdf) were obtained 
from the DTP website [20]. These files were prepared by the NIH at various points over a 
time period in which the main in vivo dataset was made electronically available. These 
various files were compiled together to produce a large chemical structure dataset which 
could be related to the NIH dataset experiments. Since some files contained duplicated 
compound information which on occasion conflicted with other files, it was considered that 
the most recently dated file contained the most accurate information and so structures 
from this file were taken in the first instance. Any remaining unidentified structures were 
then obtained from the next most recently dated file and so on until as many compound 
structures as possible were identified. Of the entire NIH dataset that contains 227,093 
unique compound numbers (NSC), all but 5,510 of the compounds were identified with a 
structure relating to them. 
Curated structures are available in Appendix A as an electronic file. 
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5.7 Molecular Descriptor and Fingerprint Generation 
For the compounds successfully classified, a set of descriptors were calculated that 
numerically encode the structural features of the compounds so they can be processed by 
the models. 24 molecular property descriptors based on the Indigo tool kit [342] were 
calculated using the Molecule Properties node in Knime (version 1.1.4.201308021053). 
Similarly MACCS key fingerprints were also generated using the CDK toolkit fingerprints 
Knime node (version 1.5.2.201409032225). This node generates 166 substructure patterns 
denoted as binary vectors which indicate the presence or absence of a particular 
substructure within the parent structure. A description of each of the MACCS keys 
fingerprints can be found here [281]. 
5.8 Descriptor Curation 
The descriptor pool generated is vast and provides a large diversity of chemical properties 
for the compounds being modelled. Since the data processing steps outlined above will 
naturally reduce the number of compounds which can be compared, the models built 
typically contained compound numbers in the low hundreds, this is discussed in more 
detail in the subsequent chapter. Due to the low number of compounds being modelled it 
is necessary to objectively screen the descriptor pool so that successful models can be built 
on a few descriptors allowing the models to generalise during the learning stage. 
Firstly descriptors that resulted in a constant value for all compounds were removed from 
the descriptor pool. Models are unable to distinguish between classes if a constant value 
for a descriptor is used and would hinder effective model learning. All but one of any two 
or more descriptors that perfectly correlated were also removed from the descriptor pool. 
Only one descriptor needs to be retained in such cases since the models do not gain any 
more information from retaining more. A mutual descriptor correlation coefficient, R2, 
value of 1 was used to determine which descriptors could be removed, although other 
studies report using values of 0.9 or above [343-345]. 
Lastly the binary class of the compounds were correlated with the remaining descriptor 
pool. The highest correlating descriptors at a 10:1 ratio of data points to descriptors were 
selected. For the decision tree models, n/10 descriptors were selected when n data points 
existed. Whilst for the random forest models, n/10 descriptors were selected from a pool 
of 2n/10 when n data points existed. For the models built using interpolation only at the 60 
% AUC threshold (see Table 6.3), this translates to 7 descriptors (n/10) given 70 data points 
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(n) for the decision trees and 7 descriptors (n/10) from a pool of 14 (2n/10) given 70 data 
points (n) for the random forest models. 
5.9 Decision Tree and Random Forest Models 
Two machine learning techniques were employed to build classification prediction models: 
the C.45 decision tree (DT) and random forest (RF). 
Briefly, the C.45 decision tree is an algorithm developed by Quinlan [346]. Attributes (in this 
case descriptors) are chosen that most effectively split the tree into their respective 
classes. The attribute that exhibits the highest normalised information gain becomes the 
chosen split criterion. To split using the binary MACCS fingerprints, this will simply be a 
presence (1) or absence (0) criterion. For the molecular properties descriptors this will be a 
cut off value in the fashion of a “greater/less than or equal to” type. C.45 then repeats on 
the smaller sub-lists. The Gini index quality measure was used for the decision tree models 
with no pruning. 
Random forest (RF) models are an ensemble learning method developed by Breiman [296]. 
RFs construct a multitude of underlying decision trees and generate an output prediction 
based on the mode of the classes of the individual trees. Put simply, RFs work on the 
principle that a “strong learner” (random forest) can be developed by combining a group of 
“weak learners” (decision trees). A subset of the training set (local set) is chosen, from 
which individual trees are built, the remaining samples are then used to estimate the 
goodness of fit. Trees are grown by splitting the local set at each node according to the 
value of a random variable (descriptor) sampled independently from a subset of variables. 
In this study the number of trees generated in the random forest was set to 100. No 
significant improvements in predictions were observed with greater numbers. 
The classified dataset which contained the binary class, e.g. Saline>CMC or CMC>Saline was 
processed for vehicle prediction using a 10-fold cross validation training method. This 
approach utilises 90 % of the data from each class to train the models, whilst providing a 
prediction for the remaining 10 %. The process is then iterated over for 10 repetitions to 
ensure predictions are made for all the compounds in the binary classified dataset. 
Using the NIH dataset several binary classification models were built which compared in a 
pairwise fashion the difference in toxicity resulting from the use of two different vehicles. 
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The results of the RF and DT models produced from this dataset are presented and 
discussed in chapter 6. 
5.10 Methodology Flowchart 
The AUC methodology providing pairwise comparisons described in this chapter is 
presented as a flowchart in Figure 5.7.  
 
 
Figure 5.7. Flowchart of the AUC pairwise comparison methodology for binary classification and 
vehicle prediction. 
 
The flowchart provides a useful overview of the methodology discussed which can in 
theory be applied to other scientific data of a similar nature. The inputs of the method are 
the Input Dataset and the Drug Structures (orange) which are discussed in sections 5.1 and 
5.6 respectively. Following this, the Data Curation, Class Curation and Drug Structure 
Curation steps (yellow) which describe the main curation approaches undertaken are 
presented in sections 5.4, 5.5 and 5.6 respectively. The Data Extraction and Model Training 
processes (purple) are discussed in sections 5.4 and 5.9 respectively. The AUC Methodology 
approach which utilises Extrapolation and Interpolation (pastel blue) to calculate the 
pairwise AUC differences (blue) for classification is discussed in section 5.3. Section 5.7 
describes the Molecular properties and Fingerprints that were generates, with section 5.8 
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explaining how descriptors were objectively screened. Finally the flowchart ends with the 
Drug-Vehicle models that were produced which are reported in the subsequent chapter. 
5.11 Conclusion 
The methodology provided in this chapter has been successfully used to build predictive 
models for the selection of drug vehicles that reduce toxicity. The method proposes an AUC 
methodology using interpolation and extrapolation techniques, which can in theory be 
applied to any scientific data where the relationship of two functional variables can be 
investigated over a range of datum points. As part of the work in this thesis this proposed 
methodology has been successfully used with the NIH dataset to successfully extract data 
and build pairwise classification models. 
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6 
6 Drug-Vehicle Model 
Results 
 
This chapter reports the results of the decision tree and random forest binary classification 
models developed with the methodology proposed in chapter 5. The results of each 
pairwise classification model are reported with data extracted from the decision tree 
models providing some interpretation of the results obtained. For each model an account is 
provided of the size of the data relating to the number of compounds that were available 
before and after data curation. The tabulated results for each model processed show 
exactly how many compounds were modelled and the number of compounds within each 
class (class split). The class accuracy and an overall balanced accuracy are provided as 
statistical measures of model performance. 
6.1 Model Overview 
Initially decision tree and random forest models were built using a 30 % AUC threshold, 
which dictates that the AUC difference between the survival versus dose curves of vehicle 1 
(𝑉1) and vehicle 2 (𝑉2) must have a percentage difference of 30 % or more for one vehicle 
to be considered more protective than the other. If 𝑉1 resulted in an AUC of 30 % or more 
greater than 𝑉2 for a particular compound (NSC number), that compound was assigned the 
class 𝑉1>𝑉2 (read, vehicle 1 is better than vehicle 2) if the reverse was true than that 
compound would be classed as 𝑉2>𝑉1 (read, vehicle 2 is better than vehicle 1) (see chapter 
5, section 5.5). Where the difference was less than 30 % the vehicles were considered 
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equivalent and those particular data points removed from the dataset. Furthermore, any 
compounds which presented conflicting trends (i.e.  𝑉1>𝑉2 and 𝑉2>𝑉1) arising from 
different experimental conditions were also removed from the dataset. Two other 
thresholds of 40 and 60 % were also considered to assess the impact on the accuracies of 
the models. The extrapolation and interpolation methods described in chapter 5, section 
5.3 were also assessed for their impact on model performance. Thus at each of the three 
different threshold levels, 30, 40 and 60 %, models were interpolated only with no 
extrapolation (Interpolation only), interpolated with only high dose extrapolation (since 
toxicity is correlated with higher doses) (Extrapolation high), and interpolated with 
extrapolation at the high and low doses (Extrapolation high-low). The classification 
assigned to the data (compounds) for each of the models is available in Appendix A as an 
electronic file. 
6.2 Vehicles Available to Model 
Six vehicles were identified as the most frequently used within the NIH dataset (see chapter 
4, Figure 4.2). These vehicles are: Saline, Saline with Tween-80, Hydroxypropylcellulose 
(HPC), Carboxymethylcellulose (CMC), Methylcellulose (MC) and Water.  
Table 6.1. Vehicle pairs with sufficient data available to model. 
 
Vehicle Pair Sufficient data available to model 
Saline & CMC Yes 
Saline & HPC Yes 
Saline & Saline with Tween-80 Yes 
Saline & MC Yes 
Saline & Water Yes 
CMC & HPC Yes 
CMC & Saline with Tween-80 No 
CMC & MC Yes 
CMC & Water No 
HPC & Saline with Tween-80 Yes 
HPC & MC No 
HPC & Water No 
Saline with Tween-80 & MC No 
Saline with Tween-80 & Water No 
MC & Water No 
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Combining these vehicles pairwise produces the 15 pairs shown in Table 6.1, for which 
sufficient data were available for 8 of these pairs to build models; sufficient data are 
considered as ≥10 compounds in each class. 
The vehicle pairs for which sufficient data were available to model are described in the 
subsequent sections of this chapter. It is important to note that using the various 
thresholds and extrapolation/interpolation methods, potentially, 18 models are produced 
for each of the vehicle pairings. Some of these models are produced from insufficient 
datum points, which is considered as any class that has < 10 compounds within it. These 
models are considered unreliable and are annotated in the data tables presented for each 
of the vehicle pairings. 
6.2.1 Other Vehicles Considered for Modelling 
Initially six of the most occurring vehicles within the NIH dataset, for which sufficient data 
were available, were considered for pairwise comparisons to build reliable models. Other 
vehicles contained within the NIH dataset which may not occur as frequently but for which 
sufficient data for pairwise comparisons were available were also considered. It was 
possible to construct four further models which involved the following pairwise 
comparison; Distilled water + alcohol & Saline, Distilled water + alcohol & MC, Distilled 
water + alcohol & CMC and Acetone & Saline. 
These models were generated using the same parameters discussed briefly in section 6.1 
for which a more detailed explanation can be found in chapter 5. 
6.3 Model Data 
As the data from the NIH dataset are curated, the total amount of data will shrink as 
erroneous data points are removed. This will subsequently have an effect on the number of 
data points which can be extracted to build each of the models discussed in section 6.2. It is 
therefore useful to understand this impact for each of the models built. Table 6.2 provides 
some informative details pertaining to the vehicle occurrence, the number of records, and 
number of compounds for each of the models reported in this chapter.  
Table 6.2 presents some key values for each of the models built. As an example, consider 
the first pairing in the table which describes the data for the models of the vehicles saline 
and CMC. Of the entire NIH dataset where vehicles were reported as being used, saline 
occurs in 28 % of these records whereas CMC occurs in 8 % (See vehicle occurrence, Table 
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6.2). After data curation, as discussed in chapter 5, section 5.4, the vehicles saline and CMC 
corresponded to a total of 747,305 individual experimental records (Total individual 
records, Table 6.2), which is accounted for by 75,504 unique NSC numbers (see No. of 
unique NSC numbers (for individual records), Table 6.2). For binary pairwise classification 
models however, both saline and CMC are required to have been used with the same drug 
(NSC number) under the same experimental conditions that were considered to be 
influential on toxicity outcome (see chapter 5, section 5.4). Aggregating the curated data to 
achieve this resulted in 2,221 records (see Total paired records, Table 6.2) corresponding to 
1,454 unique NSC numbers (see No. of unique NSC numbers (for paired records), Table 
6.2). For survival versus dose curves to be generated a minimum number of two doses 
(datum points) were necessary (i.e. n>1, see chapter 5 section 5.3). Furthermore any NSC 
numbers with sufficient datum points, but no chemical structure available, were also 
removed from the dataset. The remaining data could then be modelled using the pairwise 
classification method developed in chapter 5, section 5.5. The exact number of compounds 
from which each of the models is built is reported in the Model results section (section 6.4). 
Table 6.2. Number of records and unique NSC numbers per model. 
 
Model 
Vehicle 
occurrence 
(%) 
Total 
individual 
records 
No. of unique NSC 
numbers (for 
individual records) 
Total paired 
records 
No. of unique 
NSC numbers (for 
paired records) 
Saline & CMC 28 & 8 747,305 75,504 2,221 1,454 
Saline & Saline with 
Tween-80 
28 & 15 896,078 94,096 4,057 3,092 
Saline & HPC 28 & 13 856,496 85,767 2,475 1,743 
Saline & Water 28 & 5 693,557 58,777 1,535 589 
Saline & MC 28 & 7 729,170 85,867 1,229 1,039 
CMC & HPC 8 & 13 435,763 56,903 421 347 
CMC & MC 8 & 7 308,437 55,663 1,731 1,512 
HPC & Saline with 
Tween-80 
13 & 15 584,536 77,098 2,226 1,646 
Distilled water + 
alcohol & Saline 
3 & 28 638,257 65,033 554 454 
Distilled water + 
alcohol & MC 
3 & 7 199,389 42,489 2,100 1,864 
Distilled water + 
alcohol & CMC 
3 & 8 217,524 36,099 553 399 
Acetone & Saline 0.36 & 28 591,495 55,803 606 526 
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6.4 Model Results 
This section discusses the results produced from each of the pairwise comparisons of the 
models detailed in Table 6.2. For each vehicle pairing a discussion of the results is provided 
in relation to the different models built and the outcome of their predictivity. The most 
accurate model for each pairing is described and the findings of the DT models showing 
which MACCS keys fingerprints (described here [281]) and molecular property descriptors 
were used are reported. The model resulting in the most accurate prediction for each of 
the pairings has been highlighted in yellow in the results tables and any results shaded in 
grey are the result of unreliable models due to insufficient datum points. 
For each of the models built, the number of compounds available and the number of 
descriptors used for both the DT and RF models are reported. Descriptors were selected by 
the correlation against class and the number of descriptors used in each model is 
determined as 1/10th the number of datum points available, for RF the number of 
descriptors in the pool was twice the number to be used in the model. The number of trees 
in each RF model was 100. 
Each of the results reported describing the models also records the data bias in the dataset 
modelled, i.e. the excess of compounds in one class over the other. In the majority of cases 
the data bias was <2:1 and therefore no correction of the bias was deemed necessary in 
the training set/test set selections. 
6.4.1 Saline & CMC Model Results 
Table 6.3 shows the results of the DT and RF models for the vehicles saline and CMC at the 
three different thresholds with the different interpolation/extrapolation techniques 
applied. The output of the models show that the RFs tend to outperform the DTs, which is 
expected considering RFs are an ensemble method of “weak learners” (see chapter 5, 
section 5.9) [347, 348]. As the % AUC threshold is increased, the accuracies of both the DTs 
and RFs improve. This can be seen graphically in Figure 6.1, where for each model the 40 or 
60 % thresholds are the most accurate.  
It is important to note that as the % AUC threshold is increased more compounds fall into 
the equivalent group and are removed from the dataset, leaving behind fewer compounds 
for training and predicting. For this pairing extrapolation/interpolation changes do not 
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seem to affect the trends in model performance, although the number of compounds 
included in the model is consistently greater when extrapolating at the high end only. 
Table 6.3. Decision tree and random forest model outputs for the vehicles Saline and CMC. The 
most accurate model is highlighted in yellow. 
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DT Interpolation only 30 148 97/51 1.9 15 60.8 70.1 43.1 56.6 
DT Extrapolation high 30 170 105/65 1.6 17 58.2 63.8 49.2 56.5 
DT Extrapolation high-low 30 114 67/47 1.4 11 64.9 67.2 61.7 64.4 
RF Interpolation only 30 148 97/51 1.9 15(30) 67.6 77.3 49.0 63.2 
RF Extrapolation high 30 170 105/65 1.6 17(34) 62.9 74.3 44.6 59.5 
RF Extrapolation high-low 30 114 67/47 1.4 11(23) 65.8 73.1 55.3 64.2 
DT Interpolation only 40 112 70/42 1.7 11 64.3 77.1 42.9 60.0 
DT Extrapolation high 40 136 80/56 1.4 14 68.4 71.3 64.3 67.8 
DT Extrapolation high-low 40 89 49/40 1.2 9 73.0 73.5 72.5 73.0 
RF Interpolation only 40 112 70/42 1.7 11(22) 70.5 77.1 59.5 68.3 
RF Extrapolation high 40 136 80/56 1.4 14(27) 59.6 66.3 50.0 58.1 
RF Extrapolation high-low 40 89 49/40 1.2 9(18) 67.4 77.6 55.0 66.3 
DT Interpolation only 60 70 45/25 1.8 7 71.4 84.4 48.0 66.2 
DT Extrapolation high 60 99 61/38 1.6 10 73.7 82.0 60.5 71.2 
DT Extrapolation high-low 60 52 31/21 1.5 5 65.4 67.7 61.9 64.8 
RF Interpolation only 60 70 45/25 1.8 7(14) 68.6 80.0 48.0 64.0 
RF Extrapolation high 60 99 61/38 1.6 10(20) 74.7 78.7 68.4 73.6 
RF Extrapolation high-low 60 52 31/21 1.5 5(10) 80.8 80.6 81.0 80.8 
 
The most accurate prediction, resulted from the RF model using a 60 % threshold with data 
extrapolated at both high and low dose ranges (Extrapolation high-low), which produces a 
balanced accuracy of 80.8 %. This model also produced individual prediction accuracies of 
80.6 and 81.0 % for saline>CMC and CMC>saline respectively, showing that the individual 
predictive outcomes for the two vehicles is evenly distributed. 52 compounds were 
available for modelling at this threshold. 
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Figure 6.1. Decision tree and random forest balanced accuracies for the vehicles Saline and CMC. 
 
Whilst the RF models tend to outperform the DT models, the DTs do provide some 
insightful scientific information pertaining to the descriptors that the branches split on. 
From the nine different decision trees built (each iterated 10 times), six MACCS fingerprints 
and one molecular property descriptor were most frequently used to split branches on. 
These fingerprints include (MACCS position-description); 120-HETEROCYCLIC ATOM >1, 83-
QAAAA@1, 53-QHAAAQH 109-ACH2O, 115-CH3ACH2A and 137-HETEROCYCLE. The 
Number of heteroatoms in aliphatic rings was the most frequently used molecular property 
descriptor. 
6.4.2 Saline & Saline with Tween-80 Model Results 
The information presented in Table 6.4 shows the results of the DT and RF models for the 
vehicles saline and saline with Tween-80 at the various thresholds and different 
interpolation/extrapolation techniques used.  As with the saline & CMC models discussed 
in section 6.4.1 the RF models tend to outperform the DTs with the exception of the 40 % 
threshold, where the DTs consistently perform better. 
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Table 6.4. Decision tree and random forest model outputs for the vehicles Saline and Saline with 
Tween-80. The most accurate model is highlighted in yellow. 
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DT Interpolation only 30 153 86/67 1.3 15 58.2 74.4 37.3 55.9 
DT Extrapolation high 30 204 107/97 1.1 20 52.5 47.7 57.7 52.7 
DT Extrapolation high-low 30 125 68/57 1.2 13 52.8 60.3 43.9 52.1 
RF Interpolation only 30 153 86/67 1.3 15(31) 61.4 67.4 53.7 60.6 
RF Extrapolation high 30 204 107/97 1.1 20(41) 52.9 47.7 58.8 53.2 
RF Extrapolation high-low 30 125 68/57 1.2 13(25) 53.6 60.3 45.6 53.0 
DT Interpolation only 40 109 61/48 1.3 11 67.0 72.1 60.4 66.3 
DT Extrapolation high 40 158 79/79 1.0 16 65.8 64.6 67.1 65.8 
DT Extrapolation high-low 40 84 46/38 1.2 8 65.5 58.7 73.7 66.2 
RF Interpolation only 40 109 61/48 1.3 11(22) 58.7 60.7 56.3 58.5 
RF Extrapolation high 40 158 79/79 1.0 16(32) 55.7 54.4 57.0 55.7 
RF Extrapolation high-low 40 84 46/38 1.2 8(17) 65.5 71.7 57.9 64.8 
DT Interpolation only 60 52 29/23 1.3 5 63.5 75.9 47.8 61.8 
DT Extrapolation high 60 95 47/48 1.0 10 55.8 55.3 56.3 55.8 
DT Extrapolation high-low 60 35 22/13 1.7 4 62.9 77.3 38.5 57.9 
RF Interpolation only 60 52 29/23 1.3 5(10) 71.2 69.0 73.9 71.4 
RF Extrapolation high 60 95 47/48 1.0 10(19) 57.9 61.7 54.2 57.9 
RF Extrapolation high-low 60 35 22/13 1.7 4(7) 71.4 72.7 69.2 71.0 
 
For the DTs, better balanced accuracies are observed at the 40 % threshold than at the 30 
or 60 % thresholds (Figure 6.2). Interestingly the best accuracies for all model permutations 
are observed using interpolation only, with the exception of the RF model at a threshold of 
40 % which produces the greatest accuracy using the extrapolation at the high and low 
dosage range (Extrapolation high-low). All models that employ extrapolation at the high 
dosage ranges only (Extrapolation high) produce the greatest number of total compounds 
that can be classified and modelled although this particular permutation may not result in 
the greatest accuracies achieved. 
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Figure 6.2. Decision tree and random forest balanced accuracies for the vehicles Saline and Saline 
with Tween-80. 
 
The most accurate prediction (balanced accuracy) resulted from the RF model using a 60 % 
threshold with data interpolated only (Interpolation only), which produces a balanced 
accuracy of 71.4 %. The individual class accuracies at these settings for saline>saline with 
Tween-80 and saline with Tween-80>saline were 69.0 and 73.9 % respectively which 
suggests the model is not overly biased in favour of one class. The total number of 
compounds for this model was 52, with a class split of 29/23 for saline>saline with Tween-
80/saline with Tween-80>saline. The RF model at a 60 % threshold with extrapolation at 
the high and low dose ranges (Extrapolation high-low) produced similar results albeit with 
fewer compounds. 
Information extracted from the DT data show that five MACCS fingerprints were most 
commonly used to split branches on, these were (MACCS position-description); 93-QCH3, 
116-CH3AACH2A, 95-NAAO, 97-NAAAO and 99-C=C. 
6.4.3 Saline & HPC Model Results 
The information presented in Table 6.5 shows the results of the DT and RF models for the 
vehicles saline and HPC at the various thresholds and different interpolation/extrapolation 
techniques used. The accuracies of the DTs and RFs do not differ much at all the thresholds 
tested, although for both models the accuracies tend to improve as the threshold is 
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increased. The number of compounds available decreases as the threshold is increased and 
as with the previous models the highest number of compounds is always achieved when 
extrapolation occurs at the high dose end only (Extrapolation high). For the Interpolation 
only and Extrapolation high-low models at all thresholds the best balanced accuracies are 
observed at the 60 % threshold, for both DTs and RFs. However, for the Extrapolation high 
models, the best balanced accuracies are observed at the 30 % threshold (see Figure 6.3), 
although for both the DT and RF models the prediction accuracies of the major class are far 
greater than the minor class (see Table 6.5). 
Table 6.5. Decision tree and random forest model outputs for the vehicles Saline and HPC. The 
most accurate model is highlighted in yellow. 
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DT Interpolation only 30 124 66/58 1.1 12 53.2 60.6 44.8 52.7 
DT Extrapolation high 30 144 80/64 1.3 14 61.1 72.5 46.9 59.7 
DT Extrapolation high-low 30 90 43/47 0.9 9 62.2 44.2 78.7 61.5 
RF Interpolation only 30 124 66/58 1.1 12(25) 55.6 60.6 50.0 55.3 
RF Extrapolation high 30 144 80/64 1.3 14(29) 59.0 68.8 46.9 57.8 
RF Extrapolation high-low 30 90 43/47 0.9 9(18) 54.4 46.5 61.7 54.1 
DT Interpolation only 40 78 42/36 1.2 8 44.9 47.6 41.7 44.6 
DT Extrapolation high 40 105 59/46 1.3 11 53.3 59.3 45.7 52.5 
DT Extrapolation high-low 40 52 25/27 0.9 5 59.6 60.0 59.3 59.6 
RF Interpolation only 40 78 42/36 1.2 8(16) 65.4 73.8 55.6 64.7 
RF Extrapolation high 40 105 59/46 1.3 11(21) 54.3 66.1 39.1 52.6 
RF Extrapolation high-low 40 52 25/27 0.9 5(10) 59.6 52.0 66.7 59.3 
DT Interpolation only 60 39 18/21 0.9 4 69.2 66.7 71.4 69.0 
DT Extrapolation high 60 68 38/30 1.3 7 54.4 65.8 40.0 52.9 
DT Extrapolation high-low 60 22 10/12 0.8 2 72.7 60.0 83.3 71.7 
RF Interpolation only 60 39 18/21 0.9 4(8) 71.8 72.2 71.4 71.8 
RF Extrapolation high 60 68 38/30 1.3 7(14) 52.9 60.5 43.3 51.9 
RF Extrapolation high-low 60 22 10/12 0.8 2(4) 77.3 60.0 91.7 75.8 
 
The most accurate prediction is achieved using the RF model at the 60 % threshold with 
extrapolation at the high and low dose ranges (Extrapolation high-low), this model resulted 
in a balanced accuracy of 75.8 %. For this model, 22 compounds were available which 
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resulted in a class split of 10/12 for saline>HPC/HPC>saline. The individual accuracies of this 
model for saline and HPC were 60.0 and 91.7 % respectively, which shows that this model 
learnt better from the major class compounds. The RF model at the 60 % threshold using 
interpolation only produced a similar result (71.8 %) but with a class split of 18/21 for 
saline>HPC/HPC>saline and individual accuracies of 72.2 and 71.4 % respectively, which 
suggests that this model was trained more evenly across both classes. 
 
Figure 6.3. Decision tree and random forest balanced accuracies for the vehicles Saline and HPC. 
 
Information extracted from the DT data shows that four MACCS fingerprints were most 
commonly used to split branches on, these were (MACCS position-description); 102-QO, 
131-QH > 1, 148-AQ(A)A and 160-CH3. 
6.4.4 Saline & Water Model Results 
The information presented in Table 6.6 shows the results of the DT and RF models for the 
vehicles saline and water at the various thresholds and different 
interpolation/extrapolation techniques used. The data shaded grey are considered to be 
insufficient (i.e. <10 compounds in a class) for reliable models to be built and the accuracies 
associated with them should not be considered. At the 30 % threshold the RF models 
outperform all the DT models although this trend is not seen at the 40 % threshold for 
which the interpolation only (Interpolation only) and extrapolation at the high dose range 
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(Extrapolation high) models only are considered reliable. At the 60 % threshold, only data 
from the extrapolation at high dose range (Extrapolation high) are considered reliable, for 
which the RF model outperforms the DT. 
The accuracies of both the DTs and RFs generally improve as the threshold is increased 
from 30 to 40 % although this is difficult to assess at the 60 % threshold since 4 out of 6 
models are excluded due to insufficient datum points (see Figure 6.4). As with all previous 
models the number of compounds available per model is reduced as the threshold is 
increased leaving behind fewer compounds to build models with. 
Table 6.6. Decision tree and random forest model outputs for the vehicles Saline and Water. The 
most accurate model is highlighted in yellow. Models considered unreliable due to insufficient 
data are shaded in grey.  
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DT Interpolation only 30 42 25/17 1.5 4 52.4 68.0 29.4 48.7 
DT Extrapolation high 30 51 30/21 1.4 5 60.8 80.0 33.3 56.7 
DT Extrapolation high-low 30 33 15/18 0.8 3 60.6 46.7 72.2 59.4 
RF Interpolation only 30 42 25/17 1.5 4(8) 69.0 76.0 58.8 67.4 
RF Extrapolation high 30 51 30/21 1.4 5(10) 74.5 73.3 76.2 74.8 
RF Extrapolation high-low 30 33 15/18 0.8 3(7) 60.6 53.3 66.7 60.0 
DT Interpolation only 40 29 15/14 1.1 3 69.0 66.7 71.4 69.0 
DT Extrapolation high 40 34 18/16 1.1 3 82.4 94.4 68.8 81.6 
DT Extrapolation high-low 40 23 9/14 0.6 2 82.6 66.7 92.9 79.8 
RF Interpolation only 40 29 15/14 1.1 3(6) 89.7 86.7 92.9 89.8 
RF Extrapolation high 40 34 18/16 1.1 3(7) 76.5 83.3 68.8 76.0 
RF Extrapolation high-low 40 23 9/14 0.6 2(5) 91.3 77.8 100.0 88.9 
DT Interpolation only 60 18 10/8 1.3 2 83.3 80.0 87.5 83.8 
DT Extrapolation high 60 24 14/10 1.4 2 75.0 85.7 60.0 72.9 
DT Extrapolation high-low 60 13 7/6 1.2 1 53.8 100.0 0.0 50.0 
RF Interpolation only 60 18 10/8 1.3 2(4) 83.3 80.0 87.5 83.8 
RF Extrapolation high 60 24 14/10 1.4 2(5) 83.3 85.7 80.0 82.9 
RF Extrapolation high-low 60 13 7/6 1.2 1(3) 61.5 57.1 66.7 61.9 
 
The most accurate prediction resulted from the RF model using a 40 % threshold with data 
interpolated only (Interpolation only), which produces a balanced accuracy of 89.8 %. The 
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individual accuracies at these settings for saline and water were 86.7 and 92.9 % 
respectively. The total number of compounds for this model was 29, with a class split of 
15/14 for saline>water/water>saline. A DT model using the 40 % threshold and a RF model 
using the 60 % threshold both with extrapolation at the high dose range only (Extrapolation 
high) also produced balanced accuracies that were in the 80 % region. 
 
Figure 6.4. Decision tree and random forest balanced accuracies for the vehicles Saline and Water. 
Models with insufficient data have been excluded from the chart. 
 
Information provided from the DT data shows that one MACCS fingerprint and one 
molecular property descriptor were most commonly used to split branches on, these were; 
117-NAO (MACCS position-description) and the Number of heteroatoms in aliphatic rings 
molecular descriptor. 
6.4.5 Saline & MC Model Results 
The information presented in Table 6.7 shows the results of the DT and RF models for the 
vehicles saline and MC at the various thresholds and different interpolation/extrapolation 
techniques used. The data shaded grey are considered to be insufficient (i.e. <10 
compounds in a class) for reliable models to be built and the accuracies associated with 
them should not be considered. At the 30 % threshold all RF models outperform the DT 
models although this pattern is less apparent at the 40 % threshold. The two RF models 
deemed reliable at the 60 % threshold also outperform the two DT models considered 
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reliable at the 60 % threshold (see Figure 6.5). The accuracies for both DTs and RFs 
generally improve as the threshold is increased which correlates with a decrease in the 
number of compounds available to model. 
Table 6.7. Decision tree and random forest model outputs for the vehicles Saline and MC. The 
most accurate model is highlighted in yellow. Models considered unreliable due to insufficient 
data are shaded in grey. 
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DT Interpolation only 30 66 41/25 1.6 7 56.1 63.4 44.0 53.7 
DT Extrapolation high 30 85 52/33 1.6 9 52.9 55.8 48.5 52.1 
DT Extrapolation high-low 30 56 40/16 2.5 6 66.1 85.0 18.8 51.9 
RF Interpolation only 30 66 41/25 1.6 7(13) 65.2 68.3 60.0 64.1 
RF Extrapolation high 30 85 52/33 1.6 9(17) 61.2 69.2 48.5 58.9 
RF Extrapolation high-low 30 56 40/16 2.5 6(11) 76.8 90.0 43.8 66.9 
DT Interpolation only 40 47 31/16 1.9 5 68.1 83.9 37.5 60.7 
DT Extrapolation high 40 68 45/23 2.0 7 63.2 77.8 34.8 56.3 
DT Extrapolation high-low 40 38 28/10 2.8 4 78.9 92.9 40.0 66.4 
RF Interpolation only 40 47 31/16 1.9 5(9) 70.2 80.6 50.0 65.3 
RF Extrapolation high 40 68 45/23 2.0 7(14) 58.8 66.7 43.5 55.1 
RF Extrapolation high-low 40 38 28/10 2.8 4(8) 78.9 89.3 50.0 69.6 
DT Interpolation only 60 27 17/10 1.7 3 74.1 82.4 60.0 71.2 
DT Extrapolation high 60 51 32/19 1.7 5 60.8 81.3 26.3 53.8 
DT Extrapolation high-low 60 20 13/7 1.9 2 85.0 84.6 85.7 85.2 
RF Interpolation only 60 27 17/10 1.7 3(6) 77.8 82.4 70.0 76.2 
RF Extrapolation high 60 51 32/19 1.7 5(10) 72.5 75.0 68.4 71.7 
RF Extrapolation high-low 60 20 13/7 1.9 2(4) 90.0 100.0 71.4 85.7 
 
The most accurate prediction resulted from the RF model using a 60 % threshold with data 
interpolated only (Interpolation only), which produces a balanced accuracy of 76.2 %. The 
individual accuracies for this model for saline>MC and MC>saline were 82.4 and 70.0 % 
respectively. The total number of compounds available for this model was 27, with a class 
split of 17/10 for saline>MC/MC>saline. 
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Figure 6.5. Decision tree and random forest balanced accuracies for the vehicles Saline and MC. 
Models with insufficient data have been excluded from the chart. 
 
Information provided from the DT data shows that three MACCS fingerprints were most 
commonly used to split branches on, these were (MACCS position-description); 160-CH3 
and 114-CH3CH2A and 144-Anot%A%Anot%A. 
6.4.6 CMC & HPC Model Results 
The information presented in Table 6.8 shows the results of the DT and RF models for the 
vehicles CMC and HPC at the various thresholds and different interpolation/extrapolation 
techniques used. The data shaded grey are considered to be insufficient (i.e. <10 
compounds in a class) for reliable models to be built and the accuracies associated with 
them should not be considered. Due to the number of insufficient data available, all models 
at the 30 % threshold and only two models at the 40 % threshold were considered to have 
sufficient datum points for the models output to be acceptable. At the 30 % threshold, RF 
models marginally outperform the DT models, although at the 40 % threshold with 
extrapolation at the high dose range (Extrapolation high) the DT model outperforms the RF 
(see Figure 6.6). 
 
151 
 
 
Table 6.8. Decision tree and random forest model outputs for the vehicles CMC and HPC. The most 
accurate model is highlighted in yellow. Models considered unreliable due to insufficient data are 
shaded in grey. 
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DT Interpolation only 30 34 18/16 1.1 3 58.8 50.0 68.8 59.4 
DT Extrapolation high 30 38 20/18 1.1 4 57.9 65.0 50.0 57.5 
DT Extrapolation high-low 30 25 11/14 0.8 3 60.0 54.5 64.3 59.4 
RF Interpolation only 30 34 18/16 1.1 3(7) 61.8 66.7 56.3 61.5 
RF Extrapolation high 30 38 20/18 1.1 4(8) 57.9 55.0 61.1 58.1 
RF Extrapolation high-low 30 25 11/14 0.8 3(5) 64.0 54.5 71.4 63.0 
DT Interpolation only 40 19 12/7 1.7 2 73.7 83.3 57.1 70.2 
DT Extrapolation high 40 28 15/13 1.2 3 75.0 86.7 61.5 74.1 
DT Extrapolation high-low 40 11 6/5 1.2 1 54.5 100.0 0.0 50.0 
RF Interpolation only 40 19 12/7 1.7 2(4) 78.9 91.7 57.1 74.4 
RF Extrapolation high 40 28 15/13 1.2 3(6) 60.7 60.0 61.5 60.8 
RF Extrapolation high-low 40 11 6/5 1.2 1(2) 81.8 66.7 100.0 83.3 
DT Interpolation only 60 10 6/4 1.5 1 60.0 100.0 0.0 50.0 
DT Extrapolation high 60 19 11/8 1.4 2 78.9 81.8 75.0 78.4 
DT Extrapolation high-low 60 6 3/3 1.0 1 50.0 100.0 0.0 50.0 
RF Interpolation only 60 10 6/4 1.5 1(2) 90.0 100.0 75.0 87.5 
RF Extrapolation high 60 19 11/8 1.4 2(4) 78.9 81.8 75.0 78.4 
RF Extrapolation high-low 60 6 3/3 1.0 1(1) 66.7 66.7 66.7 66.7 
 
The most accurate prediction resulted from the DT model using a 40 % threshold with data 
extrapolated at the high dose range (Extrapolation high), which produces a balanced 
accuracy of 74.1 %. The individual accuracies for this model for CMC>HPC and HPC>CMC 
were 86.7 and 61.5 % respectively. The total number of compounds available for this model 
was 28, with a class split of 15/13 for CMC>HPC/HPC>CMC. This DT model therefore 
predicts the major class better than the minor class, although the major class was only 
marginally more populated. 
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Figure 6.6. Decision tree and random forest balanced accuracies for the vehicles CMC and HPC. 
Models with insufficient data have been excluded from the chart. 
 
Information provided from the DT data shows that three MACCS fingerprints were most 
commonly used to split branches on, these were (MACCS position-description); 103-CL, 
152-OC(C)C and 155-A!CH2!A. 
6.4.7 CMC & MC Model Results 
The information presented in Table 6.9 show the results of the DT and RF models for the 
vehicles CMC and MC at the various thresholds and different interpolation/extrapolation 
techniques used. The data shaded grey are considered to be insufficient (i.e. <10 
compounds in a class) for reliable models to be built and the accuracies associated with 
them should not be considered. The balanced accuracy of the DT models at the 30 and 40 
% thresholds do not differ greatly. The difference in the balanced accuracy for the RF 
models at the 30 and 40 % thresholds is more apparent, with one model at the 30 % 
threshold (Extrapolation high) performing better than at the 40 % threshold (see Figure 
6.7). Interestingly the DT and RF model at the 60 % threshold using Interpolation only 
produced identical outputs. 
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Table 6.9. Decision tree and random forest model outputs for the vehicles CMC and MC. The most 
accurate model is highlighted in yellow. Models considered unreliable due to insufficient data are 
shaded in grey. 
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DT Interpolation only 30 69 41/28 1.5 7 65.2 78.0 46.4 62.2 
DT Extrapolation high 30 80 49/31 1.6 8 61.3 69.4 48.4 58.9 
DT Extrapolation high-low 30 59 39/20 2.0 6 72.9 82.1 55.0 68.5 
RF Interpolation only 30 69 41/28 1.5 7(14) 59.4 70.7 42.9 56.8 
RF Extrapolation high 30 80 49/31 1.6 8(16) 66.3 75.5 51.6 63.6 
RF Extrapolation high-low 30 59 39/20 2.0 6(12) 72.9 79.5 60.0 69.7 
DT Interpolation only 40 50 29/21 1.4 5 64.0 75.9 47.6 61.7 
DT Extrapolation high 40 62 37/25 1.5 6 58.1 67.6 44.0 55.8 
DT Extrapolation high-low 40 39 26/13 2.0 4 71.8 76.9 61.5 69.2 
RF Interpolation only 40 50 29/21 1.4 5(10) 60.0 69.0 47.6 58.3 
RF Extrapolation high 40 62 37/25 1.5 6(12) 54.8 64.9 40.0 52.4 
RF Extrapolation high-low 40 39 26/13 2.0 4(8) 74.4 76.9 69.2 73.1 
DT Interpolation only 60 25 13/12 1.1 3 72.0 69.2 75.0 72.1 
DT Extrapolation high 60 40 20/20 1.0 4 75.0 55.0 95.0 75.0 
DT Extrapolation high-low 60 21 12/9 1.3 2 57.1 100.0 0.0 50.0 
RF Interpolation only 60 25 13/12 1.1 3(5) 72.0 69.2 75.0 72.1 
RF Extrapolation high 60 40 20/20 1.0 4(8) 57.5 60.0 55.0 57.5 
RF Extrapolation high-low 60 21 12/9 1.3 2(4) 76.2 83.3 66.7 75.0 
 
The most accurate prediction resulted from the DT model using a 60 % threshold with data 
extrapolated at the high dose range only (Extrapolation high), which produces a balanced 
accuracy of 75.0 %. The individual accuracies for this model for CMC>MC and MC>CMC 
were 55.0 and 95.0 % respectively. The total number of compounds for this model was 40, 
with an even 20/20 class split, which shows the model was much better at predicting the 
MC>CMC class than the CMC>MC class. 
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Figure 6.7. Decision tree and random forest balanced accuracies for the vehicles CMC and MC. 
Models with insufficient data have been excluded from the chart. 
 
Information provided from the DT data shows that four MACCS fingerprints were most 
commonly used to split branches on, these were (MACCS position-description); 105-
A$A($A)$A, 125-AROMATIC RING > 1, 151-NH and 75-A!N$A. 
6.4.8 HPC & Saline with Tween-80 Model Results 
The information presented in Table 6.10 show the results of the DT and RF models for the 
vehicles HPC and saline with Tween-80 at the various thresholds and different 
interpolation/extrapolation techniques used. The data shaded grey are considered to be 
insufficient (i.e. <10 compounds in a class) for reliable models to be built and the accuracies 
associated with them should not be considered. 
The accuracies of both DTs and RFs are generally better at the 40 and 60 % thresholds 
compared to the 30 % threshold however some models perform better at 40 % than at 60 
% (see Figure 6.8). The number of compounds available decreases as the threshold is 
increased and as with the previous models the highest number of compounds is always 
achieved when extrapolation occurs at the high dose range only (Extrapolation high). Both 
the DT and RF models employing extrapolation at the high and low dose range 
(Extrapolation high-low) resulted in insufficient data for accurate models to be built. 
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Table 6.10. Decision tree and random forest model outputs for the vehicles HPC and Saline with 
Tween-80. The most accurate model is highlighted in yellow. Models considered unreliable due to 
insufficient data are shaded in grey. 
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DT Interpolation only 30 106 55/51 1.1 11 53.8 69.1 37.3 53.2 
DT Extrapolation high 30 124 65/59 1.1 12 60.5 52.3 69.5 60.9 
DT Extrapolation high-low 30 89 43/46 0.9 9 69.7 62.8 76.1 69.4 
RF Interpolation only 30 106 55/51 1.1 11(21) 52.8 56.4 49.0 52.7 
RF Extrapolation high 30 124 65/59 1.1 12(25) 66.1 69.2 62.7 66.0 
RF Extrapolation high-low 30 89 43/46 0.9 9(18) 55.1 46.5 63.0 54.8 
DT Interpolation only 40 68 30/38 0.8 7 64.7 70.0 60.5 65.3 
DT Extrapolation high 40 86 41/45 0.9 9 64.0 68.3 60.0 64.1 
DT Extrapolation high-low 40 49 22/27 0.8 5 71.4 54.5 85.2 69.9 
RF Interpolation only 40 68 30/38 0.8 7(14) 76.5 80.0 73.7 76.8 
RF Extrapolation high 40 86 41/45 0.9 9(17) 60.5 58.5 62.2 60.4 
RF Extrapolation high-low 40 49 22/27 0.8 5(10) 67.3 63.6 70.4 67.0 
DT Interpolation only 60 32 19/13 1.5 3 65.6 78.9 46.2 62.6 
DT Extrapolation high 60 47 27/20 1.4 5 72.3 85.2 55.0 70.1 
DT Extrapolation high-low 60 20 14/6 2.3 2 70.0 100.0 0.0 50.0 
RF Interpolation only 60 32 19/13 1.5 3(6) 65.6 63.2 69.2 66.2 
RF Extrapolation high 60 47 27/20 1.4 5(9) 76.6 88.9 60.0 74.4 
RF Extrapolation high-low 60 20 14/6 2.3 2(4) 80.0 100.0 33.3 66.7 
 
Interestingly the most accurate prediction of 76.8 % was seen at the 40 % threshold for the 
RF model using the Interpolation only technique. For this model, 68 compounds were 
available which resulted in a class split of 30/38 for HPC>saline with Tween-80/saline with 
Tween-80>HPC. The individual accuracies for this model for HPC>saline with Tween-80 and 
saline with Tween-80>HPC were 80.0 and 73.7 % respectively, which shows this model to 
predict the minor class better than the major class. 
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Figure 6.8. Decision tree and random forest balanced accuracies for the vehicles HPC and Saline 
with Tween-80. Models with insufficient data have been excluded from the chart. 
 
Information extracted from the decision tree models shows that only three MACCS 
fingerprints were most commonly used to split branches on, these were (MACCS position-
description); 114-CH3CH2A, 150-A!A$A!A and 163-6M RING. 
6.4.9 Distilled Water + Alcohol & Saline Model Results 
The information presented in Table 6.11 show the results of the DT and RF models for the 
vehicles distilled water + alcohol and saline at the various thresholds and different 
interpolation/extrapolation techniques used. The data shaded grey are considered to be 
insufficient (i.e. <10 compounds in a class) for reliable models to be built and the accuracies 
associated with them should not be considered. Thus all models at the 60 % threshold are 
considered unreliable since insufficient data were available at that threshold. At the 30 % 
threshold most models produce balanced accuracies in the 50-60 % region which generally 
improves when the threshold is 40 % (see Figure 6.9). The DT models at the 30 % and 40 % 
threshold using extrapolation at the high and low dose range (Extrapolation high-low) 
resulted in balanced accuracies of <50 %. 
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Table 6.11. Decision tree and random forest model outputs for the vehicles Distilled water + 
alcohol and Saline. The most accurate model is highlighted in yellow. Models considered 
unreliable due to insufficient data are shaded in grey. 
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DT Interpolation only 30 41 17/24 0.7 4 68.3 41.2 87.5 64.3 
DT Extrapolation high 30 47 21/26 0.8 5 63.8 47.6 76.9 62.3 
DT Extrapolation high-low 30 36 13/23 0.6 4 55.6 15.4 78.3 46.8 
RF Interpolation only 30 41 17/24 0.7 4(8) 56.1 29.4 75.0 52.2 
RF Extrapolation high 30 47 21/26 0.8 5(9) 55.3 38.1 69.2 53.7 
RF Extrapolation high-low 30 36 13/23 0.6 4(8) 75.0 46.2 91.3 68.7 
DT Interpolation only 40 32 14/18 0.8 3 75.0 57.1 88.9 73.0 
DT Extrapolation high 40 38 17/21 0.8 4 57.9 47.1 66.7 56.9 
DT Extrapolation high-low 40 29 10/19 0.5 3 55.2 20.0 73.7 46.8 
RF Interpolation only 40 32 14/18 0.8 3(6) 71.9 57.1 83.3 70.2 
RF Extrapolation high 40 38 17/21 0.8 4(8) 68.4 58.8 76.2 67.5 
RF Extrapolation high-low 40 29 10/19 0.5 3(6) 62.1 40.0 73.7 56.8 
DT Interpolation only 60 19 8/11 0.7 2 78.9 100.0 63.6 81.8 
DT Extrapolation high 60 27 9/18 0.5 3 63.0 55.6 66.7 61.1 
DT Extrapolation high-low 60 17 5/12 0.4 2 70.6 0.0 100.0 50.0 
RF Interpolation only 60 19 8/11 0.7 2(4) 63.2 62.5 63.6 63.1 
RF Extrapolation high 60 27 9/18 0.5 3(5) 55.6 44.4 61.1 52.8 
RF Extrapolation high-low 60 17 5/12 0.4 2(3) 82.4 60.0 91.7 75.8 
 
The best prediction accuracy, of 73.0 % is seen using Interpolation only for the DT model at 
the 40 % threshold, which is the highest threshold available for these models. For this 
model, 32 compounds were available which resulted in a class split of 14/18 for distilled 
water + alcohol>saline/saline>distilled water + alcohol. The individual accuracies for this 
model for distilled water + alcohol>saline and saline>distilled water + alcohol were 57.1 
and 88.9 % respectively, showing the major class is predicted much more accurately than 
the minor class. Interestingly the RF model at the 40 % threshold using Interpolation only 
produces a balanced accuracy of 70.2 % but also predicts the major class significantly 
better than the minor class (see Table 6.11). 
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Figure 6.9. Decision tree and random forest balanced accuracies for the vehicles Distilled water + 
alcohol and Saline. Models with insufficient data have been excluded from the chart. 
 
Information extracted from the decision tree models shows that three MACCS fingerprints 
were most commonly used to split branches on, these were (MACCS position-description); 
98-QAAAAA@1, 166-FRAGMENTS and 94-QN. 
6.4.10 Distilled Water + Alcohol & MC Model Results 
The information presented in Table 6.12 show the results of the DT and RF models for the 
vehicles distilled water + alcohol and MC at the various thresholds and different 
interpolation/extrapolation techniques used. The data shaded grey are considered to be 
insufficient (i.e. <10 compounds in a class) for reliable models to be built and the accuracies 
associated with them should not be considered. The greatest accuracies for this model 
were achieved at the 30 % threshold. Only the Extrapolation high models at the 60 % 
threshold produced sufficient data, but both the DT and RF produced balanced accuracies 
in the 50 % region (see Figure 6.10). Of the four models available at the 40 % threshold, the 
RF models were either equivalent or better than the DT models. It is important to note that 
the DT model at the 40 % threshold using Interpolation only predicted the major class with 
100 % accuracy but predicted the minor class with 0 % accuracy indicating that the 
compounds in these two classes cannot be successfully modelled using the descriptors that 
were used. 
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Table 6.12. Decision tree and random forest model outputs for the vehicles Distilled water + 
alcohol and MC. The most accurate model is highlighted in yellow. Models considered unreliable 
due to insufficient data are shaded in grey. 
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DT Interpolation only 30 50 32/18 1.8 5 66.0 59.4 77.8 68.6 
DT Extrapolation high 30 78 43/35 1.2 8 57.7 67.4 45.7 56.6 
DT Extrapolation high-low 30 31 19/12 1.6 3 74.2 57.9 100.0 78.9 
RF Interpolation only 30 50 32/18 1.8 5(10) 74.0 75.0 72.2 73.6 
RF Extrapolation high 30 78 43/35 1.2 8(16) 65.4 72.1 57.1 64.6 
RF Extrapolation high-low 30 31 19/12 1.6 3(6) 77.4 78.9 75.0 77.0 
DT Interpolation only 40 41 28/13 2.2 4 68.3 100.0 0.0 50.0 
DT Extrapolation high 40 68 39/29 1.3 7 61.8 69.2 51.7 60.5 
DT Extrapolation high-low 40 22 16/6 2.7 2 72.7 100.0 0.0 50.0 
RF Interpolation only 40 41 28/13 2.2 4(8) 75.6 89.3 46.2 67.7 
RF Extrapolation high 40 68 39/29 1.3 7(14) 60.3 64.1 55.2 59.6 
RF Extrapolation high-low 40 22 16/6 2.7 2(4) 81.8 100.0 33.3 66.7 
DT Interpolation only 60 25 16/9 1.8 3 60.0 87.5 11.1 49.3 
DT Extrapolation high 60 53 28/25 1.1 5 56.6 57.1 56.0 56.6 
DT Extrapolation high-low 60 11 8/3 2.7 1 72.7 100.0 0.0 50.0 
RF Interpolation only 60 25 16/9 1.8 3(5) 80.0 68.8 100.0 84.4 
RF Extrapolation high 60 53 28/25 1.1 5(11) 56.6 57.1 56.0 56.6 
RF Extrapolation high-low 60 11 8/3 2.7 1(2) 100.0 100.0 100.0 100.0 
 
The greatest prediction accuracy of 78.9 % is achieved with a DT model at the 30 % 
threshold using extrapolation at the high and low dose range (Extrapolation high-low). For 
this model, 31 compounds were available which resulted in a class split of 19/12 for 
distilled water + alcohol>MC/MC>distilled water + alcohol. The individual accuracies for this 
model for distilled water + alcohol and MC were 57.9  and 100.0 % respectively, which 
shows the minor class is better predicted than the major class. 
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Figure 6.10. Decision tree and random forest balanced accuracies for the vehicles Distilled water + 
alcohol and MC. Models with insufficient data have been excluded from the chart. 
 
Information extracted from the decision tree models shows that three MACCS fingerprints 
were most commonly used to split branches on, these were (MACCS position-description); 
112-AA(A)(A)A, 72-OAAO and 79-NAAN. 
6.4.11 Distilled Water + Alcohol & CMC Model Results 
The information presented in Table 6.13 show the results of the DT and RF models for the 
vehicles distilled water + alcohol and CMC at the various thresholds and different 
interpolation/extrapolation techniques used. The data shaded grey are considered to be 
insufficient (i.e. <10 compounds in a class) for reliable models to be built and the accuracies 
associated with them should not be considered. At the 60 % threshold only the 
Extrapolation high DT and RF models were considered to have sufficient data for the 
models to be considered reliable (see Figure 6.11). Interestingly the models in the 30 % 
threshold generally resulted in better predictions than at the 40 or 60 % thresholds. 
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Table 6.13. Decision tree and random forest model outputs for the vehicles Distilled water + 
alcohol and CMC. The most accurate model is highlighted in yellow. Models considered unreliable 
due to insufficient data are shaded in grey. 
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DT Interpolation only 30 42 21/21 1.0 4 73.8 81.0 66.7 73.8 
DT Extrapolation high 30 51 27/24 1.1 5 74.5 70.4 79.2 74.8 
DT Extrapolation high-low 30 35 15/20 0.8 4 62.9 33.3 85.0 59.2 
RF Interpolation only 30 42 21/21 1.0 4(8) 78.6 81.0 76.2 78.6 
RF Extrapolation high 30 51 27/24 1.1 5(10) 76.5 77.8 75.0 76.4 
RF Extrapolation high-low 30 35 15/20 0.8 4(7) 65.7 46.7 80.0 63.3 
DT Interpolation only 40 29 16/13 1.2 3 55.2 56.3 53.8 55.0 
DT Extrapolation high 40 39 20/19 1.1 4 61.5 50.0 73.7 61.8 
DT Extrapolation high-low 40 25 11/14 0.8 3 60.0 81.8 42.9 62.3 
RF Interpolation only 40 29 16/13 1.2 3(6) 75.9 68.8 84.6 76.7 
RF Extrapolation high 40 39 20/19 1.1 4(8) 69.2 65.0 73.7 69.3 
RF Extrapolation high-low 40 25 11/14 0.8 3(5) 56.0 45.5 64.3 54.9 
DT Interpolation only 60 17 10/7 1.4 2 100.0 100.0 100.0 100.0 
DT Extrapolation high 60 27 14/13 1.1 3 66.7 64.3 69.2 66.8 
DT Extrapolation high-low 60 14 7/7 1.0 1 100.0 100.0 100.0 100.0 
RF Interpolation only 60 17 10/7 1.4 2(3) 100.0 100.0 100.0 100.0 
RF Extrapolation high 60 27 14/13 1.1 3(5) 70.4 71.4 69.2 70.3 
RF Extrapolation high-low 60 14 7/7 1.0 1(3) 92.9 85.7 100.0 92.9 
 
The greatest prediction accuracy was observed to be 78.6 % for a RF model at the 30 % 
threshold using Interpolation only. For this model there were 42 compounds available with 
a class split of 21/21 for distilled water + alcohol>CMC/CMC>distilled water + alcohol. The 
individual accuracies of this model were 81.0 and 76.2 for distilled water + alcohol>CMC 
and CMC>distilled water + alcohol respectively, showing that this model was marginally 
better at predicting the distilled water + alcohol>CMC class despite the even class split. 
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Figure 6.11. Decision tree and random forest balanced accuracies for the vehicles Distilled water + 
alcohol and CMC. Models with insufficient data have been excluded from the chart. 
 
Information extracted from the decision tree models shows that four MACCS fingerprints 
were most commonly used to split branches on, these were (MACCS position-description); 
156-NA(A)A, 16-QAA@1, 109-ACH2O and 94-QN. 
6.4.12 Acetone & Saline Model Results 
The information presented in Table 6.14 show the results of the DT and RF models for the 
vehicles acetone and saline at the various thresholds and different 
interpolation/extrapolation techniques used. The data shaded grey are considered to be 
insufficient (i.e. <10 compounds in a class) for reliable models to be built and the accuracies 
associated with them should not be considered. It is interesting to note that all the models 
extrapolated at the high and low dose range (Extrapolation high-low) were the models that 
resulted in insufficient data (see Figure 6.12). Of the remaining models, at each of the 
thresholds the RF models tend to outperform the DT models with the exception at the 60 % 
threshold using Interpolation only. Both DT models at the 40 and 60 % threshold with 
extrapolation at the high dose range (Extrapolation high) resulted in a 0 % accuracy for 
predicting the minor class which always happens to be acetone. 
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Table 6.14. Decision tree and random forest model outputs for the vehicles Acetone and Saline. 
The most accurate model is highlighted in yellow. Models considered unreliable due to insufficient 
data are shaded in grey. 
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DT Interpolation only 30 42 22/20 1.1 4 57.1 59.1 55.0 57.0 
DT Extrapolation high 30 54 17/37 0.5 5 72.2 17.6 97.3 57.5 
DT Extrapolation high-low 30 22 8/14 0.6 2 63.6 0.0 100.0 50.0 
RF Interpolation only 30 42 22/20 1.1 4(8) 83.3 72.7 95.0 83.9 
RF Extrapolation high 30 54 17/37 0.5 5(11) 70.4 23.5 91.9 57.7 
RF Extrapolation high-low 30 22 8/14 0.6 2(4) 81.8 50.0 100.0 75.0 
DT Interpolation only 40 35 19/16 1.2 4 54.3 52.6 56.3 54.4 
DT Extrapolation high 40 49 14/35 0.4 5 71.4 0.0 100.0 50.0 
DT Extrapolation high-low 40 17 6/11 0.5 2 64.7 0.0 100.0 50.0 
RF Interpolation only 40 35 19/16 1.2 4(7) 68.6 57.9 81.3 69.6 
RF Extrapolation high 40 49 14/35 0.4 5(10) 77.6 28.6 97.1 62.9 
RF Extrapolation high-low 40 17 6/11 0.5 2(3) 88.2 66.7 100.0 83.3 
DT Interpolation only 60 27 16/11 1.5 3 77.8 93.8 54.5 74.1 
DT Extrapolation high 60 38 11/27 0.4 4 71.1 0.0 100.0 50.0 
DT Extrapolation high-low 60 12 4/8 0.5 1 66.7 75.0 62.5 68.8 
RF Interpolation only 60 27 16/11 1.5 3(5) 66.7 75.0 54.5 64.8 
RF Extrapolation high 60 38 11/27 0.4 4(8) 81.6 36.4 100.0 68.2 
RF Extrapolation high-low 60 12 4/8 0.5 1(2) 66.7 50.0 75.0 62.5 
 
The best prediction is observed for the RF model at the 30 % threshold using Interpolation 
only which results in a balanced accuracy of 83.9 %. For this model 42 compounds were 
available which resulted in a class split of 22/20 for acetone>saline/saline>acetone. The 
individual accuracies for this model for acetone>saline and saline>acetone were 72.7 and 
95.0 % respectively, which shows that this model is better at predicting the minor class 
albeit marginally minor. Interestingly the DT models at the 40 and 60 % threshold using 
extrapolation at the high dose range (Extrapolation high) result in a 0 % prediction accuracy 
for the minor class (acetone>saline) and 100 % accuracy for the major class 
(saline>acetone), which indicates the data available cannot be suitably modelled with the 
descriptors that were used. 
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Figure 6.12. Decision tree and random forest balanced accuracies for the vehicles Acetone and 
Saline. Models with insufficient data have been excluded from the chart. 
 
Information extracted from the decision tree models shows that one MACCS fingerprint 
and one molecular property descriptor were most commonly used to split branches on. 
This MACCS fingerprint was, 38-NC(C)N (MACCS position-description) and the molecular 
property descriptor was the Number of carbons. 
6.5 Knowledge Extraction From Predictive Models 
Information extracted from the DT models pertaining to the fingerprints and molecular 
descriptors used to split trees on provides a useful insight into how each model makes 
decisions prior to providing a prediction.  
If any descriptor(s) used, correlate highly with the binary class of a model then these 
descriptors may be useful in turning this information into valuable scientific knowledge. 
More specifically if any descriptors discovered are to perfectly correlate with the class of a 
model, this would provide invaluable information about the type of compounds that are 
suitable for toxicity reduction and generalisations can be formed from this information. 
To discover such information, all the DT models can be assessed for descriptor correlation. 
Models that were deemed unreliable for predictions due to insufficient data can also be 
used to gather descriptor information. To reiterate, insufficient datum points are 
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considered as <10 compounds in any one class. These models are considered unreliable for 
predictions due to the 10-fold cross validation method used in training the models (see 
chapter 5 section 5.9).  
For the models reported in this chapter using the AUC methodology, the 60 % threshold is 
the point at which the most signal is observed, i.e. there is less noise in the data. Models at 
the 60 % threshold therefore become the point at which any knowledge discovery would 
be most apparent, despite the number of datum points being low. 
An analysis of the DT data for all vehicle pairings using all interpolation/extrapolation 
techniques was conducted at the 60 % threshold to assess any strong correlations which 
may occur between a descriptor and the binary class. 
6.5.1 Distilled Water + Alcohol & CMC Knowledge Extraction 
The models for the vehicle pairing distilled water + alcohol & CMC are reported in section 
6.4.11 of this chapter. At the 60 % threshold only 2 of the 6 possible models contained 
sufficient datum points to be considered reliable. For this vehicle pairing at the 60 % 
threshold the descriptors used by the DT models for Interpolation only, Extrapolation high 
and Extrapolation high-low were extracted regardless of model reliability. It is not effective 
predictions but rather compound descriptions that are sought after here. Models 
considered unreliable may still contain this information from the descriptor generation 
step, prior to descriptor filtering. Furthermore it is often the models at the 60 % threshold 
that are able to eliminate noise from the data. 
For two of the DT models at the 60 % threshold; Interpolation only and Extrapolation high-
low, two MACCS fingerprints perfectly correlate with the binary class. These fingerprints 
are (MACCS position-description); 16-QAA@1 and 22-3M RING, which implies that 
compound structures containing a 3-membered ring, are solely classified into one class. 
Upon inspection of the compounds contained within the two models (Interpolation only 
and Extrapolation high-low, both at the 60 % threshold) it was identified that the 3-
membered ring contained within these compounds was an aziridine ring structure. For 
both the Interpolation only and Extrapolation high-low models all compounds which 
contained the aziridine ring were classified as CMC>distilled water + alcohol, which implies 
that the use of the vehicle CMC with structures containing the aziridine functional group 
are better suited to a toxicity reduction compared to the vehicle distilled water + alcohol. 
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To demonstrate this, consider the information presented in Table 6.15, which shows the 
structures of the compounds that were available for the Interpolation only model at the 60 
% threshold. The table shows the class that each of these compounds were assigned to 
prior to developing predictive models. For predictive purposes this particular model is 
considered unreliable due to insufficient data points being present in the CMC>Distilled 
water + alcohol class (i.e. <10 compounds). The MACCS fingerprint information shown in 
the table however provides some interesting scientific interpretations. The fingerprint 16-
QAA@1 (MACCS position-description) relates to a structure containing a 3-membered ring 
with a heteroatom present, this is indicated by the presence (1) or absence (0) in the table. 
When comparing this fingerprint column to the class column it becomes apparent that for 
all compounds with the 3-membered ring present, belong to one class (CMC>distilled water 
+ alcohol), whilst the compounds for which the 3-membered ring is not present, belong to 
the other class (distilled water + alcohol>CMC). An identical observation is seen with the 
Extrapolation high-low model at the 60 % threshold, only with fewer compounds. 
Table 6.15. Compound structures for the Distilled water + alcohol & CMC model. Information 
extracted from the Interpolation only DT model using a 60 % threshold. 
 
Structure NSC 16-QAA@1 Class 
 
762 0 Distilled water + alcohol>CMC 
 
3434 0 Distilled water + alcohol>CMC 
 
4236 0 Distilled water + alcohol>CMC 
 
7532 0 Distilled water + alcohol>CMC 
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11440 0 Distilled water + alcohol>CMC 
 
15788 0 Distilled water + alcohol>CMC 
 
17019 0 Distilled water + alcohol>CMC 
 
21934 0 Distilled water + alcohol>CMC 
 
30911 0 Distilled water + alcohol>CMC 
 
56408 0 Distilled water + alcohol>CMC 
 
9717 1 CMC>Distilled water + alcohol 
 
55740 1 CMC>Distilled water + alcohol 
 
56296 1 CMC>Distilled water + alcohol 
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56410 1 CMC>Distilled water + alcohol 
 
57561 1 CMC>Distilled water + alcohol 
 
58944 1 CMC>Distilled water + alcohol 
 
60096 1 CMC>Distilled water + alcohol 
 
The correlations observed for this model can thus be used to form generalisations about 
the type of compounds for which the vehicle CMC may offer better toxicity protection than 
distilled water + alcohol. In this specific example it can be argued that any compounds 
containing the 3-membered aziridine ring can have their toxicity reduced relative to 
distilled water + alcohol through the use of the vehicle CMC. 
6.6 Constructing Partially Ordered Sets from Vehicle 
Pairings 
With a strong correlation observed for aziridine containing compounds and their respective 
class for the distilled water + alcohol & CMC models, an analysis of the classification of all 
aziridine containing structures for all other models developed in the chapter was 
conducted.  
For each of the vehicle pairings using Interpolation only at the 60% threshold the 
classification divide of all aziridine containing compounds was extracted. The aim was to 
assess the class divide for all the other models and determine whether aziridine containing 
compounds predominantly favour one class for these other models also. If this can be 
demonstrated then the data collected can be used to form a partially ordered set which 
forms an ordering of vehicles which provide progressively better toxicity reduction for this 
group of compounds. 
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The class divide extracted from all possible models for all aziridine containing compounds is 
shown in Table 6.16. The table shows the vehicle pairings represented as X & Y and the 
number of aziridine containing compounds that are classified into each binary class (X>Y or 
Y>X). For example, consider the first vehicle pairing in Table 6.16 (Row ID 1), Saline & CMC. 
This vehicle pairing is represented as X & Y for saline & CMC respectively. The two binary 
classes formed are therefore saline>CMC represented as X>Y and CMC>saline represented 
as Y>X. The numbers in the table represent the number of aziridine containing compounds 
that fall into each class using Interpolation only at the 60 % threshold for all the models 
discussed in this chapter. Vehicle pairings for which no aziridine containing compounds are 
detected contain no data in the table and are shaded grey. 
Table 6.16. Classification divide of aziridine containing compounds for all vehicle pairings. Data 
shaded in grey did not have any aziridine containing compounds. 
 
 
Vehicle Pairing 
Number of aziridine containing 
compounds per class 
Row 
ID 
X Y X>Y Y>X 
1 Saline CMC 5 1 
2 
Distilled water + 
alcohol 
CMC 0 7 
3 
Distilled water + 
alcohol 
MC 2 0 
4 
Distilled water + 
alcohol 
Saline 1 8 
5 Saline MC 4 0 
6 CMC MC 2 1 
7 Saline 
Saline with 
Tween-80 
3 0 
8 Saline HPC 0 2 
9 Saline Water - - 
10 CMC HPC - - 
11 HPC 
Saline with 
Tween-80 
- - 
12 Acetone Saline - - 
 
From the data presented in Table 6.16 it is apparent that the number of aziridine 
containing compounds for each of the vehicle pairings is relatively low, however for many 
of the vehicle pairings it is easy to see that one class is predominantly favoured over the 
other. It is therefore possibly to arrange an ordering of these vehicles to show how the 
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toxicity of aziridine containing compounds can be reduced when the vehicles are compared 
to one another. 
To begin with consider the first vehicle pairing of saline & CMC (Row ID 1) in the table. The 
data shows that 5 aziridine containing compounds are assigned to the class saline>CMC and 
only 1 aziridine compound to the class CMC>saline. With the class saline>CMC being 
predominantly favoured by these compounds we can create the following ordering: 
 (1) 
 
This ordering can be read as “saline is better than CMC” and is the first step of the partially 
ordered set. Now consider Row ID 2 of Table 6.16, which shows the vehicle CMC to be 
completely favoured over the vehicle distilled water + alcohol at a ratio of 7 to 0. For 
aziridine containing compounds CMC can therefore be considered as better than distilled 
water + alcohol and can be used to create the following ordering: 
 
(2) 
 
Taking the data from Row ID 3 of Table 6.16 and applying these same ordering principles 
shows the vehicle distilled water + alcohol to be predominantly favoured over the vehicle 
MC (i.e. distilled water + alcohol is better than MC), the ordering can then be represented 
as: 
 
(3) 
 
This ordering (3) has been constructed from the data contained in Table 6.16 and can be 
cumbersomely read as “saline is better than CMC which is better than distilled water + 
alcohol which is better than MC”. This ordering of vehicles that reduce the toxicity of 
aziridine containing compounds shows that the vehicle saline is best suited at reducing 
toxicity, whilst MC is the least suited. 
Although each of the individual orderings shown holds true, as seen from Row IDs 1, 2 and 
3 of Table 6.16, arranging this information into such an ordered set must satisfy the other 
relationships that can be made from this ordering. More specifically, from the ordering 
shown in (3), the following three relationships can be deduced: 1) saline is better than 
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distilled water + alcohol, 2) saline is better than MC and 3) CMC is better than MC. These 
deduced relationships must hold true for the ordered set shown in (3) to be valid. 
As proof of concept, the data from the other vehicle pairings shown in Table 6.16 must 
agree with these deduced relationships. 
Row ID 4 of Table 6.16 shows the first deduced relationship to hold true. That is, for the 
vehicle pairings distilled water + alcohol & saline, 8 aziridine containing compounds were 
classified as saline>distilled water + alcohol whilst only 1 aziridine containing compound 
was classified as distilled water + alcohol>saline. The class saline>distilled water + alcohol is 
therefore predominantly favoured and agrees with the first deduced relationship. This is 
shown as a red dotted arrow in the ordering below: 
 
(4) 
 
The second deduced relationship can be satisfied from the data in Row ID 5 of Table 6.16, 
which shows the class saline>MC is completely favoured over the class MC>saline. This 
relationship therefore satisfies the second deduced relationship and is shown as a green 
dotted arrow in the ordering below: 
 
(5) 
 
Lastly, the third deduction made can be shown to hold true from the data in Row ID 6 of 
Table 6.16, which shows the class CMC>MC to be favoured over the class MC>CMC. 
Although this preference is marginal (i.e. 2:1), it agrees with the third deduced relationship 
and from the data available does not suggest a counter argument. This relationship can 
therefore be considered true and is shown as a blue dotted arrow in the ordering below: 
 
(6) 
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To complete this ordering and form a partially ordered set, two other relationships shown 
in Row IDs 7 and 8 of Table 6.16 are to be included. Row ID 7 shows the class saline>saline 
with Tween-80 is completely favoured over the class saline with Tween-80>saline. Similarly, 
Row ID 8 shows the class HPC>saline to be completely favoured over the class saline>HPC. 
Including these two relationships into the ordered set results in the partially ordered set 
shown below: 
 
(7) 
 
This completed partially ordered set (7) shows that the vehicle HPC is better than the 
vehicle saline for aziridine containing compounds. It also shows the vehicle saline is better 
than the vehicle saline with Tween-80 for aziridine containing compounds. The vehicle HPC 
has been connected to saline via a dashed arrow, which indicates that although the 
relationship between HPC and saline is shown to be true from the data in Table 6.16, the 
other relationships cannot be confirmed through any available data (i.e. HPC is better than 
CMC, HPC is better than distilled water + alcohol or HPC is better than MC). 
The vehicle saline in the partially ordered set (7) has also been connected to the vehicle 
saline with Tween-80, showing that saline is better than saline with Tween-80 for aziridine 
containing compounds. The vehicle saline with Tween-80 however has been placed off the 
main branch connecting the other vehicles. It has been arranged as such since from the 
data available it is impossible to determine where in the main branch of this partially 
ordered set saline with Tween-80 should sit. Although it is known that saline is better than 
saline with Tween-80, it is not known if CMC, distilled water + alcohol or MC is better or 
worse than saline with Tween-80 and therefore saline with Tweet-80 cannot be integrated 
into the main branch. Furthermore, the vehicle saline with Tween-80 has been connected 
to the vehicle saline with a dashed line to show the potential relationship that reads HPC is 
better than saline with Tween-80 is untested due to insufficient data.  
The partially ordered set (7) shows the ordering of the vehicles which can be used for 
aziridine containing compounds, it is considered a partial order since not every element is 
related (or has insufficient data to make a relation). The ordering from left to right shows 
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progressively less toxicity protection offered by the vehicles for aziridine containing 
compounds in relation to each other.  
6.7 Conclusion 
This chapter has presented twelve classification models that have been developed using 
the AUC methodology proposed in chapter 5. The methodology has been successfully 
demonstrated to show how classifiers can be built through the repurposing of in vivo 
scientific data for knowledge extraction. An additional feature of this methodology is the 
use of the interpolation/extrapolation techniques which increases the size of the AUC 
which can be compared, whilst possibly reducing the noise in the data. 
The pairwise vehicle relationships that were possible tend to be between the most 
commonly occurring vehicles within the NIH dataset, although vehicles such as acetone and 
distilled water + alcohol which have an occurrence of 0.36 and 3 % respectively were 
successfully paired with other vehicles to build models from. 
For any given vehicle pairing, as the % AUC threshold is increased a decrease in the number 
of compounds available to model is observed. This is explained by the larger threshold 
resulting in more vehicles falling into the equivalent class and therefore being removed 
from the dataset. With the vehicle saline being the most commonly occurring vehicle 
within the NIH dataset it is unsurprising that the models with the largest data points 
included the vehicle saline paired with another vehicle.  
Figure 6.13 provides a graphic for the number of data points that were available for the 
various models developed using different thresholds and interpolation/extrapolation 
techniques. The dotted lines represent models at the 30 % threshold, the dashed lines 
represent the models at the 40 % threshold and the solid lines represent the models at the 
60 % threshold. The colours blue, red and yellow represent the Interpolation only, 
Extrapolation high and Extrapolation high-low techniques respectively. For each vehicle 
pairing reported at a given % AUC threshold, the Extrapolation high procedure always 
results in the highest number of compounds, followed by the Interpolation only, with 
Extrapolation high-low resulting in the lowest number of compounds.  
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Figure 6.13. Data points per model using different thresholds and interpolation/extrapolation 
techniques. 
 
Of the different thresholds and interpolation/extrapolation techniques used, a trend is not 
observed when correlated against the predictive accuracies of each model. Rather different 
models achieve their best predictive outcomes at different thresholds which use different 
interpolation/extrapolation techniques. 
Of the 12 vehicle pairing models reported, RFs produce better balanced accuracies for 8 of 
these models with the remaining 4 models producing better balanced accuracies from the 
DT models, this is generally expected given RFs are an ensemble method. Of the different % 
AUC thresholds tested, 5 of the 12 models produce better accuracies at the 60 % threshold, 
4 at the 40 % threshold and 3 at the 30 % threshold. This indicates that better predictive 
outcomes are made when the % AUC threshold is set to 60 % which filters out more noise 
from the data. It is important to note that some models, for example the CMC & HPC 
model and the distilled water + alcohol & saline model, did not produce sufficient data 
points at the 60 % threshold and as a result produced their best accuracies at a 40 % 
threshold. Had sufficient data been available to build models at the 60 % threshold then 
those models may also have resulted in better predictive outcomes at the 60 % threshold. 
This would provide further reassurance that more signal within the data is observed at a 
higher % AUC difference. Of the interpolation/extrapolation techniques tested, 
Interpolation only results in the best model for 7 out of the 12 vehicle pairings, with 
Extrapolation high-low and Extrapolation high representing 3 and 2 models respectively. 
The Extrapolation high technique results in lower accuracies despite having the most 
datum points, suggesting this technique is ineffective with the NIH dataset used in this 
study. 
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The overall balanced accuracies of the different models varies, with balanced accuracies 
exceeding 80 % for some models. For all vehicle pairings, the best balanced accuracy 
achieved is always above 70 %. These results suggest that the methodology proposed and 
tested is a reliable way to build predictive classifiers. More specifically these classifiers 
were built from in vivo real scientific data which is prone to high variability [341]. For all the 
models developed the data bias of the two binary classes is never greater than 3 fold and 
for the models which produced the best balanced accuracies for each of the vehicle 
pairings this bias is never greater than 2 fold between the two classes. The low data bias 
seen with all these models meant any corrective measures to balance the two classes was 
not necessary. This is reflected with some models producing better individual accuracies for 
the minor class which is possible given the class imbalance is not significant. 
Information extracted from the DT tree models is presented for each vehicle pairings in 
Table 6.17. The MACCS keys fingerprints are more frequently used across all models than 
the molecular property descriptors. Many of the fingerprints used by the models contain 
oxygen and/or nitrogen atoms, for example, 72-OAAO, 79-NAAN, 95-NAAO, 97-NAAAO, 
117-NAO and 151-NH, which may infer some element of hydrogen bonding occurring 
between the compound and a vehicle used. Fingerprints such as 53-QHAAAQH can also be 
implicated in hydrogen bonding if the atom symbol Q in this fingerprint is a nitrogen (N) or 
oxygen (O) atom. In Table 6.17, fingerprints which are potentially implicated in hydrogen 
bonding are highlighted in yellow, whilst the fingerprints not implicated in hydrogen 
bonding are highlighted in blue. Furthermore, vehicles such as HPC, CMC and MC are 
polymers and have the potential to form a chelate with the compound, supported by 
hydrogen bonding which can lower the entropy of the system resulting in less disorder. The 
effects of hydrogen bonding may aid the solubilisation and/or permeability of a compound 
and as discussed in chapter 2, an improved solubility/permeability can confer to a 
reduction in toxicity. Interestingly, many fewer fingerprints which represent branching are 
used by the DT models, which can potentially hinder the chelating ability of a vehicle 
towards a compound, reducing the potential of forming hydrogen bonds. 
Of the 12 models produced, four MACCS fingerprints and one molecular property 
descriptor occur in 2 different models. The MACCS fingerprint 109-ACH2O is present in the 
saline & CMC models and the distilled water + alcohol & CMC models, both of which 
contain CMC as one of the vehicles being modelled. Similarly 160-CH3 is present in the 
saline & HPC and saline & MC models, both of which contain saline as one of the vehicles.  
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Table 6.17. Frequently used fingerprints and descriptors extracted form DT models. Descriptors 
highlighted in yellow can potentially form hydrogen bonds whilst descriptors in blue are not 
implicated in hydrogen bonding. 
 
Vehicle Pair MACCS Key Fingerprints Molecular Descriptors 
Saline & CMC 
120-HETEROCYCLIC ATOM >1 Number of heteroatoms in aliphatic rings 
83-QAAAA@1 - 
53-QHAAAQH - 
109-ACH2O - 
115-CH3ACH2A - 
137-HETEROCYCLE  - 
Saline & Saline with Tween-80 
93-QCH3 - 
116-CH3AACH2A - 
95-NAAO - 
97-NAAAO - 
99-C=C - 
Saline & HPC 
102-QO - 
131-QH > 1 - 
148-AQ(A)A  - 
160-CH3 - 
Saline & Water 117-NAO Number of heteroatoms in aliphatic rings 
Saline & MC 
160-CH3 - 
114-CH3CH2A - 
144-Anot%A%Anot%A - 
CMC & HPC 
103-CL - 
152-OC(C)C - 
155-A!CH2!A - 
CMC & MC 
105-A$A($A)$A - 
125-AROMATIC RING > 1 - 
151-NH - 
75-A!N$A. - 
HPC & Saline with Tween-80 
114-CH3CH2A - 
150-A!A$A!A - 
163-6M RING - 
Distilled water + alcohol & Saline 
98-QAAAAA@1 - 
166-FRAGMENTS - 
94-QN - 
Distilled water + alcohol & MC 
 
 
112-AA(A)(A)A - 
72-OAAO - 
79-NAAN - 
Distilled water + alcohol & CMC 
 
156-NA(A)A - 
16-QAA@1 - 
109-ACH2O - 
94-QN - 
Acetone & Saline 38-NC(C)N Number of carbons 
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94-QN occurs in the distilled water + alcohol & MC and distilled water + alcohol & CMC 
models, both of which contain distilled water + alcohol as one of the vehicles. Lastly the 
fingerprint 114-CH3CH2A, occurs in the saline & MC and HPC & saline with Tween-80, 
however neither of those two models contain a common vehicle. The one molecular 
property descriptor which occurs in 2 different models is the Number of heteroatoms in 
aliphatic rings. This descriptor is present in the saline & CMC and saline & water models for 
which saline is the common vehicle between the two different models. 
From the DT information extracted, it was possible to identify descriptors which strongly 
correlated with the class of a model. This was initially done with one of the distilled water + 
alcohol & CMC models, which led to the discovery of compounds containing the 3-
membered ring aziridine which correlated strongly with the class of the model data. From 
this information it was clearly apparent that compounds containing the aziridine ring 
structure were better suited to the vehicle CMC than distilled water + alcohol. This builds 
on the predictive model work discussed earlier and demonstrates how such information 
extracted from in vivo data can be turned into knowledge. 
Furthermore, an analysis of all the other vehicle pairings identified similar strong 
correlations between one class of a particular model and any aziridine containing 
compounds. Using this information it was possible to construct a partially ordered set of 
the vehicles according to the toxicity reduction afforded by them for any aziridine 
containing compounds. The data extracted also acted as proof of concept for the main 
branch of the partially ordered set. Although the partially ordered set was constructed 
from low numbers of data, none of the data resulted in counter arguments to the ordering 
of the vehicles. Whilst the polymer HPC seems to be the most protective vehicle against the 
toxicity of aziridine containing compounds, MC was deemed the least protective overall. 
The vehicle saline appeared to offer better protection than saline with Tween-80, which 
suggests that the surfactant Tween-80 may reduce the ability of saline to offer any kind of 
toxicity relief to aziridine containing compounds. The vehicle distilled water + alcohol also 
rated low in toxicity protection, potentially due to the alcohol content within this vehicle. 
Interestingly the vehicles which appear more frequently within the entire NIH dataset (HPC, 
saline, and saline with Tween-80) also seem to be the vehicles which offer the better 
toxicity relief against aziridine containing compounds. Whilst the vehicles which appear less 
often within the entire NIH dataset seem to be the ones offering the least toxicity 
protection against aziridine containing compounds. 
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7 
7 Thesis Conclusion 
 
The work presented in this thesis is a multidisciplinary effort which involves the use of 
computational machine learning techniques with real scientific data, for the purpose of 
data extraction, data visualisation, data modelling, and knowledge discovery. 
The main objective of this thesis, as set out in chapter 1, was to demonstrate that drug 
formulations can be modelled for toxicity reduction. This has been shown in the original 
contributions made by chapters 5 and 6 of this thesis. Furthermore, at the time of writing, 
there is no known published work in the public domain of similar credit. 
7.1 Research Contributions 
Formulating drugs to mitigate toxicity is extremely useful to the pharmaceutical industry 
and allows NCEs that would originally be dropped due to unacceptable toxicities, to 
continue through the developmental pipeline. This translates to a saving in cost and time 
allowing better medicines to reach the end user. Knowing which formulation will provide 
toxicity relief for a specific drug is an interesting challenge but often requires the input of 
an expert with many years of experience.  
The objective of this thesis was therefore to develop models capable of predicting which 
formulation would be suited to a particular drug. 
To begin with an extensive literature review was required which covered all aspects of drug 
toxicology relating to formulation work. Chapter 2 reports the information gathered from 
this review. An overview of the different types of drug toxicities are discussed as well as the 
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various ways of studying toxicity and taking measurements, such as dose related 
measurements, biomarker measurements and histopathological measurements. The 
chapter also reports on the various technologies currently available for toxicity reduction 
through drug formulation, surprisingly there are relatively few different types.  
More importantly it is imperative to understand the underlying pharmacokinetic and 
pharmacodynamic principles of drug toxicity when considering drug formulations. All drugs 
will exhibit an underlying pharmacokinetic and pharmacodynamic based toxic response.  
Understanding these responses allows formulations to counter these effects thereby 
reducing toxicity. The mechanism(s) by which a formulations reduces a drug’s toxicity can 
be grouped into the following four strategies; 1) active organ protection, 2) avoid 
susceptible organs, 3) active targeting and 4) availability enhancement. 
The majority of the drugs reported in the literature that have been formulated for toxicity 
reduction were the cytotoxics and anti-infectives. This resulted in a small diversity of drugs 
which would prove difficult to model. 
Nevertheless, if a sufficient number of data can be gathered it is possible to build a toxicity 
protection pathway based on the AOP framework which plots the upstream and 
downstream events of a drug’s toxicity pathway. An example for the drug gentamicin was 
provided in section 2.8. Along this pathway, formulations known to prevent specific toxic 
mechanisms are added. If two different drugs shared a common pathway, then they may in 
principle benefit from the same formulation to reduce toxicity.  
The work presented in chapter 2 provides a good scientific overview of drug formulations 
and toxicity which has relevance to all subsequent chapters. 
Chapter 3 of this thesis presents an overview of how predictive models are built and the 
processes undertaken, from data collection through to model validation. This chapter 
discusses some of the pitfalls encountered with this type of work and provides useful 
information with regards to data curation and more importantly chemical data 
representation. The chapter goes on to discuss some of the more popular machine learning 
techniques used for binary classification problems (ANN, DT, RF, SVM, kNN and Naïve 
Bayes) in reference to toxicity studies, which will also support the soft computing 
approaches explored later in the thesis. References to the literature are provided where 
necessary. The chapter ends by reporting on the different ways models can be statistically 
analysed using accuracy and precision metrics, with the balanced accuracy or Matthews 
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Correlation Coefficient (MCC) favoured with unbalanced datasets. The work presented in 
this chapter is directly relevant to chapters 5 and 6 of this thesis. 
Chapter 4 proposes a methodology based on graph theory and Venn diagram 
representation for the extraction of interesting data relationships that can contribute to a 
knowledge-based approach of modelling toxicity in drug-vehicle relationships. The 
methodology presented can in theory be used for other types of data where the 
relationship between two variables is sought. Using the NIH dataset, which was largely un-
curated, a novel bipartite graph arrangement using labelled edges was shown to provide 
the optimal solution to the problem of visualising and extracting interesting drug-vehicle 
relationships. Subgraphs were extracted to demonstrate the capabilities of visualising such 
data using this arrangement. From the graph paired comparisons between vehicles were 
made and each drug grouped into one or more list. After removing conflicting or equivalent 
data these lists were plotted onto a Venn diagram from which multiple vehicle 
relationships can now be identified for drugs in the overlapping segments of the Venn 
diagram. This methodology helps to quickly identify the number of interesting datum 
points a particular dataset may contain.  
Chapter 5 proposes a novel methodology based on the area under a curve principle that 
uses interpolation and extrapolation methods to classify data based on multiple data 
points. The methodology is applied to the NIH dataset for the pairwise classification of 
drug-vehicle relationships, from which binary classification models are built (RF and DT). To 
investing the effectiveness of this methodology, three % AUC thresholds were used with 
three different interpolation/extrapolation methods. This methodology along with some of 
the results from chapter 6, contributes to original work in this field and has been published 
in Springer, Soft Computing (doi:10.1007/s00500-015-1925-9) see publications section for 
details.  
Chapter 6 presents the results of the various models created from the 12 vehicle pairings 
extracted from the NIH dataset using the methodology proposed in chapter 5. Potentially 9 
RF and 9 DT models could be produced for each vehicle pairing, although this is dependent 
on sufficient data being available. Models that used a 60 % AUC threshold with 
interpolation only generally seemed to perform better, suggesting a 60 % threshold is 
required for any signal to be observed amongst the noise in the dataset.  
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These findings provide some reassurance with regards to the methodology developed and 
shows which parameters produce the better results for this particular dataset. For each of 
the vehicle pairings the best accuracy produced is always above 70 % with some models 
resulting in accuracies of 80 % or more. 
Descriptor information extracted from the DT models shows that the decision trees were 
using fingerprints that have the potential to form hydrogen bonds much more frequently 
than fingerprints that do not. Interestingly vehicles such as HPC, CMC and MC have the 
ability to form chelates with compounds which are supported by hydrogen bonding, which 
lowers the entropy of the system making a drug-vehicle relationship more stable. 
Of all the models developed, one vehicle pairing, distilled water + alcohol & CMC, resulted 
in the class of the data strongly correlating with a single descriptor. This descriptor was 
identified as a 3-membered ring descriptor. Inspection of the structures revealed this 3-
membered ring to be aziridine. Extracting data from the other 11 vehicle pairing models 
revealed a similar pattern, with aziridine containing compound generally correlating 
strongly with one class of the model. 
The vehicle pairings of these models could thus be arranged into a sequence of partially 
ordered sets which provided an ordering of vehicles which progressively provide better 
toxicity protection for aziridine containing compounds. 
Thus using the methodology proposed in chapter 5 it was possible to build successful 
classification models from which interesting relationships could be formed and previously 
unknown knowledge, pertaining to aziridine containing compounds extracted. 
To summarise, the possibility of building toxicity protection pathways as shown for 
gentamicin in chapter 2 for the prediction of drug formulations is an interesting one and 
constitutes a knowledge based approach, which can be time consuming but also lacking in 
sufficient data. Alternatively it is also possible to build predictive models using a data 
driven approach as demonstrated by the work in chapters 5 and 6 of this thesis. From this it 
has also been possible to derive rules for groups of compounds. 
7.2 Future work 
Given the novelty of some of the work presented in this thesis, there are many future 
directions that are possible and worth considering. From the work presented in chapter 2 
of this thesis there is the potential to build toxicity protection pathways for other drugs and 
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assess if any integration of pathways are possible. If so this may provide another unique 
direction into what is considered to be a relatively unexplored domain. The potential to 
integrate information from publicly available data such as the AOP Wiki page [349] is also 
something to be considered. The literature can also be searched for more drug formulation 
data that have become available since the initial collection of data. 
In chapter 4 of this thesis, bipartite graph representation was introduced and a 
methodology discussed for the quick visualisation and extraction of interesting 
relationships. At present these relationships were extracted in the form of ‘”better than” 
according to the binning values. If however bins are not used but replaced with continuous 
values then the comparisons become quantifiable. Comparisons are not simply better or 
worse; rather they can be quantified to give a measure of how much better something is. 
Using this approach allows ordering of data which adds another dimensionality to the 
methodology. 
Of the drug-vehicle classification models presented in chapters 5 and 6 of this thesis, there 
is scope for model refinement as well as expert model interpretations. For instance would 
replacing the MACCS fingerprints in the model with a large number of alternative 
descriptors that are objectively screened improve the results; or would using alternative 
models such as SVMs or ANN produce better predictions? The current approach of 
classification may also be extended to non-linear dataset preparations which may 
potentially generate more data points to model with or describe the datum more 
accurately. 
Model refinement is a worthwhile approach; however, alternative ways to handle noisy 
data with low concordance may be a better approach. Given the models developed in 
chapters 5 and 6 resulted in their most accurate predictions at the 60 % AUC threshold, this 
is suggestive of a noisy dataset with low concordance and ways of handling such data could 
be a better starting point. Many articles in the literature report on methods of handling 
noisy data for linear and non-linear data [350, 351]. An alternative solution could be based 
on the use of fuzzy numbers to represent the data in order to explore a robust approach to 
the noise invariably present in such data collected from multiple experiments. 
To assess the robustness of the AUC methodology proposed an alternative dataset could be 
used. Moreover since the methodology is not specific to toxicity data it could be tried with 
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other types of data where two functional variables are to be compared, microarray data or 
cosmetics data are two such alternatives. 
From a scientific knowledge perspective it would be interesting to explore the models 
developed to see if other drug structures with specific functional groups show strong 
correlations with any descriptors. This was demonstrated for the aziridine containing 
compounds in the work reported in chapter 6, from which it was possible to create partially 
ordered sets and derive rules. 
Lastly, the findings of the DT models, showed a preference for hydrogen bonding 
fingerprints overwhelmingly over non-hydrogen bonding fingerprints. Discussing these data 
and the aziridine ring structure data with a formulation expert, may provide interpretations 
that cannot be derived from the model descriptors. Predictive models tend to reveal 
correlation but not causation unless the correlation can be scientifically interpreted. For 
example, it is understood that aziridines are reactive alkylating agents that may react by 
ring opening [352]. Could it be possible therefore that the vehicles which reduce the 
toxicity of aziridine ring containing compounds do so by attenuating ring opening? 
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Appendix A 
 
Appendix A is an electronic zip file titled: 
Pritesh Mistry PhD Thesis 2015 
Appendix A contains the following files: 
1) NIH dataset 
2) Curated drug structures (sdf file) 
3) Compound classification tables for 12 vehicle pairings  
